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Abstract
The asialoglycoprotein receptor (ASGP-R) is a C-type lectin, abundantly expressed on
hepatocytes. It mediates the clearance of desialylated glycoproteins carrying terminal
galactose (Gal) or N-acetyl-galactosamine (GalNAc) residues through endocytosis. The
receptor consists of two subunits, H1 and H2, both containing a carbohydrate
recognition domain (CRD), responsible for ligand binding. Organ specific expression
and high ligand specificity makes the ASGP-R a potential candidate for targeted drug
delivery to the liver.
The aim of this work has been to improve the understanding of H1-CRD by linking
function and structure of the subunit. Site-directed mutagenesis was used to deduce the
role of three N-terminal cysteines in dimer formation seen upon expression of H1-CRD
in vitro. Step-wise substitution of the cysteines by serines proved to reduce and even
completely abolish the dimerization. However, GalNAc affinity of the mutant proteins
was impaired as a result of the modification(s).
Site-directed mutagenesis was applied in a second study to investigate the functional
importance of selected amino acid residues in the binding site of H1-CRD. Five single
mutant proteins were created, identifying one residue of major importance for GalNAc
binding. Two other residues displayed only minor influence on ligand binding, while
one mutation was seen to result in an improvement of the affinity for GalNAc. In
addition, one mutant was created to investigate the role of a histidine vs. a glutamate in
pH-dependent ligand binding exhibited by H1-CRD.
Finally, a method for high efficiency isotope labeling of H1-CRD was established. The
method was shown to yield protein with high incorporation levels of both 13C and 15N,
providing a good basis for a future structure determination of H1-CD by NMR.
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11 Introduction
1.1 Background
It has been roughly 100 years since Paul Ehrlich suggested the concept of drug
targeting by coining the expression “the magic bullet”. Ehrlich, a German
bacteriologist, saw the magic bullet as an entity consisting of two components with
separate actions and objectives. One part of the bullet/drug should recognize and
selectively bind the predetermined target, while the purpose of the second part was to
provide a therapeutic action. Such a drug would theoretically be devoid of any side
effects, as it would only attack invading pathogens or bind to the anticipated receptor,
effectively fight the disease but leave the patient unharmed [1,2]. The magic bullet, as
Ehrlich envisaged it, is in essence targeted drug delivery and remains a trait modern
drug discovery and development strive for.
Design of drugs for targeted delivery makes use of molecules capable of specific
recognition and binding to a predestined site. Such molecules, also referred to as target
moieties, can for instance be antibodies, lectins, lipoproteins, saccharides etc. The
actual target in turn can be any receptor or compound/antigen that is specific for the
organ or tissue of interest [1].
An attractive target for drug delivery is the liver, or more specifically the hepatocytes.
These cells are of great importance as they play a major role in many aspects of lipid
and carbohydrate metabolism, and are the main site for the synthesis of numerous
serum proteins. In addition, hepatocytes can produce inflammatory mediators upon
damage, leading to pathological cascades. Drug targeting of the liver presents
interesting opportunities, e.g. to influence hepatocyte related metabolism, correct
genetic defects and attenuate liver injury. A potential target candidate suggested for
drug delivery directed to the liver is the asialoglycoprotein receptor (ASGP-R) [3]. The
receptor is abundantly expressed on mammalian hepatocytes and recognizes ligands
bearing terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues with high
specificity. Following binding, the receptor-ligand complex is internalized through
endocytosis, whereupon the ligand is released into the endosome and the receptor is
recycled back to the plasma membrane [4].
2ASGP-R is composed of two subunits, the major H1 and the minor H2, both containing
a carbohydrate recognition domain (CRD) responsible for the ligand binding. The
crystal structure of H1-CRD was determined in 2000, providing valuable information
on the structure of the binding site and folding of the protein [5].
The aim of this work has been to further investigate functional and structural elements
of H1-CRD in an attempt to gain deeper insight into the functionality of the subunit.
Three main projects, addressing different aspects of the question at hand, have been
undertaken.
1) Elucidation of the importance of the three cysteines (Cys, C) 152, 153 and 164
at the N-terminus for the functionality of the subunit. The cysteines in question
represent a probable cause for the subunit dimer formation seen upon
expression in vitro. A strong incentive for this study was to investigate the
possibility of substituting the cysteines or even shortening the protein, and
thereby preventing the dimerization.
2) Investigation of specific amino acid residues in the actual binding site of H1-
CRD to determine their individual contributions to ligand binding. The binding
site of the rat ASGP-R H1 (RHL-1) was the focus of numerous mutagenesis
studies during the mid nineties, revealing the basis for the specificity of ASGP-R
CRD for Gal/GalNAc over other sugars [6-8]. However, the studies stopped
before a complete overview of the binding site could be established. This
project aimed to provide a finalized summary of the binding site, assigning
function and relevance to each residue.
3) Development of a method for isotope labeling of H1-CRD to enable studies by
three-dimensional heteronuclear nuclear magnetic resonance (NMR).
Multidimensional NMR is a most valuable method for studying proteins in
solution under native-like conditions, e.g. to determine the structure or study
protein-ligand interactions [9]. However, the method necessitates proteins
enriched with stable isotopes such as 13C and/or 15N, rationalizing the need for
isotope labeling of H1-CRD.
In summary, all three projects aim to characterize the ASGP-R H1-CRD by
establishing a structure-function relationship. A secondary, long-term goal and
expectation is that the information obtained during this work ultimately will aid the
3development of targeted drug delivery to the liver through the asialoglycoprotein
receptor.
1.2 The Asialoglycoprotein Receptor (ASGP-R)
The ASGP-R was the first mammalian lectin to be described, identified by Ashwell and
Morell in the mid sixties [10,11]. The receptor is a member of the C-type lectin family,
which is defined by their characteristics to require Ca2+ for ligand binding and to
contain disulfide bridges in the carbohydrate recognition domain [12-14]. ASGP-R is
an integral membrane protein, predominately expressed on the sinusoidal surface of
mammalian hepatocytes. Although the physiological function of the receptor has yet to
be established, it is known to mediate the clearance of desialylated glycoproteins
carrying terminal galactose or N-acetylgalactosamine residues from the circulation
through endocytosis. The receptor is an excellent model and one of the best-
characterized systems for receptor-mediated endocytosis via the clathrin-coated pit
pathway [4,15].
1.2.1 Structural organization of ASGP-R
The functional ASGP-R in vivo is a hetero-oligomer composed of two homologous
subunits, the major H1 and the minor H2, sharing 55% sequence identity. Each subunit
consists of four domains, a N -terminal cytoplasmic domain, a single-pass
transmembrane domain, an extracellular stalk segment and a carbohydrate recognition
domain (CRD), the latter being responsible for the ligand binding (Figure 1A) [4,16]. A
notable difference between H1 and H2 is an 18-amino acid insert present in the
cytoplasmic domain of only H2 [4,17]. Furthermore, while H1 only occurs as one
protein isoform, three splice variants of H2, designated H2a, H2b and H2c, have been
isolated from human liver and HepG2 cells. However, H2a does not occur in native
ASGP-R complexes. In contrast, both H2b and H2c associate with H1 in functional
ASGP-Rs, but never together in the same receptor complex [18].
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Figure 1. Schematic presentation of ASGP-R [19]. A) Each subunit, H1 and H2, consists of four domains; a
N-terminal cytoplasmic domain, a single-pass transmembrane domain, an extracellular stalk segment and
a carbohydrate recognition domain. B) A hetero-oligomeric complex of two H1 and one H2 subunits has
been proposed as the minimum size of an active ASGP-R.
Presence of both subunits is a prerequisite for the ASGP-R to reach full functionality.
Nevertheless, the subunit composition of the native receptor remains unspecified [4]. A
stoichiometry of 2:1 of H1 and H2 has been proposed as the minimum size of an active
ASGP-R complex, exhibiting high affinity ligand binding (Figure 1B) [20,21]. This
subunit ratio is partially supported by another study in which the functional receptor is
suggested to be a 2:2 heterotetramer. Extracellular stalk segments of H1 and H2,
responsible for the subunit oligomerization, were expressed and shown to associate in
homo- and heterooligomers in vitro [22]. Conditions mimicking the cellular expression
levels of H1 and H2 at a molar ratio of 3:1 favored formation of the 2:2
heterotetramers.
1.2.2 Ligand binding properties of ASGP-R
The ASGP-R specifically binds terminal Gal and GalNAc residues (Figure 2), present on
desialylated glycoproteins. Studies have shown that the binding affinity is highly
dependent on the number, distance and three-dimensional arrangement of the sugar
moieties. A single Gal residue exhibits only modest binding affinity with a dissociation
constant (KD) in the order of 1 mM. Additional sugars, going from a mono- to a
triantennary structure, result in a significant increase in affinity with dissociation
constants in the nanomolar range. Hence, high affinity binding is achieved through
multiple interactions between the CRDs in a receptor complex and multiple sugar
residues [23,24]. Furthermore, the sugar spacing has been shown to be important for
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from the branching point of the ligand, results in high affinity binding to the ASGP-R of
Gal containing ligand constructs [24,25]. In addition, the ASGP-R clearly favors
binding of GalNAc over Gal, showing an approximate 50-fold higher affinity for the
former [25,26].
Figure 2. Monosaccharide ligands of H1-CRD A) D-Galactose B) N-Acetyl-D-galactosamine
Two of the best-characterized and most commonly used ligands for the ASGP-R are
asialo-orosmucoid (ASOR) and asialofetuin (ASF), two glycoproteins with five and three
N-linked glycans respectively [27]. ASOR displays a KD of ∼10 nM for the native
receptor. It has also been observed to bind H1, overexpressed in transfected COS-7
cells, in the absence of H2 with a KD of ∼40 nM [23].
1.2.3 Physiological functions of ASGP-R
The primary function of the ASGP-R has been considered to be the removal and
degradation of desialylated glycoproteins from the circulation. Normally, many
oligosaccharide chains on glycoproteins carry terminal sialic acid residues. Upon
removal of the sialic acid, caused by the action of neuraminidases, penultimate
galactose residues are exposed and recognized by the ASGP-R [4,28].
As previously noted, both H1 and H2 are required to reach full functionality of the
receptor. In addition, the expression of the two subunits has been shown to be
interdependent. Studies of mice lacking the minor subunit (MHL-2), due to disruption
of the corresponding gene, also showed clearly decreased levels of the major subunit
(MHL-1) and were unable to clear asialo-orosmucoid from the plasma [29]. Further
experiments with a reversed approach revealed that MHL-1-deficient mice were unable
to express detectable levels of MHL-2 and also incapable of clearing ASOR from the
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R, but HL-1 appears to be more strictly required than HL-2. Interestingly, even though
the clearance of ASOR by ASGP-R was severely impaired in both MHL-1- and MHL-2-
deficient mice, neither accumulation of plasma glycoproteins nor any obvious
phenotype could be observed [28]. These results suggest that ASGP-R is not ultimately
responsible for the clearance of plasma glycoproteins, but is likely to possess other
functions.
ASGP-R has been proposed to be involved in the metabolism of plasma lipoproteins
[30] and cellular fibronectin [31]. However, studies with ASGP-R knock-out mice
could not confirm this theory, as the plasma levels of fibronectin and lipoprotein
appeared unaffected in the absence of the receptor [28]. ASGP-R has also been
implicated in the clearance of apoptotic cells by the liver. Studies showed that the
uptake of apoptotic bodies was blocked in the presence of an ASGP-R specific
antibody or following the addition of receptor specific ligands such as ASF or GalNAc
[32]. Immunoglobulin A has also been proposed as a ligand for the receptor [33].
Finally, ASGP-R is thought to act as an entry point for a few specified pathogenic
viruses to the hepatocytes. Experimental data indicate that the Marburg virus [34], the
hepatitis B virus [35,36] and the hepatitis C virus [37] are capable of binding to the
receptor, followed by infection of the host cell.
1.2.4 ASGP-R – a model for endocytosis
Receptor-mediated endocytosis serves as a mechanism by which cells can internalize
macromolecules like peptides and proteins. The ASGP-R has been the focus of several
studies aiming to understand endocytosis via the clathrin-coated pit pathway, see figure
3. Upon ligand binding, the ASGP-Rs cluster into clathrin-coated domains of the
membrane, which in turn invaginates. Clathrin-coated pits are then formed and
subsequently turned into coated vesicles, which are internalized by the cell. Following
the uptake, the coat detaches and the vesicle fuses with intracellular endosomes. The
acidic environment in the endosomes will cause the receptor and ligand to dissociate
and part ways. The ligand-containing endosomes proceed to fuse with lysosomes,
where the ligands are degraded. The ASGP-Rs meet a less grim fate as they are recycled
and transported back to the plasma membrane [38,39].
7Figure 3. Schematic representation of receptor-mediated endocytosis [40]. Membrane-bound receptors (1)
cluster upon ligand binding in clathrin-coated domains (2), which proceed to form a pit (3) and
subsequently a vesicle that is internalized (4). The vesicle loses the clathrin coat (5) and fuses with an
endosome where the ligand is released (6). The receptor is recycled back to the surface (7), while the
ligand is degraded (8).
Recycling of the ASGP-R is a continuous process. It occurs several hundred times
during the life span of an individual receptor, the time of which is estimated to
approximately 30 hours [41]. Internalization of the ASGP-R takes place independently
of ligand binding, but was shown to increase 2-fold upon binding of ASOR.
Speculations attribute this enhanced internalization rate to a possible conformational
change induced by ligand binding [27]. Furthermore, a tyrosine residue in H1 has been
shown to be of critical importance for efficient endocytosis of the ASGP-R. The
corresponding residue in H2, a phenylalanine, does not appear to contribute to the
internalization of hetero-oligomeric receptor complexes [42,43].
1.2.5 Extrahepatic occurrence of ASGP-R
ASGP-R is predominantly expressed by hepatocytes, at an estimated density of
100’000-500’000 binding sites per cell [44,45]. However, the receptor has also been
detected on extrahepatic cells. Studies using antibodies raised in mice against H1 were
8able to provide evidence of expression of the receptor in the T-cell line Jurkat.
Moreover, Tera-1 cells derived from human testis tissue gave rise to a weak signal,
indicating presence of ASGP-R when analyzed by fluorescence activated flow
cytometry [46]. Further studies support these findings, and also report on ASGP-R
expression in cells originating from human bone intestine and kidney [47,48].
1.2.6 H1-CRD – the crystal structure
The structure of ASGP-R H1-CRD was solved in 2000 by X-ray crystallography [5], see
figure 4. It is a globular protein, containing two α-helices and eight β-strands. The β-
strands are arranged in a bent plane and form the core of the protein, while the α-
helices are positioned on either side of the plane. Three calcium ions can be seen in
the structure, forming an integral part of the protein as they pin together several loops.
The two calcium ions at site 1 and 2 are seen in close proximity, both coordinated by
glutamate residue 252. Site 2 is of particular interest as it is essential for sugar binding
and is present in all C-type lectins. Calcium binding site 3 is found close to the N- and
C-terminus of the protein.
A
9Figure 4. A) Ribbon diagram of the H1-CRD [5]. The three calcium ions can be seen in green. The second
calcium binding site, which is part of the sugar binding site, is denoted by a black arrow. The disulfide
bridges are marked in yellow. The structure is deposited in the RCSB Protein Data Bank, entry code 1DV8.
B) Primary sequence of H1-CRD. The disulfide bridges are high-lighted pairwise. The sugar binding site
can be seen in bold.
C-type CRDs can be classified into short-form CRDs, with two disulfide bridges, or
long-form CRDs, containing a conserved extension with an additional disulfide bond at
the N-terminus. H1-CRD falls into the latter category, containing seven cysteines out of
which six are engaged in three disulfide bridges. One bridge constitutes part of the
sugar binding site, seen in the crystal structure between Cys254 and Cys268. A second
bond is formed between Cys181 and Cys276, bringing the C- and N-terminus close
together, and contributes to the tertiary structure of the subunit. Finally, a third typical
long-form CRD disulfide bridge is found at the N-terminus between Cys153 and
Cys164. The N -terminal residues 147-152, including the seventh odd cysteine
(Cys152), and the C-terminal residues 281-290 could not be positioned into the
electron density and hence, cannot be seen in the crystal structure [5].
1.2.7 The sugar binding site of H1-CRD
The binding characteristics of ASGP-R, high affinity and specificity for Gal and
GalNAc, are properties ultimately dependent on the primary structure of the protein.
The region around the sugar binding site in H1-CRD is formed by one continuous
stretch of the polypeptide chain from Arginine (Arg) 236 to Cys268. Numerous
mutagenesis studies have been carried out with the closely related protein RHL-1,
aiming to deduce the residues giving rise to it’s ligand binding specificity. RHL-1 has
been used as a reference in attempts to mimic its Gal- and GalNAc-binding properties
B
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in other lectins, e.g. the mannose binding protein (MBP) [6] and the macrophage
galactose receptor (MGR) [7] (Figure 5). Such studies form the basis for the explanation
of H1-CRDs sugar preference as well as its distinction between high- and low-affinity
ligands.
H1-CRD 200 VQHHIGPVNT WMGLHDQNGP WKWVDGTDYE 229
RHL-1 200 VQQHMGPLNT WIGLTDQNGP WKWVDGTDYE 229
MGR 222 LQTHMGSVVT WIGLTDQNGP WRWVDGTDYE 251
MBP 147 IQ-EVAKTSA FLGITDEVTE GQFMYVTGGR 175
H1-CRD 230 TGFKNWRPEQ PDDWYGHGLG GGEDCAHFTD 259
RHL-1 230 TGFKNWRPGQ PDDWYGHGLG GGEDCAHFTT 259
MGR 252 KGFTHWAPKQ PDNWYGHGLG GGEDCAHFTS 281
MBP 176 LTYSNWKKDE PND---HG-- SGEDCVTIVD 200
H1-CRD 260 DGRWNDDVCQ RPYRWVCETE LDKASQEPPL L
RHL-1 260 DGHWNDDVCR RPYRWVCETE LGKAN----- -
MGR 282 DGRWNDDVCQ RPYRWVCEMK LAKDS----- -
MBP 201 NGLWNDISCQ ASHTAVCEFP ---------- A
Figure 5. Sequence comparison of the binding site in CRDs of human H1, RHL-1, MGR and MBP. The
numbers correspond to the first and last residue in each sequence. The highlighted residues in the RHL-1
sequence have been shown to contribute to the Gal- and GalNAc-specificity of the subunit.
Introduction of two point mutations in MBP, E185Q and N187D, corresponding to
Q239 and D241 in RHL-1, was sufficient to achieve galactose binding in the protein,
which is normally binding mannose [6]. However, as the Gal affinity of the MBP
mutant, designated QPD, was rather low it was concluded that other residues in H1-
CRD also must contribute to the ligand binding. An additional mutation, H189W,
showed to increase the affinity significantly, making the galactose binding of mutant
QPDW comparable to that of RHL-1. Selectivity for galactose over mannose was
achieved by incorporating a glycine-rich stretch following the QPDW sequence,
referred to as the QPDWG mutant. Stepwise mutations within the glycine rich loop,
corresponding to residues Y244, G245 and H246 in RHL-1, showed that they all
contribute to the selectivity for Gal [6]. However, the influence of the amino acids on
the selectivity could equally well be attributed to stabilization and support of the
protein structure as to an actual effect on the ligand binding.
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RHL-1, as well as H1-CRD, shows preferential binding to GalNAc over Gal. The
selectivity for GalNAc has been probed by mutations studies of MGR, which binds Gal
and GalNAc with roughly equal affinity. The CRDs of RHL-1 and MGR are highly
homologues (77%) and the difference in selectivity is likely to stem from divergences in
the sequences. It was concluded that substitution of four amino acids in MGR, V230N,
A258R, K260G and S281T, is sufficient to induce GalNAc binding comparable with
that of RHL-1. N230 increased the selectivity 20-fold, while the contributions by R258
and G260 were less prominent. The latter two residues only showed marginal or no
effect at all when substituted individually, but a 2-fold increase when present together.
It is possible that glycine contributes to the affinity by positioning arginine, which has
the potential for forming hydrogen bonds with the ligand. T281 significantly increased
the selectivity for GalNAc when inserted into MGR simultaneously with R258 and
G260, but is more likely to play an indirect role for ligand binding as it is predicted to
be positioned at a considerable distance (10 Å). The residue appearing most important
for achieving GalNAc binding is a histidine (His, H), found in both RHL-1 and MGR at
position 256 and 278 respectively. Initial studies exchanging H278 in MGR for an
alanine (Ala, A) resulted in an almost complete loss of GalNAc selectivity, but without
any apparent effect on the galactose binding. The importance of the histidine was
further investigated by repeating the substitution in RHL-1, causing a 25-fold loss in
affinity for GalNAc, but without affecting that for Gal [7]. Corresponding residue in
MBP, T202, was also substituted by histidine and resulted in a 14-fold increase in the
relative affinity for GalNAc of the protein (referred to as the QPDWGH mutant) [49].
1.2.8 Sugar binding to H1-CRD
A model for sugar binding to H1-CRD has been proposed based on the mutagenesis
experiments with MBP [8,49]. Crystallographic data of the QPDWG mutant could
show that Gal and GalNAc bind directly to the Ca2+ in the second calcium binding site.
The 3-OH and 4-OH groups of the sugar replaces two water molecules, normally
coordinated by the calcium (Figure 6A). In addition, the same OH groups also forms
hydrogen bonds with amino acid chains that are Ca2+ site 2 ligands (Q239, D241,
E252, N264 in H1-CRD). Further interactions between the ligand and the protein are
formed by stacking of the apolar face of the sugar against the side-chain of a tryptophan
(W243 in H1-CRD) [8].
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The GalNAc-specific MBP mutant QPDWGH was also analyzed by crystallography
(Figure 6B). The results revealed direct interactions between the inserted histidine and
the methyl group of the N-acetyl substituent of the sugar. The formed van der Waals
contact serves as an explanation for the increase in GalNAc specificity exhibited by the
mutant protein [49].
Figure 6. A) Schematic representation of interactions formed between Gal and H1-CRD. B) Ribbon
diagram of the sugar binding site of MBP mutant QPDWGH (PDB entry code 1BCH) complexed with
GalNAc [49]. Residues binding to the calcium ion (green) and the ligand are shown as ball-and-sticks [50].
Q185
W185
D187
E198
N210
H202
A
B
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1.2.9 ASGP-R – a candidate for targeted drug delivery
The ASGP-R presents a most appealing opportunity for targeted drug delivery to the
liver. A recent review covers a number of different approaches for targeting liposomes
and other carrier systems to the ASGP-R [3]. Labeling conventional liposomes with
asialofetuin was seen to result in a significant increase of liver uptake, compared to
unlabeled liposomes, after intravenous injection into mice. The enhanced uptake was
most likely mediated by the ASGP-R [51]. Another study used glycolipids containing a
cluster galactoside moiety for targeting to ASGP-R. The glycolipids were incorporated
into liposomes at a ratio of 5% (w/w) and injected intravenously into mice. The liver
uptake of the glycolipid-liposomes was estimated to exceed 80% compared to less than
10% for conventional liposomes 30 minutes after injection. Furthermore, pre-injection
of ASF was seen to almost completely abolish the liver uptake of the glycolipid-
enriched liposomes, implicating the ASGP-R as an active participant in the process
[52].
To further aid the development of drug targeting to the liver aimed at ASGP-R it is
important to understand the intricate relationship between structure and function of the
receptor. Characterization of H1-CRD provides a good basis for expanding the
knowledge and gaining a deeper understanding. Numerous methods can be employed
in the pursuit of elucidating the relevance of structural elements or study protein-ligand
interactions. The starting point for most methods is access to the protein and hence,
recombinant protein production. A method for expression and purification of H1-CRD
from E.coli was developed and reported in 2000 by Meier et al., enabling structure
determination of the subunit by X-ray crystallography [5].
1.3 Recombinant protein production
Pure, soluble and functional proteins are of high demand in modern biotechnology,
e.g. for biochemical or three-dimensional analysis studies etc. Natural protein sources
are rarely able to provide sufficient amounts, and even less in a cost-efficient manner,
making recombinant protein production an appealing alternative [53]. Recombinant
protein production involves several steps (Figure 7), starting with cloning of the gene
into an expression vector, choosing an appropriate expression system and finally
optimizing the protein production both in terms of expression yields and subsequent
purification of the gene product [54].
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Figure 7. Schematic overview of recombinant protein production in E.coli [19]. The plasmid containing the
target sequence is transformed into E.coli for expression. The expressed protein accumulates (most often) in
the cells as inclusion bodies, which are released by lysis. In order to recover the protein and restore its
native structure, the inclusion bodies are denatured and the protein is refolded. Finally, the protein is
purified to remove contaminant bacterial proteins.
E.coli was the first organism used for production of recombinant proteins and still
remains one of the most common expression systems [55]. Part of the bacterium’s
appeal surely lies in its ability to grow rapidly and at high cell densities on inexpensive
substrates, its well-characterized genetics and the availability of an increasingly large
number of cloning vectors and mutant strains [56]. Several informative and most useful
reviews covering different aspects of the use of E.coli as expression system and offering
advice on how to achieve high-level production have been published during the years
[53,54,57,58]. This section will also focus on E.coli as it is the expression host used
within this work.
1.3.1 Starting at the DNA-level
The gene of interest is initially cloned into an expression plasmid. For efficient
expression of the target gene a number of structural elements has to be considered. The
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most fundamental are a transcriptional promotor, a ribosome binding site (RBS) and a
translational as well as a transcriptional terminator [53,58]. A promotor should be
strong, resulting in high yields of the desired protein, but simultaneously showing low
basal expression levels in the absence of an inducer. Transcription can be regulated
through the presence of a repressor, encoded by a gene either integrated in the host
chromosome or present on the vector itself. In addition, simple and cost-effective
induction is desirable [57,58]. The RBS includes the Shine-Dalgarno site, which
interacts with the 3’ end of the 16S ribosomal RNA during translational initiation of the
transcribed messenger RNA (mRNA). A translational terminator is found at the end of
the gene encoding sequence, termination efficiency increasing with consecutive stop
codons. Finally, a transcription terminator located downstream of the target sequence
not only puts an end to the transcription, but also stabilizes the mRNA as an added
benefit [58,53].
Additional elements not directly involved in the gene expression, but important for
propagation and maintenance of the plasmid within the host cell are origin of
replication and antibiotic resistance markers. The origin of replication controls the
plasmid copy number, which in turn can influence the expression levels [58]. High-
copy number vectors (e.g. pBR322, 15-60 copies) are often chosen to achieve
maximum gene expression and might appear superior, but there are also drawbacks.
Large amounts of foreign protein can prove to be toxic for the host cell, favoring use of
medium- to low-copy number plasmids. Furthermore, protein aggregation can occur as
a result of high expression levels, but can be prevented if the amount of protein is
sufficiently reduced [54]. Antibiotic resistance markers are a valuable feature of
plasmids. By conferring resistance to the host cell, the markers aid selection and
propagation of the plasmid. Newly transformed bacteria are plated on selective agar-
plates, allowing for growth only of the cells that were successful taking up the plasmid.
Commonly used antibiotic markers are ampicillin, kanamycin, chloramphenicol and
tetracycline. Ampicillin present in cultivation medium is especially susceptible to
degradation. Plasmid evoked resistance towards ampicillin is accomplished by
expression of β-lactamase from the bla gene. The enzyme is secreted into the
periplasm, where it catalyzes hydrolysis of the antibiotic. Ampicillin can also be
degraded by acidic conditions in high-density cultures, a risk that can be circumvented
by using the less degradation prone ampicillin analog carbenicillin [53].
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1.3.2 The pET expression system
There are several expression systems available for production of recombinant proteins,
differing in their use of promotors and applications etc. One of the most widely used
systems is the T7 based pET expression system, commercialized by Novagen [59]. The
system makes use of T7 RNA polymerase, which is highly selective for its own
promotors and shows a high rate of transcription. The T7 promotors, present on pET
plasmids, do not normally occur in E.coli, nor are they recognized by E.coli RNA
polymerase. Expression is achieved exclusively by T7 RNA polymerase, which can be
provided by induction of the T7 gene 1. Host cells that are lysogenes of the
bacteriophage DE3 carry a DNA fragment containing the T7 gene 1 under the control
of the lacUV5 promotor, and also the lacI gene. The lac1 gene gives rise to Lac1
monomers, forming tetramer complexes. The tetramers inhibit transcription of the T7
gene 1 and hence, protein expression. When administered, isopropyl-β-D-
thiogalactopyranoside (IPTG) binds the tetramer complexes, thus the T7 gene 1 is
transcribed and the T7 RNA polymerase can initiate transcription of the target gene, see
figure 8. T7 RNA polymerase is so selective and active that under optimized conditions
essentially all of the resources of the cell can be converted to target gene expression,
resulting in yields as high as up to 50% or more of the total cell protein [60,53].
Figure 8. Protein expression initiated from the T7 promotor in a pET plasmid. The host cell, a DE3 lysogen,
carries a copy of the T7 gene 1 under the control of the lacUV5 promotor. Addition of IPTG to a growing
culture will induce T7 RNA polymerase production, which initiates the protein expression [59].
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Adding to the advantages of the pET system are the many different vectors available,
designed and developed for a variety of expression applications. The pET plasmids offer
the option of different cloning sites and allows for incorporation of different fusion
partners and tags [53,59].
1.3.3 Protein expression
The choice of expression strain can influence the protein production, both in terms of
protein quality and yield. In general, expression strains should be deficient in the most
harmful natural proteases and maintain the expression plasmid at stable levels.
Depending on further requirements, various E. coli strains have been genetically
engineered for different purposes such as promotion of cytoplasmic disulfide bond
formation (e.g. Novagen Origami and AD494), enhancement of expression of proteins
containing rare codons (e.g. Novagen Rosetta) or soluble expression of membrane or
aggregation prone proteins (e.g. Avidis C41(DE3) and C43(DE3)) etc [53]. The most
commonly used expression host is E.coli BL21 from Novagen, derived from E.coli B and
as such deficient in lon  and ompT proteases that can degrade proteins during
purification [59].
Cultivation conditions should be carefully considered and optimized to achieve high
expression levels of the target protein. The culture medium composition constitutes one
important factor subject to optimization as it can influence both cell growth and
protein production. The expression temperature is a second parameter worth
investigating. Naturally, the final expression levels will also be dependent on the
expression time [58,61].
Recombinant protein expressed intracellularly by E.coli can either accumulate as
soluble protein in the cytoplasm or precipitate and form inclusion bodies, i.e. large
insoluble aggregates of misfolded and inactive protein. Aggregation can occur when
the expression rate is high, resulting in an accumulation of folding intermediates, or
due to insufficient folding abilities, e.g. the inability to form native disulfide bonds. In
order to avoid inclusion body formation, different strategies can be attempted,
including optimization of expression temperature and rate, use of different E.coli
strains, co-expression of molecular chaperones or use of affinity tags or fusion partners
to increase the protein solubility etc [62]. However, there are also advantages
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associated with the inclusion bodies. Normally toxic proteins cannot harm the host cell
when present in aggregates, often resulting in high expression levels. Concurrently, the
protein itself is protected from degradation by proteases. Nevertheless, the necessity to
purify and refold the protein into its native structure remains [63].
1.3.4 Protein purification
Expression is followed by isolation and purification of the target protein. Soluble
proteins accumulated in the cytoplasm of E.coli are initially released by cell lysis,
through chemical treatment or mechanical-disruption techniques, followed by
purification e.g. using different chromatography methods. In contrast, proteins
accumulated as inclusion bodies require additional solubilization and renaturation
steps [63].
There exists no universal protocol for optimal recovery of recombinant protein from
inclusion bodies, but there are guidelines listing general measures [64,65,63]. A
common procedure is to first isolate the inclusion bodies by cell lysis and
centrifugation, which is easily done due to the high density of the protein aggregates. A
washing step, utilizing detergents or low concentration of denaturants, is sometimes
included to remove contaminating host proteins that may have absorbed onto the
hydrophobic inclusion bodies. Next, the inclusion bodies are solubilized by use of high
concentration of denaturants, such as guanidinium chloride and urea. If the
recombinant protein contains cysteine residues, a reducing agent should also be
included in the solubilization buffer and added in slight molar excess to ensure
complete reduction of all cysteines and to prevent non-native disulfide bond formation.
Typical reducing agents are beta-mercaptoethanol and dithiotreitol. The native
structure and function of the protein is restored by renaturation, realized by the
removal of denaturant and reducing agent by dialysis or dilution [65]. The renaturation
conditions have to be carefully optimized to avoid incorrect folding or protein
aggregation of folding intermediates. Correct folding is generally favored at low protein
concentration, but might not always be practical. Different strategies have been
attempted to facilitate correct folding, e.g. presence of denaturants at low non-
denaturing concentrations or use of additives that prevent aggregation and/or enhance
the stability and solubility of folding intermediates etc. In addition, if the target protein
contains disulfide bonds, it is advisable to include a redox system in the renaturation
buffer, allowing for formation and reshuffling of disulfide bonds [64].
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1.3.5 General concluding remarks
E.coli is one of the most widely used expression systems for recombinant protein
production. Even so, there exists no universal fail-proof protocol on how to design an
expression set-up to obtain optimal yields, but it has to be determined empirically for
each individual protein. Similarly, protein purification and refolding protocols also
have to be developed on a case-by-case basis. If the final product cannot be recovered
in sufficient amounts due to inefficient purification or refolding an alternative
expression system, e.g. mammalian cells, ought to be considered. The same is true if
post-translational modifications are required for the biological activity [63].
1.4 Site-directed mutagenesis
Site-directed mutagenesis (SDM) has proved to be of great value in the study of
proteins. Its power lies in its ability to change a specific DNA target in a predetermined
way, and consequently the gene product can be altered. As is known, the function of
any given protein is highly dependent on its three-dimensional structure, which in turn
is determined by the primary sequence. Therefore, SDM not only enables investigation
of the protein structure and function, but also of the relation in-between [66,67].
SDM can be summarized as any of various techniques used to create specific
alterations in the sequence of a gene. Such alterations do not merely refer to point
mutation(s), which is the focus of this section, but also entail insertion or deletion of
nucleotides. At the outset, SDM was performed with a single-stranded template
(created by subcloning in M13), an oligonucleotide primer carrying the mutation and a
thermolabile DNA polymerase. Although able to produce the desired mutation, this
method was often time-consuming and not very efficient as also the wild-type
sequence was produced. The introduction of the polymerase chain reaction (PCR) has
therefore been of outstanding importance for the further development and
improvement of SDM in vitro, making it a highly efficient process. Today, several
techniques based on PCR are used for the creation of point mutations, a few of which
are described below [67,68].
Regardless of the method used, four essential components are required in an in vitro
DNA mutagenesis reaction. First, the template, i.e. the DNA sequence to be mutated,
must be provided, and can be double- or single-stranded, linear or circular. Second,
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primers of which at least one carries the mutation have to be included. The design of
the primers is important to ensure successful mutagenesis. In general, it is
recommended to place mismatches in the middle of the primer, but for some methods
it is preferable to put the mutation at the 5’-terminus. Hence, the primer design should
be carefully considered for each new method to be used. Third, building blocks in the
form of the four dNTPs have to be supplied to enable DNA synthesis. Finally, a DNA
polymerase, realizing the DNA synthesis reaction, is necessary. DNA polymerases used
in PCR applications have to be thermostable to remain active under the high
temperatures used during the reaction. As an example, denaturation of the template
DNA is carried out around 95°C. Furthermore, when choosing a polymerase, the
fidelity rate should be considered. Some polymerases, e.g. Taq, are more prone to
cause unintended and non-desirable mutations compared to others, e.g. Pfu or Vent.
The low fidelity of Taq is partly due to lack of 3’-5’ exonuclease activity that
“proofreads” and corrects sequence errors caused during DNA synthesis. As a final
point, buffers and various other conditions also contribute to the success and fidelity of
the DNA mutagenesis reaction. Following the mutagenesis reaction, the PCR product
can be cloned into a vector for subsequent transformation and characterization [67].
1.4.1 PCR-based mutagenesis strategies
PCR was applied in SDM almost immediately after its establishment in 1985 and since
then a number of techniques have been developed. Initial conditions, special
requirements and the purpose of the mutagenesis reaction serve as guidelines when
choosing a method. Three strategies used within this work are presented in the
following sections.
1.4.1.1 Conventional PCR introducing mutation into the terminus of a sequence
If the intended mutation is located close to either end of the DNA sequence, it can be
introduced by a conventional PCR set-up. Two primers are used, complimentary to the
termini of the sequence, with the exception of the desired mutation(s) encoded by one
of the primers (Figure 9).
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Figure 9. Introducing a point mutation into one of the termini. Primer 1 carries the mutation (marked as ♦),
while primer 2 is completely complimentary to the second terminus of the target sequence.
The PCR reaction is run according to standard procedures, producing the mutated
DNA. A pair of restriction sites is also usually built into the two primers, enabling
subsequent cloning of the PCR product into a suitable vector [69].
1.4.1.2 Overlap extension PCR
To create mutations in the middle of a DNA sequence requires a different approach.
One commonly used technique is overlap extension PCR (OE-PCR), consisting of two
individual reactions. In a first step, two separate PCR reactions are performed,
generating two fragments with overlapping sequences containing the mutation. The
two fragments are produced by pairing a flanking forward primer with an internal
reversed mutagenic primer and vice versa. In the second step, the two fragments are
combined in a PCR reaction and the flanking primers are added. The overlapping
sequences will allow annealing of the two fragments, giving rise to two heteroduplexes.
Only the heteroduplex carrying two 3’ termini at the joint can be extended by the
polymerase to form full-length double-stranded DNA. The extended double-stranded
DNA is further amplified by the flanking primers [70,67], see figure 10.
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Figure 10. Introducing a point mutation into the middle of a sequence using overlap extension PCR. Primer
1 and 4 are completely complimentary to the termini of the sequence, while primer 2 and 3 carry the
mutation, marked as ♦. In a first step, two reactions are carried out simultaneously, generating two
overlapping halves of the target sequence. In a second step, the combined fragments will anneal and
extend to full-length double stranded DNA. Addition of the flanking primers will promote amplification of
the DNA.
1.4.1.3 Inverse PCR
A third example of how to introduce mutation(s) is the inverse PCR method. The target
sequence is located in a plasmid and a pair of tail-to-tail primers are used, the mutation
located in one of the two. During the PCR reaction, the entire plasmid will be amplified
by the primers, resulting in a linear double-stranded PCR product (Figure 11) [71].
Figure 11. Introducing a point mutation into a sequence using inverse PCR. A pair of tail-to-tail primers are
used, where primer 1 carries the mutation (marked as ♦). The primers will amplify the entire plasmid
during the PCR reaction, while simultaneously introducing the mutation. The produced double-stranded
linear DNA is ligated prior to transformation into E.coli.
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The product is subsequently circularized through ligation and transformed into E.coli.
Worth mentioning is that the ligation requires phosphorylated 5’-termini of the PCR
products to succeed. This can be accomplished either by phosphorylating the primers
in advance or the PCR products afterwards. Inverse PCR suffers from difficulties to
separate the mutated product from the wild-type template, often leading to
transformation of cells with a mixture and hence, resulting in lower mutagenesis
efficiency [71,67].
1.4.2 Planning a mutation
The choice of a mutation is often based on previous knowledge about the protein
under investigation, e.g. X-ray crystallographic data or genetic studies. Regions
assumed to be important for the protein function, stability, pH tolerance or other
properties are examined by changing strategically chosen residues [66]. Similarly, the
mutant residue into which the wild-type amino acid is converted is also tactically
selected to yield maximum information. As an example, cysteine residues probed by
mutagenesis studies are often exchanged for alanine and/or serine residues [72,73].
While replacement with alanine conserves the hydrophobic character, a cysteine to
serine conversion gives a relatively small change in size of the polar amino acid side
chain. SDM is particularly useful for comparison of proteins, which might be related
but with different functions. In such an event, the mutations are simply chosen on basis
of the sequences differences to deduce the amino acids responsible for any dissimilar
behavior.
1.4.3 Alanine-scanning mutagenesis
Alanine-substituted proteins can be used for effective identification of amino acid
residues important for protein function, stability and structure. Conversion into alanine
will result in the removal of all side chain atoms past the β-carbon. Systematic alanine
replacement also referred to as alanine-scanning mutagenesis, will therefore make it
possible to conclude the role of side chain functional groups at specific positions [74].
Alanine is the substitution residue of choice for several reasons. It does not change the
backbone conformation, nor does it impose any extreme electrostatic or steric effects.
Like alanine, glycine also invalidates the side chain, but the latter amino acid is not a
good option as it could introduce conformational flexibility into the protein backbone
[74,75]. Nonetheless, even though alanine-scanning mutagenesis is able to provide a
detailed map of important functional residues, it is a very laborious method. Each
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alanine-substituted protein must be separately created, expressed and purified before
the loss of the side chain functionality can be evaluated.
1.5 Receptor-ligand binding assays
The interactions between a ligand and a receptor can be studied and evaluated by
means of different assay formats. It is a central feature in drug discovery as well as in
basic research for the determination of the behavior and biological function of a
protein. Due to the wealth of assay technologies, it is possible to measure ligand
binding under a multitude of conditions, e.g. in solution or in solid state, using isolated
receptors or whole cells or organs, with or without labeling of the receptor or ligand,
using fluorescence or enzyme-induced color development [76]. This section will
introduce two assay formats used within this work.
1.5.1 A solid-phase competition assay
A solid-phase competition assay was developed within a diploma thesis by Daniela
Stokmaier at the Institute of Molecular Pharmacy (IMP) (Pharmacenter, University of
Basel, Switzerland), with the purpose to measure interactions between the ASGP-R H1-
CRD and potential ligands [77]. The assay is based on a similar assay for E-selectin [78]
and makes use of polyacrylamide-based glycoconjugates described by Bovin [79].
The assay consists of three basic steps (Figure 12). In the first, the protein is coated onto
a 96-well plate. Second, a biotinylated polymer carrying sugar residues, in this case
Gal or GalNAc, is added to the protein together with the substance under investigation.
The substance is prepared as a dilution series while the polymer concentration is kept
constant. The polymer is precomplexed with streptavidin-peroxidase, allowing for
detection and evaluation of the binding, which is the third step. A substrate for
horseradish peroxidase is added, here 2,2’-azino-di-[3-ethylbenzthiazoline-6-sulfonic
acid] (ABTS), and a colored product is formed. Absorbance is measured at 415nm,
quantifying the degree of binding [77].
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Figure 12. Schematic representation of the solid-phase competition assay. The protein is coated onto a 96-
well plate. Inhibitor substance is added simultaneously with a biotinylated β-GalNAc-polymer
precomplexed with streptavidin-peroxidase. ABTS substrate is added and an emerald green color appears.
The assay set-up using a constant concentration of protein and polymer while varying
the inhibitor concentration permits the construction of an inhibition curve. An IC50
value, i.e. the substance concentration that inhibits 50% of the maximum polymer
binding, can then be determined from the curve.
1.5.2 Surface plasmon resonance (SPR)
Surface plasmon resonance can be used to monitor molecular interactions in real-time
and determine the equilibrium dissociation constant, KD. The method relies on the
measurement of changes in refractive index and resonance angle, which can occur
upon ligand binding [80,81,76]. The principle components of Biacore, an SPR-based
instrument, are a sensor chip, a flow cell, a light source and a detector. A schematic
overview of the set-up can be seen in figure 13.
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Figure 13. Experimental setup of a Biacore instrument. A target molecule is immobilized on the sensor
chip. An analyte is injected into the flow cell and it’s binding detected through changes in resonance angel
[82].
In short, the protein (or the ligand) is immobilized on a modified gold surface, i.e. the
sensor chip, which is illuminated with polarized light. Following immobilization, the
ligand (or the protein) is injected into the flow cell, running over the sensor chip.
Association between the receptor and the ligand will result in an increase in mass and
hence, also a change in refractive index and a change in the angle of reflected light.
Once the injection is stopped, washing continues with running buffer and the ligand
will dissociate from the receptor. Anew the signal changes as the mass decreases and
the angle of reflected light is restored to its original position. The shifts in resonance
angle are recorded by the detector, and can be plotted in dependence of time. The
signal-to-time plot, refereed to as a sensogram, will visualize the binding behavior of
the ligand, illustrated in figure 14 [81,76].
27
Figure 14. Schematic representation of a sensogram and the different stages of a binding event. Upon
injection of the analyte, the signal increases as binding occurs until steady state is reached and the curve
flattens out. Once the injection is stopped, running buffer will replace the bound analyte and the signal
decreases. Some assays require an additional regeneration step to reach the baseline again [82].
Parameters such as the association and dissociation constants (kon and koff, respectively)
can be derived from the binding curve. The equilibrium dissociation constant can be
calculated by dividing koff with kon.
1.6 Isotope labeling of recombinant proteins
The need for proteins labeled with stable isotopes became apparent in parallel to the
development of biomolecular NMR. There are many applications for NMR in protein
studies, one of the most prominent being structure determination. Compared to X-ray
crystallography, NMR holds the advantage that proteins can be studied in solution
under native-like conditions and hence, no crystallization is needed. It also offers the
possibility to monitor protein-ligand interactions [9], which is discussed further below.
Still, NMR suffers from drawbacks, the two main problems being signal overlap and
low signal-to-noise ratio. Both problems become increasingly acute as the size of the
study object increases. These hurdles are partly surmounted by labeling of the protein
with stable isotopes such as 13C and 15N [83].
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The most abundant isotopes of carbon and nitrogen, i.e. 12C and 14N, cannot be used
for NMR measurements as they either lack a net nuclear spin or, in the case of 14N, are
unable to produce strong, useful signals. In contrast, the less common isotopes 13C and
15N exhibit nuclei specific signals, making them suitable for NMR measurements and
enabling multidimensional heteronuclear NMR experiments. In short, by labeling a
protein with 13C and/or 15N, one or more additional dimensions are added to the
spectra, further separating the NMR signals. Consequently, the signal overlap
decreases, allowing for proteins on the order of 20 kDa to be studied by NMR when
double-labeled with 13C and 15N [84,85].
1.6.1 Uniform labeling
For consistency and of relevance to this work, isotope labeling using E.coli as
expression host is addressed in this section. Uniform labeling of recombinant proteins,
i.e. labeling of all nitrogens and/or carbons with stable isotopes, can be achieved by
growing E.coli cells and inducing protein expression in medium containing 13C and/or
15N. Rich medium containing isotope labeled nutrients is commercially available and
represents one possibility, but can be rather expensive when used repeatedly or for
large-scale production. Therefore, it is common procedure to grow E.coli in so-called
“chemically defined” or “minimal” medium, where only one or a very limited number
of carbon and nitrogen sources, isotopically labeled, are provided. The bacteria are
forced to produce all metabolites themselves; including amino acids, and as a result the
isotopes are incorporated into the recombinant protein during expression [86,87].
The composition of minimal medium can vary depending on the requirements of the
expression strain. Nevertheless, commonly used standard or modified versions of M9
minimal medium [88] are based on a number of general and essential components.
The M9 salts, supplying phosphorus atoms, consist of potassium dihydrogenphosphate,
disodium hydrogenphosphate and sodium chloride. Glucose and/or glycerol often
constitute the carbon source, while nitrogen is supplied in the form of ammonium
chloride or ammonium sulfate [86]. Finally, magnesium sulfate, calcium chloride and a
B-vitamin mixture are added to provide the bacteria with essential salt and nutrients.
Some media also include a trace element solution, consisting of metal ions such as
Co2+, Cu2+, Fe2+, Zn2+ etc, for the benefit of the bacteria [89].
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Even though the production of isotope labeled proteins can appear rather straight-
forward, it can be both costly and time-consuming. Efforts are constantly being made to
improve the yields and reduce the costs. One alternative approach to achieve efficient
isotope labeling of recombinant proteins was presented by Marley et al., in 2001 [90].
It is a two-stage protocol that generates cell mass using unlabeled rich medium
followed by exchange into an equal or smaller volume labeled minimal medium. A
short period of growth recovery and clearance of unlabeled metabolite is included
before the cells are induced. This expression set-up is deemed both cost and time
efficient. The isotope consumption is reduced as the majority of the cell mass is
generated using unlabeled medium, while labeled minimal medium is introduced only
at the stage of or shortly before induction. Furthermore, the growth rate of E.coli is
generally faster in rich medium. Finally, by exchanging the cells into fresh medium
prior to induction, byproducts, which can hamper both cell growth and protein
expression, are removed. The volume of minimal medium may equal that of the starter
culture or can be reduced to obtain higher cell density. The optimal cell density for
induction has to be determined empirically for each protein [90]. A further suggestion
for improvement of expression yields is addition of labeled rich medium to the minimal
medium [91].
1.6.2 NMR as a tool to detect and investigate protein-ligand interactions
NMR is a valuable method for detection of protein-ligand binding, also without isotope
labeled proteins. NMR experiments based solely on protons can provide qualitative
measures whether or not binding takes place. However, multidimensional NMR and
the use of isotope labeled protein also permits quantitative measurements of the
binding, and furthermore, can ascribe the interactions to specific residues or involved
regions. By performing a 1H-15N heteronuclear single quantum correlation (HSQC)
experiment, a two-dimensional spectrum is obtained, ideally containing one cross-peak
for each amide in the protein. Addition of the ligand can cause a change in the signal
distribution, if binding takes place. The signals of those amides involved in binding and
whose environments are changed will experience obvious chemical shift changes. If
resonance assignment and a 3D structure are available, these changes can be mapped
onto the protein structure, indicating the location of the binding site [92]. In addition, a
similar set-up can be used to determine the equilibrium dissociation constant by
titration of ligand to the protein [93].
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1.7 Scope of thesis
The overall aim of this work has been to investigate functional and structural elements
of ASGP-R H1-CRD in order to gain a deeper insight into the functionality of the
subunit. The work encompasses three main projects with the different focuses and
backgrounds presented below.
1.7.1 The role of the three cysteines at the N-terminus
H1-CRD contains seven cysteines, six of which are engaged in disulfide bridges. Based
on the crystal structure [5], two of the bridges appear to be of great importance for the
overall structure and functionality of the subunit. Disulfide bond Cys254-Cys268
contributes to the structure of the binding site, while the second S-S bond, Cys181-
Cys268, brings the two termini together, shaping the overall fold of the subunit. In
contrast, the third bridge, Cys153-Cys164, is more likely to be of limited importance
and only influence the local structure at the N -terminus. Here it should also be
mentioned that an alternative pairing of the third disulfide bond was indicated in an
earlier doctoral thesis at IMP by Rita Born [94]. Results derived from MS analysis
indicated a disulfide bond between Cys152 and Cys153. Nevertheless, the seventh odd
cysteine (Cys152 according to the crystal structure) lacks a thiol-group to react with
within the subunit. It can, however, react with a free cysteine in a second subunit and
hence, could be the cause of H1-CRD dimer formation seen upon expression in vitro
[94]. The dimerization presents a problem as it is neither possible to control, nor
reproducible, giving rise to in heterogeneous samples of H1-CRD. A further
disadvantage of the dimers is the uncertainty of how they behave and whether they
exhibit different binding affinities compared to the monomers. For consistency,
receptor-ligand assays such as Biacore and NMR, aiming to determine ligand binding
affinity, should therefore always be performed with homogenous samples of
monomeric H1-CRD.
A method to separate monomers and dimers of H1-CRD was developed within a
doctoral thesis of Daniel Ricklin at IMP [95]. HPLC ion-exchange chromatography (IEC)
was employed for this purpose, resulting in a clear and reproducible separation of the
two species. However, analysis of the monomer samples was seen to show an ever-
present fraction of dimers, most likely formed after the separation as the result of an
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equilibrium forming between monomers and dimers. Therefore, merely separation of
monomers and dimers is not sufficient to obtain pure samples of monomeric H1-CRD.
If the dimer formation is caused by the seventh odd cysteine, it can theoretically be
inhibited by replacing the cysteine with e.g. a serine through SDM. All three cysteines
closest to the N-terminus could be implicated in the intermolecular disulfide bonding,
as proposed by the conflicting indications concerning the pairing of the third disulfide
bond [5,94]. Hence, it seems reasonable to exchange all three cysteines by serines to
ensure that dimer formation is completely prevented. A second concern that has to be
addressed is the activity of a mutant subunit. Even if the dimerization is abolished by
mutations, it is absolutely crucial that the protein maintains its native behavior and
binding affinity to be of use in future studies. As an alternative approach, shortening the
protein could also be considered.
1.7.2 Investigation of the binding site
The binding characteristics of H1-CRD, high specificity and affinity for Gal and
GalNAc, have been attributed to a number of residues in the binding site. Out of the 33
amino acid long binding site, stretching from Arg236 to Cys268, the functional
importance of the great majority of the residues have been explored and elucidated [4-
7,49,96]. However, the studies stopped before a complete overview of the binding site
could be established. Therefore, previously uninvestigated residues, lacking assigned
function and relevance, were probed by SDM and subsequent expression and
evaluation within this work. The residues under investigation were chosen with respect
to location, functional group of the side chain and, occasionally, based on previous
studies (Figure 15).
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Figure 15. Ribbon diagram of H1-CRD. The residues that were mutated within the project are drawn as
ball-and-sticks. The N-terminus of the backbone can be seen in red, while the C-terminus ends in blue
[50].
Proline 237 and aspartate 260 are conserved residues in H1-CRD, whose functional
contributions have not been investigated before. Both residues are conserved in H1-
CRD of human, mouse and rat. In addition, Asp260 is also found in H2-CRD of the
same species. In order to evaluate the significance of these residues, they were
replaced by alanines.
Aspartate 259 was also substituted for alanine. The corresponding residue in RHL-1 is a
threonine, which has been shown to contribute to the binding of GalNAc. As the
threonine is predicted to be rather distant from the bound sugar, it is more likely to be
P237
D259
D260
H256
E238
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of structural than functional importance [7]. Investigations to elucidate the role of
aspartate in this position have not been pursued up till now.
The influence of glutamate 238 in H1-CRD has not been previously determined.
Mutagenesis studies have identified the corresponding residue in RHL-1, a glycine, as
an important residue for the selectivity of GalNAc [7]. However, the distinction in
activity between glutamate and glycine has not been established.
Histidine 256 has been revealed to be of crucial importance for the GalNAc selectivity
of H1-CRD [7,49]. In addition, it has also been implicated as an important residue for
the ligand release during endocytosis [96]. Mutagenesis studies have shown that
His256 renders RHL-1 more sensitive to acidic pH and influences the ligand binding in
a pH dependent manner. His256 is thought to act as a hydrogen bond (H-bond)
acceptor for the amide group of asparagine (Asn) 264. Asn264 in turn interacts with the
second calcium binding site and is also involved in the ligand binding. A drop in pH,
as in the endosomes, will cause protonation of the histidine, making it unable to accept
the hydrogen bond from Asn264. As a consequence, Asn264 is destabilized and will
subsequently release the ligand [96,97]. The corresponding residue in H2-CRD is a
glutamate (Glu), and as such it will be deprotonated in the endosomes. Glutamate is
then capable of accepting H-bonds, stabilizing Asn264 and sustaining ligand binding.
In order to confirm this hypothesis, His256 was exchanged for Glu as one of the
binding site mutants created during this work. This subproject will serve two purposes.
For one, it will further facilitate our understanding of the influence of pH on ligand
binding to ASGP-R. Secondly, it also offers an intriguing insight into the differences in
behavior and properties of the two subunits making up the receptor.
1.7.3 Isotope labeling of H1-CRD
The third project within this work has been to establish a method for isotope labeling of
H1-CRD. It is the first step in an endeavor aiming to determine the structure of H1-CRD
by NMR. The crystal structure of H1-CRD has been resolved by X-ray [5]. Still, X-ray
crystallography does not exclude the use of NMR or vice versa. As previously noted,
NMR can further improve the understanding of H1-CRD by studying the protein in
solution. An additional benefit is the possibility to study protein-ligand interactions, and
by doing so determine the mechanism for ligand binding to the receptor subunit.
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A relatively large amount of isotope labeled H1-CRD is required for the NMR studies.
As a general rule of thumb, 2-8 mg protein is needed for structure determination by
NMR [9]. Hence, a reproducible method for high efficiency isotope labeling of H1-
CRD is necessary, ensuring a sufficient supply of protein.
1.7.4 Aim
In summary, in order to further improve the knowledge on H1-CRD, three projects
have been undertaken, all aiming to elucidate the relationship between structural
elements and functional behavior of the subunit. The following goals have been set for
the work:
• To determine the relative importance of disulfide bridge 153-164 and the odd
cysteine 152 for the function of H1-CRD, as well as their involvement in dimer
formation, by use of SDM.
• To investigate the contributions of residues in the binding site of H1-CRD to the
functionality of the subunit using SDM. In addition, the influence of histidine
vs. glutamate, in position 256, on the pH-dependent ligand binding should be
determined.
• To establish a method for high efficiency isotope labeling of H1-CRD
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2 Material and Methods
2.1 Material and reagents
Double-distilled Millipore water was used for the preparation of all buffers and
solutions unless otherwise specified.
E.coli strains DH5α and Top10 were originally from Invitrogen, while AD494(DE3) and
BL21(DE3) originated from Novagen. E.coli XL-Blue 1 was purchased together with the
ExSite PCR-based site-directed mutagenesis kit from Stratagene. Bacterial medium
components such as Bacto-tryptone, Bacto-yeast extract and Bacto-agar were acquired
from Becton Dickinson BD. Ampicillin sodium salt from Applichem, Carbenicillin
disodium salt from Sigma and Kanamycin monosulfate from Fluka was used. IPTG was
from Promega. 15N ammonium chloride (>99%) and 13C-D-Glucose (>98%) were
purchased from Spectra Stable Isotopes. Thiamine hydrochloride and BME vitamins
solution 100X were both purchased from Sigma.
Sepharose® 6B for chromatography was acquired from Sigma. Acrylamide 30%
solution was purchased from Applichem. Sodium dodecylsulfate (SDS) from Biorad,
N,N,N,N,’- Tetra-methylene-diamine (TEMED) from Serva and ammonium persulfate
(APS) >98% for electrophoresis from Sigma was utilized for SDS polyacrylamide gel
electrophoresis (PAGE). Coomassie Brilliant Blue G-250 was purchased from Biorad.
Poinceau S solution and anti-chicken-IgG coupled with alkaline phosphatase (AP) were
both purchased from Sigma. Nitro-blue tetrazoliumchloride, 5-bromo-4-chloro-3-
indolylphosphate toluidine (NBT/BCIP), 67% in DMSO was from Fluka. Protein
standard of bovine serum albumin (BSA) 1 mg/ml and SigmaMarker Low range were
bought from Sigma.
The restriction enzymes Bam H1 and Nde 1 from New England Biolabs (NEB) were
used together with 10X Bam H1 buffer and 100X BSA from the same supplier. λ-DNA
was also acquired from NEB. DNA gel loading buffer 10X was purchased from
Eppendorf. DNA molecular weight marker X and alkaline phosphatase enzyme with a
10X buffer was bought from Roche. The ExSite PCR-based site-directed mutagenesis kit
(including rATP), Pfu turbo polymerase and REDTaq  DNA polymerase were
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purchased from Stratagene. Pfu polymerase and T4 DNA ligase with buffers were
purchased from Promega. A 10 mM stock solution of dNTPs was made from dATP,
dCTP, dGTP and dTTP from Roche. Big dye terminator v1.1. ready reaction kit was
bought from Applied biosystems.
The β -GalNAc-polymer was purchased from Lectinity and streptavidin-peroxidase
came from Roche Applied Sciences. ABTS peroxidase substrate kit was bought from
Biorad. D-Galactose was from Senn Chemicals AG and N-acetyl-D-galactosamine from
Acros.
2.2 Equipment
Incubation of liquid cultures was performed in Innova 4000 incubator Shaker from
New Brunswick Scientific, while bacteria on plate were incubated in an incubator from
Memmert. Bacteria cultures were prepared in a VS 120 AFY laminar flow from Skan.
Cell cultures were centrifuged in a Sorvall RC-5B Refrigerated Superspeed Centrifuge
using a GS 3 Rotor. Cultures of competent cells were harvested in centrifuge 5804R
from Eppendorf. Finally, small culture samples (<2 ml) were centrifuged in Biofuge 13
from Heraeus Sepatech. Cell density was measured with SmartSpec3000
spectrophotometer from Biorad.
Ultrasonication was carried out using a VibraCell sonication apparatus from Biorad
unless otherwise specified. Ultracentrifugation of the protein suspensions during the
purification procedure was done with a centrikon T-1075 centrifuge from Kontron
instruments. ZelluTransRoth 6.0 dialysis tube with a 10 kDa cutoff was purchased from
Roth. The FPLC-system BioLogic duo-flow version 3 and Bio-Scale MT2, MT10, MT20
columns from Biorad were used for affinity chromatography. The second
chromatography system used within this work was the HPLC system Agilent 1100
purification system from Agilent. A Shodex IEC DEAE-825 column from Brechbühler
AG and a C18 column from Vydac were utilized with this system. A mini-Protean 2
system from Biorad was employed for SDS-PAGE. The TransBlot semi-dry transfer cell
used for immunoblotting also came from Biorad. A heatblock of model Thermomixer
comfort from Eppendorf was used for heating and incubation of samples volumes <2
ml. The Spectramax 190 plate reader from Bucher Biotec was employed for absorbance
measurements.
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GFX microprep plasmid kit was purchased from Amersham Biosciences, Qiagen
Plasmid Maxi kit from Qiagen and Perfect Prep Clean-up kit from Eppendorf.
Electroporation was carried out with Gene/E.coli pulser cuvettes and a micropulser
electroporater, both from Biorad. PCR reactions were performed in the iCycler 1.259
thermal cycler from Biorad. Small sample volumes (≤2ml) were centrifuged in a 5415D
centrifuge from Eppendorf, while larger volumes (up to 50 ml) were centrifuged in a
5804R centrifuge also from Eppendorf. Special 96-well plates, Nunc-Immuno Plate
MaxiSorp Surface from Nunc  Brand products were used for the solid phase
competition assay.
2.3 General methods for working with E.coli as expression
system
2.3.1 E.coli strains used for cloning and protein expression
E.coli strains eligible for cloning are strains with background expression kept to a
minimum. Consequently, the stability of the plasmid increases since there is no
production of proteins, which could be of potential harm to the host cell [59].
In this work, E.coli strains DH5α and Top 10 from Invitrogen and XL-Blue 1 from
Stratagene were used for cloning of H1-CRD and mutants. All strains lack the T7 RNA
polymerase gene and have the genotype endA1 recA1, i.e. reduced endonuclease
activity and recombinant deficiency, facilitating plasmid stability.
E.coli strains suitable for protein expression are lysogens of the bacteriophage DE3, i.e.
they contain the gene for T7 RNA polymerase under the control of the lacUV5
promotor. Addition of IPTG will lead to transcription of the T7 gene 1, yielding T7 RNA
polymerase, which in turn will transcribe the target DNA in the plasmid and the protein
is expressed [53].
For expression of H1-CRD, E.coli AD494(DE3) from Novagen was used. The strain
AD494(DE3) holds an advantage as it contains a mutation for the enzyme thioredoxin
reductase (trxB) and thereby promotes formation of disulfide bonds in the E.coli
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cytoplasm. AD494(DE3) cells also harbor an internal resistance to kanamycin at 15
µg/ml.
The E.coli strain BL21(DE3) from Novagen was used for expression of isotope labeled
H1-CRD. It is a general purpose expression host, lacking the proteases lon and ompT,
which can cause degradation of proteins during purification. Due to the protease
deficiency, target proteins should be more stable in BL21(DE3) cells compared to other
expression hosts [59].
2.3.2 Bacterial growth and expression medium
The bacterial growth media and supplements used for the cloning and protein
expression procedures within this work are listed below [88]. All medias, additives and
antibiotics were prepared using Millipore water. Medias were autoclaved at 121°C for
20 minutes prior to use, while the antibiotics, susceptible to heat degradation, were
filter sterilized using a MillexGP 0.22 µm filter (Millipore).
LB medium, 1 liter
Bacto-tryptone 10 g
Bacto-yeast extract 5 g
NaCl 10 g
Adjust pH to 7.5
LB-agar medium, approximately 20 plates
LB medium 500 ml
Bacto-agar 7.5 g
Cool to 50°C before adding antibiotics and pouring plates, ca. 25 ml per plate
TB medium, 1 liter
900 ml:
Bacto-tryptone 12 g
Bacto-yeast extract 24 g
Glycerol 4 ml
100 ml:
KH2PO4 2.31 g
K2HPO4 12.54 g
SOB medium, 1 liter
Bacto-tryptone 20 g
Bacto-yeast extract 5 g
NaCl 0.5 g
KCl 250 mM 10 ml
Add 5 ml 2 M MgCl2 prior to use
39
SOC medium, 1 liter
SOB medium with addition of 20 ml 1 M glucose
Ampicillin 1000X, 5 ml
Ampicillin 0.5 g
Carbenicillin 1000X, 5 ml
Carbenicillin 0.25 g
Kanamycin 1000X, 5 ml
Kanamycin monosulfate 0.075 g
IPTG 0.4 M, 5 ml
IPTG 0.476 g
The bacteria cultures were prepared under sterile conditions in a laminar flow.
Autoclaved Erlenmeyer flasks were used as vessels, filled maximum to half the volume
to allow for good aeration of the bacteria. Typically the cells were grown at 37°C and
300 rpm, varying the choice of medium and the time depending on the purpose of the
culture.
2.3.3 Competent cells
In order to clone and later express H1-CRD, competent E.coli cells of the previously
mentioned strains were prepared. Competence refers to the ability of E.coli cells to take
up foreign DNA, a property the bacteria normally lack, but which the cells can obtain
through special treatments. One can distinguish between electrocompetent and
calciumcompetent cells [66].
2.3.4 Electrocompetent cells
Uptake of free DNA can be induced in electrocompetent cells by subjecting the
bacteria to a high-strength electric field. The mechanism by which the DNA is taken up
into the cells is not fully known. However, it is believed that the electroshock leads to
formation of transient pores in the cell wall, through which the DNA can pass into the
bacteria [66,68].
Electrocompetent cells were made of the bacterial strains E.coli DH5α and Top10.
Non-transformed cells were streaked out on non-selective LB-agar plates and incubated
at 37°C overnight (O/N). A single colony was picked and grown in 5 ml SOB medium
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at 37°C and 300 rpm O/N. The preculture was inoculated into 250 ml SOB medium
with addition of 10 mM MgCl2. The culture was grown at 37°C and 300 rpm until the
cell density reached an OD value of 0.5-0.6. The cells were centrifuged at 5000 rpm
and 4°C for 10 minutes and the pellet resuspended in an equal volume 10% glycerol.
Centrifugation was repeated twice, followed by resuspension in 50 ml and 1 ml of 10%
glycerol respectively. The final cell suspension was aliquoted as 50 µl in Eppendorf
tubes and frozen in liquid nitrogen. The electrocompetent cells were stored at –80°C
[68].
2.3.5 Calciumcompetent cells
An alternative method to induce bacterial uptake of recombinant DNA is the use of
calciumcompetent cells. The cells are initially treated with ice-cold CaCl2 and then
exposed to a high temperature, most often 42°C, for approximately 90 s. The
mechanism of action is not fully known for this procedure either, but it is assumed that
the bacterial cell wall become permeable in localized regions, allowing plasmid DNA
to enter into the cells [66].
Calciumcompetent cells were made of bacterial strains E.coli AD494(DE3) and
BL21(DE3). A single colony of non-transformed bacteria was picked from a freshly
streaked plate and grown in 4 ml LB medium O/N at 37°C and 300 rpm. 1 ml
preculture was inoculated into 100 ml LB medium and the culture grown at 37°C and
300 rpm until a cell density of 0.4-0.5 was reached. The cell culture was placed on ice
for 20 minutes, followed by centrifugation at 5000 rpm and 4°C for 10 minutes. The
cells were resuspended in 10 ml pre-chilled 50 mM CaCl2 and left on ice for 40
minutes. Centrifugation was repeated once and the cells resuspended in 1 ml pre-
chilled 50 mM CaCl2/20% glycerol. The final cell suspension was aliquoted as 80 µl in
Eppendorf tubes and frozen in liquid nitrogen. The calciumcompetent cells were stored
at –80°C [68].
2.4 General methods for working with recombinant DNA
2.4.1 Plasmid
The vector pET-3b from Novagen was used within this work. It belongs to the pET
system, derived from the plasmid pBR322. The pET-3b plasmid is 4639 bp in total with
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a Bam H1 cloning site. It carries the T7 promotor and confers resistance to ampicillin
[98].
2.4.2 Agarose gel electrophoresis analysis
Gel electrophoresis is a commonly used technique to separate DNA fragments as well
as proteins. Samples are loaded onto a gel and an electric field is applied, causing e.g.
the DNA fragments in the samples to migrate through the matrix toward the anode. The
distance and the speed with which the fragments will move is dependent on the size of
the macromolecules and the pore size of the gel [66,68].
Agarose gel electrophoresis was used in this work to analyze isolated plasmids, PCR
products and digested DNA fragments. By varying the percentage of agarose in the gel,
the separation resolution could be influenced. A 1.0% agarose gel was prepared by
dissolving 1.0 g agarose in 100 ml TBE buffer (44.6 mM Tris, 44.6 mM boric acid, 1
mM EDTA) during heating in a microwave. Once completely dissolved, the liquid
agarose was allowed to cool down to approximately 50°C before adding 2 µl ethidium
bromide 1% (w/v) to 80 ml agarose solution. The agarose was poured into an
electrophoresis apparatus and combs forming wells were inserted. Once polymerized,
the combs were removed and the gel covered with TBE buffer. DNA marker X from
Roche was loaded as a reference. The samples were prepared with DNA gel loading
buffer 10X and diluted with water if necessary. The gel electrophoresis was run at 80 V.
2.4.3 Restriction digestion
A prerequisite for recombinant DNA technology is the ability to cut the target DNA and
the cloning vector into precise and reproducible fragments to enable further cloning of
the gene. Restriction endonucleases are enzymes, which possess the capability to
recognize and cut DNA molecules internally at specific base pair sequences, and have
proven to be crucial for molecular cloning [66].
The sequence of H1-CRD, inserted into the cloning region of pET-3b between the Bam
H1 and Nde  1 restriction sites, was kindly provided by Prof. Spiess (Biocenter,
University of Basel, Switzerland). Restriction digestion was carried out according to one
of the following set-ups, the choice depending on the sample volume (Table 1).
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Table 1. Two alternative set-ups were used for the restriction digestion of DNA, the choice depending on
the volume of the sample to be digested. Water was added in an adequate amount to reach the final
volume specified for each set-up.
Digest set-ups Set-up 1 (µl) Set-up 2 (µl)
DNA sample 8-12 30/50
Nde 1 1 2
Bam H1 1 2
10X Bam H1 buffer 2 4/6
BSA 100X (1 mg/ml) 2 -
Water (sterile) q.s. q.s.
Σ 20 40/60
The buffer 10X Bam H1 from NEB was used as both Bam H1 and Nde 1 have been
reported to exhibit 100% activity under these conditions. The samples were prepared
by adding the restriction enzymes last. Digestion was carried out at 37°C in a heatblock
without shaking for 4-5 hours, alternatively O/N for set-up 1.
2.5 Expression, purification and analysis of ASGP-R H1-CRD
2.5.1 Confirming the sequence of H1-CRD DNA
Prior to expression and purification of H1-CRD, the accuracy of the protein encoding
DNA sequence was confirmed. Small-volume cultures consisting of 3 ml LB medium
supplemented with 50 µg/ml carbenicillin and 15 µg/ml kanamycin were inoculated
with E.coli AD494(DE3) cells carrying the construct pET-3bH1. The cultures were
grown O/N at 37°C and 300 rpm. The following day, cells were streaked onto a freshly
prepared LB-ampicillin agar plate and sent to Microsynth for sequencing.
2.5.2 Expression of WT H1-CRD
AD494(DE3)cells, carrying the construct pET3bH1, were grown in 500 ml TB medium
supplemented with 1% glucose, 50 µg/ml carbenicillin and 15 µg/ml kanamycin at 300
rpm and 37°C. The culture was initially inoculated with cells grown O/N under the
same conditions, aiming at an OD of 0.1 to start the growth. Expression was induced at
OD ∼ 0.8 by addition of IPTG to a final concentration of 0.4 mM, and lasted five hours.
Cells were harvested by centrifugation at 4°C and 5000 rpm for 10 minutes. The
supernatant was discarded and the cell pellets stored either at 4°C when followed by
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purification the next day, or at –20°C when purification was carried out two or more
days later.
2.5.3 Material for the purification of WT H1-CRD
The purification procedure of H1-CRD requires material such as dialysis tubes and a
Galactose-Sepharose-column (Gal-Sep-column). These were prepared beforehand as
described in the sections below.
2.5.3.1 Dialysis tubes
Dialysis tubes with a 10 kDa cutoff were prepared from ZelluTransRoth 6.0 dialysis
tube. The tubes, 20 cm long, were gently stirred in 500 ml 10mM NaHCO3 (pH 8), 1
mM EDTA, preheated to 80°C, during 30 minutes. The buffer was exchanged with
water, decreasing the temperature stepwise to 60°C, 40°C and 25°C every 10th minute.
The tubes were transferred into 1 mM EDTA and stored at 4°C [99].
2.5.3.2 Preparation of a Galactose-Sepharose column
40 ml Sepharose 6B was divided into two Falcon tubes and washed with water by
centrifugation at 3000 rpm for 5 minutes three times. 20 ml 0.5 M carbonatbuffer (pH
11) and 2 ml divinylsulfon was added to each tube, which was subsequently incubated
for 1 hour at room temperature (RT) during light shaking. The sepharose was rinsed
with water by filtration and divided into new tubes in equal amounts. 20 ml 20% D-
galactose in 0.5 M carbonatbuffer (pH 10) was added to each tube and thoroughly
mixed with the sepharose prior to incubation at RT under light shaking O/N. The
sepharose was centrifuged at 3000 rpm for 5 minutes and washed once with water as
described above. 20 ml 0.5 M carbonatbuffer (pH 8.5) and 400 µ l beta-
mercaptoethanol was added to each tube, followed by incubation for 2 hours at RT
under light shaking. The sepharose was centrifuged at 3000 rpm for 5 minutes and
washed with water twice as previously described. Finally the sepharose was added
stepwise to the column, allowing the slurry to settle and ensure proper packing up to
the top, before the column was fully assembled and closed (Fornstedtetal1975). Sterile
filtered water was run through the column at a flow rate of 2 ml/min for a minimum of
40 minutes, before switching to 20% methanol, using the same settings. The column
was stored in 20% methanol at 4°C [100].
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2.5.4 Solubilization and renaturation of WT H1-CRD
A cell pellet originating from 500 ml expression culture was resuspended in 25 ml 20
mM Tris-HCl (pH 8) with addition of 8 M urea and 0.1‰ beta-mercaptoethanol.
Complete cell lysis was achieved by ultrasonication on ice, in intervals of 20 seconds
sonication and 10 seconds stop, for a total of 30 minutes. The protein suspension was
centrifuged at 4°C and 19000 rpm for 20 minutes to separate soluble proteins and cell
debris. The supernatant containing solubilized proteins was collected and stored on
ice. The cell debris pellet was resuspended once more in 5 ml 20 mM Tris-HCl (pH 8)
with addition of 8 M urea and 0.1‰ beta-mercaptoethanol, followed by 4 minutes
ultrasonication and centrifugation as described above. The two supernatants were
combined and 20 mM Tris-HCl (pH 8) added to reach a final volume of 50 ml with
addition of 0.5 M NaCl, 25 mM CaCl2 and 0.3‰ beta-mercaptoethanol. The protein
suspension was incubated 1 hour on ice under light shaking followed by dilution with
25 ml 20mM Tris-HCl (pH 8), 0.5 M NaCl, 25 mM CaCl2 and centrifugation at 4°C and
22000 rpm for 20 minutes. The supernatant was collected and partitioned into three
dialysis tubes holding 25 ml protein suspension each. The dialysis tubes were
immersed in 400 ml precooled (4°C) dialysis buffer, 20 mM Tris-HCl (pH 7.5), 0.5 M
NaCl, 25 mM CaCl2, and allowed to equilibrate for 8-12 hours under light stirring. Five
buffer changes were made in total, each step lasting 8-12 hours, to ensure complete
refolding. The dialyzed protein solution was centrifuged at 4°C and 22000 rpm for 1
hour to remove any precipitate prior to purification by affinity chromatography.
2.5.5 Purification by FPLC affinity chromatography
Affinity chromatography was used to purify H1-CRD on an FPLC-system, as described
below (Table 2). The dialyzed protein solution was loaded onto a 10 ml Galactose-
Sepharose column, followed by washing with 20 mM Tris-HCl (pH 7.8), 0.5 M NaCl,
25 mM CaCl2 to remove non-bound proteins. Elution of H1-CRD was carried out with
20 mM Tris-HCl (pH 7.8), 0.5 M NaCl, 2 mM EDTA containing buffer. The
chromatography was monitored at 280 nm.
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Table 2. FPLC program for the purification of WT H1-CRD by affinity chromatography.
Step Volume (ml) Flow rate (ml/min)
Load 100-200 1
Wash 25 1
Elution 30 1
Wash 2 5 2
Eluted fractions were stored at 4°C. The column was rinsed with water, before storage
in 20% methanol at 4°C.
2.5.6 Protein analysis by SDS-PAGE
Protein samples, both after expression and purification as well as final products, were
analyzed by SDS-PAGE electrophoresis according to the procedure by Laemmli [101].
SDS renders the proteins denatured and uniformly negatively charged. Similar to
agarose gel electrophoresis, the proteins in a sample will migrate with different speed
through the polyacrylamide gel towards the anode based on their size [102].
As the expected molecular mass of H1-CRD is 17 kDa, a 15% separating gel was
prepared together with a stacking gel according to the set-up in table 3.
Table 3. Composition of a separating gel with 15% polyacrylamide and a stacking gel as used for SDS-
PAGE analysis of H1-CRD.
Substance Separating gel 15% Stacking gel
Acrylamide solution 30% 7.5 ml 1.7 ml
Water 4.3 ml 7.2 ml
Separating buffer 3.0 ml -
Stacking buffer - 1.0 ml
SDS 10% 150 µl 100 µl
TEMED 7.5 µl 10 µl
APS 40% 50 µl 33 µl
The compositions of the buffers used for SDS-PAGE are listed in table 4.
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Table 4. Compositions of the buffers used for SDS-PAGE analysis.
Buffers Composition
Separating buffer 1.9 Tris-HCl (pH 8.8)
Stacking buffer 1.25 M Tris-HCl (pH 6.8)
Running buffer 10X 0.25 M Tris-HCl (pH 8.3), 2 M glycine,
1% SDS
SDS-PAGE sample buffer 5X
- non-reducing
200 mM Tris-HCl (pH 6.8), 37.5%
glycerol, 5% SDS, bromphenol blue
SDS-PAGE sample buffer 5X
- reducing
200 mM Tris-HCl (pH 6.8), 37.5%
glycerol, 5% SDS, bromphenol blue, 2 M
beta-mercaptoethanol
The SDS-PAGE was run at 30 mA per gel during the stacking gel and 40 mA per gel
during the separating gel. For visualization, the gels were stained either with Coomassie
staining or silver staining.
2.5.6.1 Silver staining
Silver staining can detect proteins in the nanogram range [103]. It is the method of
choice whenever high staining sensitivity is desirable. SDS-PAGE gels were stained
with a silver staining kit from Amersham Biosciences, Pharmacia, according to the
supplier’s protocol.
2.5.6.2 Coomassie staining
Gels stained by Coomassie were initially incubated in a fixation solution containing
20% EtOH and 5% glacial acetic acid in water for 20 minutes under light shaking. The
gels were washed with water 3x5 minutes before transfer to Enhanced Coomassie
solution (0.02% Coomassie Brilliant Blue G-250, 2% phosphoric acid, 5% aluminum
sulfate, 10% ethanol) for a minimum of 2 hours [104]. Destaining was done with water
until desired contrast was reached.
2.5.7 Western Blot analysis
Western blot analysis [102] was used to confirm the identity of H1-CRD in protein
samples after FPLC affinity chromatography and HPLC chromatography.
18 Whatman papers, typically of size 6x8.5 cm, were incubated as 6, 3 and 9 sheets in
anode buffer I, anode buffer II and cathode buffer respectively for 5 minutes. For buffer
compositions see table 5.
47
Table 5. Composition of the buffers used for Western Blot.
Buffers Composition
Anode buffer I 300 mM Tris, 20% Methanol
Anode buffer II 25 mM Tris, 20% Methanol
Cathode buffer 40 mM Aminocaproic acid, 20%
Methanol
Blocking buffer 20 mM Tris-HCl (pH 7.5), 500 mM NaCl,
4% non-dried milk powder
TTBS 20 mM Tris-HCl (pH 7.5), 500 mM NaCl,
0.05% Tween-20)
TBS 20 mM Tris-HCl (pH 7.5), 500 mM NaCl
Substrate solution 100 mM Tris-HCl (pH 8.8), 100 mM NaCl,
5 mM MgCl2
A nitrocellulose membrane of the corresponding size was incubated 2 minutes in water
followed by 5 minutes in anode buffer II. Finally, the gel was put in cathode buffer for 5
minutes. The protein transfer was accomplished by using TransBlot semi-dry transfer
cell, stacking the papers on top of the anode in the following order: 6 sheets from
anode buffer I, 3 sheets from anode buffer II, the nitrocellulose membrane, the gel and
on the very top 9 sheets from cathode buffer. Immunoblotting was done at 14V for 1
hour.
The membrane was reversibly stained with poinceau S solution 0.1% for 3-5 minutes to
confirm that the transfer had been successful. The molecular weight marker bands were
marked with a pencil and the membrane was washed with water. The membrane was
further incubated with blocking buffer at 4°C O/N. The following day, the membrane
was washed 3x5 minutes with TTBS, followed by incubation with a primary antibody
(polyclonal anti-H1-CRD-IgY produced in chicken [94] and diluted 1/5000 in blocking
buffer) during light shaking at RT for 2 hours. Washing was repeated prior to incubation
with the second antibody (polyvalent anti-chicken-IgG-AP produced in rabbit and
diluted 1/5000 in blocking buffer) at RT for 2 hours. The membrane was washed twice
with TTBS and once with TBS. 15 ml substrate solution supplemented with 0.4%
NBT/BCIP was added for incubation under light shaking. Once bands became visible,
developing was stopped by addition of water.
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2.5.8 Separation of monomer and dimers by HPLC ion exchange
chromatography
All buffers used for HPLC chromatography were prepared with gradient-grade water G
chromasolv from Sigma.
Ion exchange chromatography was used to separate monomers and dimers of H1-CRD
on a HPLC system. A DEAE column, a weak positively charged anion exchanger, was
employed for the separation. The column was preconditioned with running buffer A
and B, containing 25 mM Tris-HCl (pH 8) and 25 mM Tris-HCl  (pH 8), 250 mM CaCl2
respectively. The buffers were run at 0.5 ml/min in a ratio of 85:15 (DR-thesis).
In theory, separation of monomers and dimers is achieved by slowly increasing the
percentage of running buffer B. By changing the gradient, the concentration of CaCl2
increases, gradually displacing the proteins from the column [105]. Monomers, which
are less charged than the dimers, will elute at a lower CaCl2 concentration. Therefore,
an initially low salt content of the samples is crucial as the elution is ion concentration
dependent. Since the H1-CRD samples contained a high salt molarity (500 mM NaCl)
as a result of previous purification steps, a buffer change was necessary prior to IEC
separation. Desalting was accomplished by loading 1.5 ml sample onto a HiTrap
desalting column followed by elution with 2 ml running buffer A.
The protein samples were injected, typically 1400 µl at a time, on the DEAE column
and separation carried out according to the program below (Table 6).
Table 6. Program for the separation of monomers and dimer by HPLC IEC.
Time (min) % buffer B
2 15
25 40
27 40
29 15
32 Stop
Peaks were detected at 280 nm and collected for further analysis. While the column
was kept at 20°C, both samples and collected fractions were stored at 5°C during the
run.
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2.5.9 Separation of monomers and dimers by HPLC reversed phase
chromatography
An alternative method used to separate monomers and dimers of H1-CRD, developed
by Dr. Said Rabbani at IMP, was HPLC reversed phase chromatography (RP). A C18-
column was employed and run at 1 ml/min with a solvent gradient of 0.01 M TFA in
water and acetonitrile respectively. Samples were loaded onto the column and eluted
by increasing the acetonitrile proportion from 25% to 38% during 10 minutes. The
acteonitrile was kept constant for an additional 10 minutes and then reduced again to
25% during 5 minutes. Collected fractions were frozen in liquid nitrogen and
lyophilized. The column was washed and stored in water/acetonitrile 50/50.
2.5.10 Purification by HPLC affinity chromatography
Monomers purified by HPLC IEC were further run on a 2 ml GalNAc-Sep column (Bio-
scale MT2 column) on HPLC, both to reconfirm the binding activity of the protein and
to concentrate the samples. The column was preconditioned with running buffer
containing 10 mM HEPES (pH 7.4), 10 mM CaCl2 and kept at a constant flow-rate of 1
ml/min. The samples were loaded onto the column by repeated injections of 1400 µl,
and eluted with 10 mM HEPES (pH 7.4), 2 mM EDTA, see program in table 7.
Table 7.  Program used for final purification and pooling of H1-CRD monomers by HPLC affinity
chromatography.
Time (min) % buffer B
2 0
12 100
14 100
15 0
25 Stop
Peaks were detected at 280 nm and collected fractions stored at 5°C for further
analysis.
2.5.11 Concentration determination by the Bradford assay
The Bradford assay was employed to measure the concentration of final protein
samples [106]. A standard curve was established by using a dilution series of protein
standard BSA, ranging from 100 ng/µl to 1000 ng/µl. The concentration of unknown
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protein samples was then determined from the standard curve based on measured
absorbance intensity.
A 96-well microplate was loaded with 200 µl Bradford dye per well. 10 µl protein
solution was added to each well and mixed by gently tapping the plate. Standard
solutions of BSA were added as triplicates and unknown samples as quadruplicates.
The plate was incubated at RT for 5 minutes and the absorbance was measured at 595
nm. Final protein samples were stored at –20°C after determining the concentration.
2.6 Cloning, expression and characterization of mutants of
H1-CRD
Site-directed mutagenesis can be performed with template DNA either in the form of an
isolated DNA fragment or with the target sequence present in a plasmid. Template
DNA isolated from cloning strains of E.coli shows higher quantities and quality when
compared to DNA isolated from expression strains. [59,66] The construct pET-3bH1,
carrying the sequence for WT H1-CRD, was therefore to be isolated from AD494(DE3)
cells and transformed into a cloning strain prior to the planned mutagenesis studies.
2.6.1 Isolation of pET-3bH1
The plasmid pET-3bH1 was isolated from AD494(DE3) cells after confirmation that the
DNA sequence encoding H1-CRD was correct. Plasmid isolation was carried out by
alkaline lysis using the GFX microprep plasmid kit (Amersham Biosciences). 1.5 ml
O/N cultures were processed according to the manufacturer’s protocol with one
exception, i.e. the final elution of the miniprep was done in 50 µl instead of the
recommended 100µl, in order to obtain samples of higher concentration. The isolated
DNA was analyzed by agarose gel electrophoresis, prior to transformation into cloning
strains of E.coli.
2.6.2 Preparation of template H1-CRD DNA
The plasmid pET-3bH1 was transformed into calciumcompetent DH5α and Top10
cells, as well as electrocompetent DH5α cells.
Transformation of the calciumcompetent cells was induced by heat shock. An aliquot
of 80 µl DH5α or Top10 cells was thawed on ice and 1.5 µl DNA was added. The cells
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were incubated on ice for 30 minutes, followed by a heat shock at 42°C in a
thermoblock for 90 seconds. The cells were placed on ice for another 2 minutes. LB
medium was added to a total volume of 1 ml and the cell suspension was incubated at
37°C and 550 rpm for 1 hour. The cells were centrifuged at 15000 rpm for 1 minute,
resuspended in 100 µl LB medium and plated on a LB-ampicillin agar plate. The plate
was incubated at 37°C O/N.
Electroporation was carried out with 50 µl DH5α cells. The cells were transferred to a
pre-chilled electroporation cuvette and 1.5 µl DNA added. The cuvette was placed in
an electroporater with the settings 400 Ω , 1.75 kV and 25 µF. Following the
electroporation, the cells were immediately mixed with 950 µl SOC medium and
transferred to an Eppendorf tube. The cell suspension was incubated at 37°C and 550
rpm for 1 hour. 300 µl cell suspension was plated on a LB-ampicillin agar plate and
incubated at 37°C O/N.
In order to obtain sufficient amounts of DNA template, plasmid isolation using both
miniprep and maxiprep kits was performed.
Cultures consisting of 3 ml LB medium supplemented with 100 µg/ml ampicillin were
inoculated with a single colony of the transformed DH5α or Top10 cells. The cells
were grown at 37°C and 300 rpm for approximately 8 hours, followed by plasmid
isolation using GFX microprep plasmid kit. 1.5 ml of each culture was processed
according to the manufacturer’s protocol, with the final elution in 70 µl. The miniprep
samples were stored at –20°C.
Plasmid purification was also carried out using the Qiagen Plasmid Maxi kit. A 3 ml LB
medium culture, supplemented with 100 µg/ml ampicillin, was inoculated with a single
colony of transformed DH5α cells. The culture was incubated at 37°C and 300 rpm.
After 8 hours the starter culture was diluted 1/100 into 100 ml selective LB medium
and grown at 37°C and 300 rpm O/N. The cells were harvested by centrifugation at
4°C and 5500 rpm for 20 minutes. Plasmid isolation and purification was done
according to the manufacturer’s protocol using a QIAGEN-tip 500. The final DNA
pellet was resuspended in 500 µl TE buffer consisting of 10 mM Tris-HCl (pH 8), 1 mM
EDTA and stored at –20°C.
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In order to confirm the presence of the H1-CRD sequence in the isolated plasmids,
both the miniprep and maxiprep samples were digested with the restriction enzymes
Bam H1 and Nde 1 O/N. Restriction digestion was done according to set-up 1 (see
section 2.4.3) with 12 µl miniprep and maxiprep sample respectively.
2.6.3 Quantification of DNA
The concentration of the isolated DNA was determined by agarose gel electrophoresis.
A dilution series of known concentrations λ-DNA, ranging from 2.5 ng to maximum
600 ng, was prepared and loaded onto the gel together with the plasmid DNA. The gel
was run at 80 V.
Quantification of the DNA was done partly by independent estimates, partly by using
the software Quantity One from Biorad Laboratories, Inc. A calibration curve was
established based on the λ-DNA series, and the concentration of the unknown samples
calculated based on the standard curve.
2.6.4 Preparing plasmid pET-3b
The plasmid pET-3b was to be used for down-stream applications and therefore had to
be prepared without insert(s). 50 µl pET-3bH1 isolated from DH5α-cells was digested
with Bam H1 and Nde 1 according to set-up 2 (see section 2.4.3). To avoid self-
ligation, the digested vector was dephosphorylated according to the set-up below, see
table 8.
Table 8. Set-up for the dephosphorylation of a digested vector.
Substance Volume (µl)
Digested vector sample 60
Alkaline phosphatase enzyme 1.5
Alkaline phosphatase buffer 10X 1.5
Water (sterile) 7
Σ 70
Dephosphorylation was carried out at 37°C for 60 minutes, followed by incubation at
65°C for 10 minutes to deactivate the enzyme. The vector was loaded onto a 1.25%
agarose gel for isolation and purification using the Perfect Prep Clean-up kit from
Eppendorf.
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2.7 Site-directed mutagenesis
Three different methods were employed to create point mutations in H1-CRD;
conventional PCR with mutagenic primers, overlap extension PCR and ExSite PCR-
based site-directed mutagenesis system. The choice of method was ultimately
dependent on the location of the desired mutation in the template DNA sequence.
Point mutations residing within 10 amino acids from either end of the sequence were
attempted by conventional PCR with mutagenic primers, while overlap extension PCR
was used for mutations further into the sequence. ExSite PCR-based site-directed
mutagenesis system, a commercial kit available from Stratagene, could be used
regardless of the position of the mutations.
2.7.1 Primers
Primers were designed according to the guidelines for each specific method. A
requirement for the ExSite PCR-based mutagenesis system was the phosphorylation of
one primer in a pair [107]. The primers used within this work for site-directed
mutagenesis are summarized in table 9 below, with sequence and melting
temperatures (Tm) specified. The mutations are highlighted with bold capitals in the
sequences.
Table 9. Summary of the primers used in mutagenesis reactions of H1-CRD. The given names are specified
along with the primer sequences, the method for which they were designed and utilized, as well as the
melting temperatures as calculated by the manufacturer.
Name Primer sequence Method Tm
H1-CRD FW 5’- GGA ATT CCA TAT GGG
CTC AGA AAG GAC CTG CTG
–3’
Amplification 66.1°C
H1-CRD RW 5’- CGC GGA TCC TTA TTA
AAG GAG AGG TGG CTC
CTG GCT -3’
Amplification 69.0°C
H1-CRD mut 152 FW 5’- GGA ATT CCA TAT GGG
CTC AGA AAG GAC CTC CTG
CCC G -3’
PCR wi th
mut. primers
69.8°C
H1-CRD mut 153 FW 5’- GGA ATT CCA TAT GGG
CTC AGA AAG GAC CTG CTC
CCC G -3’
PCR wi th
mut. primers
69.8°C
H1-CRD mut 152/153
FW
5’- GGA ATT CCA TAT GGG
CTC AGA AAG GAC CTC CTC
CCC G -3’
PCR wi th
mut. primers
69.8°C
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H1-CRD mut 164 FW 5’- GAC CGC AGC TCC TAC
TGG TTC –3’
OE-PCR 61.5°C
H1-CRD mut 164 RW 5’- GAA CCA GTA GGA GCT
GCG CTC -3’
OE-PCR 61.5°C
H1-CRD mut 237 FW 5’- AAC TGG AGG GCG GAG
CAG CCG –3’
OE-PCR 65.2°C
H1-CRD mut 237 RW 5’- CGG CTG CTC CGC CCT
CCA GTT –3’
OE-PCR 65.2°C
H1-CRD mut 238 FW 5’- TGG AGG CCG GGG CAG
CCG GAC - 3’
OE-PCR 69.3°C
H1-CRD mut 238 RW 5’- GTC CGG CTG CCC CGG
CCT CCA -3’
OE-PCR 69.3°C
H1-CRD mut 256 FW 5’- GAC TGT GCC GAG TTC
ACC GAC -3’
OE-PCR 61.5°C
H1-CRD mut 256 RW 5’- GTC GGT GAA CTC GGC
ACA GTC -3’
OE-PCR 61.5°C
H1-CRD mut 259 FW 5’- CAC TTC ACC GCC GAC
GGC CGC -3’
OE-PCR 67.3°C
H1-CRD mut 259 RW 5’- GCG GCC GTC GGC GGT
GAA GTG -3’
OE-PCR 67.3°C
H1-CRD mut 260 FW 5’-  TTC ACC GAC GCC GGC
CGC TGG -3’
OE-PCR 67.3°C
H1-CRD mut 260 RW 5’- CCA GCG GCC GGC GTC
GGT GAA -3’
OE-PCR 67.3°C
H1-CRD mut 152/153
1/1
5’- TCC TCC CCG GTC AAC
TGG GTG -3’
ExSite 63.6°C
H1-CRD mut 152/153
1/2
5’- GGT CCT TTC TGA GCC
CAT ATG -3’
ExSite 57.4°C
All primers were ordered from and synthesized by Microsynth. Prior to use, the
lyophilized primers were dissolved in sterilized water to make stock solutions of 200
µM. The primers were briefly vortexed and incubated at 65°C for 5 minutes. Working
solutions were prepared by diluting the stock solutions 1/10 with sterile water. All
primers were stored at –20°C.
2.7.2 ExSite PCR-based site-directed mutagenesis system
The ExSite system can be used to introduce site-specific mutations at any position in
double-stranded DNA [107]. Starting with plasmid DNA, the mutation(s) is introduced
by a mutagenic primer simultaneously with amplification of the complimentary strand
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by a reverse primer. ExSite utilizes a DNA polymerase blend consisting of both Taq and
Pfu polymerase, increasing both the efficiency and reliability of the transcription. After
completion of the PCR reaction two plasmid populations exist, the parental template
plasmids and the produced linear DNA carrying the desired mutation. The restriction
enzyme Dpn 1 is added, causing digestion of all methylated parental plasmids, leaving
only the mutated DNA intact. The latter is polished with Pfu DNA polymerase and
recircularized by T4 DNA ligase prior to transformation into competent E.coli cells
[107].
The mutagenesis reaction was carried out in accordance with the producer’s protocol
and the supplied reagents. Different reaction set-ups were tested to define the optimal
conditions. Primer H1-CRD mut 152/153 1/1, carrying the mutations C152S/C153S,
was used together with primer H1-CRD mut 152/153 1/2 (see table 9). The reaction set-
ups, which were tried, are summarized in table 10.
Table 10. Different set-ups attempted for mutation C152/153S using the ExSite PCR-based site-directed
mutagenesis system.
Component Reaction A Reaction B Reaction C Reaction D
Template 1.68 µg 1.68 ng 16.8 ng 16.8 ng
Primer 1 15 pmol/95 ng 15 pmol/95 ng 15 pmol/95 ng 19 pmol/120 ng
Primer 2 15 pmol/95 ng 15 pmol/95 ng 15 pmol/95 ng 19 pmol/120 ng
dNTP (25 mM) 1 µl 1 µl 1 µl 1 µl
10X mutagenesis
buffer
2.5 µl 2.5 µl 2.5 µl 5 µl
DNA polymerase
blend
1 µl 1 µl - -
Pfu turbo
polymerase
- - 1 µl 1 µl
Water (sterile) q.s. q.s. q.s. q.s.
Σ 25 µl 25 µl 25 µl 50 µl
Reaction A is based on the recommendations for the ExSite system, differing from
reaction B only in the amount of template used. Reaction C and D utilize Pfu turbo
polymerase and differ in primer concentration.
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The maxiprep DNA sample, purified from DH5α cells, was used as template. The
reaction samples were prepared on ice, adding the polymerase last. PCR was run
according to the program in table 11.
Table 11. PCR program when using the ExSite PCR-based site-directed mutagenesis system. Reaction A
and B were run with the first alternative times specified at 72°C, and reaction C and D with the second
option.
Step Cycles Temperature Time
94°C 4 min
55°C 2 minDenaturation 1x
72°C 11/6 min
94°C 1 min
57°C 2 minAnnealing 12x
72°C 5.5/6 min
72°C 5/10 min
Elongation 1x
4°C ∞
Reaction A and B were digested and polished by 1 µl Dpn 1 and 0.5 µl Pfu respectively
at 37°C during 1 hour followed by incubation at 72°C for an additional 30 minutes.
The DNA samples were diluted with water, 10X mutagenesis buffer and rATP
according to the protocol prior to ligation of 10 µl sample and 1 µl T4 DNA ligase at
37°C for 1 hour. Small samples were taken from the reactions for subsequent agarose
gel electrophoresis after completing the PCR reaction, digestion and dilution to analyze
the integrity of the DNA product throughout the mutagenesis procedure. Finally, an 80
µl aliquot of XL1-Blue supercompetent cells was incubated with 2 µl ligation product
on ice for 30 minutes. Transformation was carried out through heat pulse at 42°C for
60 seconds and the cells were plated on selective LB-ampicillin agar plates. Plates were
then incubated at 37°C O/N.
In contrast, digestion of reaction C and D was carried out at 37°C for 3 hours before the
samples were cooled to 4°C. The incubation time was prolonged to ensure that all
parental plasmids were fully digested. No additional Pfu was added to reaction C and
D, as the PCR was carried out exclusively with Pfu Turbo polymerase from the start. In
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order to reduce the risk of contaminants interfering with downstream applications, the
digested DNA was purified with the Perfectprep Gel CleanUp sample kit from
Eppendorf following the manufacturer’s protocol. Dilution of the samples, ligation and
transformation was carried out according to the same procedures as applied for
reaction A and B.
Single clones were randomly picked from the selective plates and grown in 3 ml LB
cultures supplemented with 100 µg/ml ampicillin at 37°C and 300 rpm O/N. Plasmid
purification was carried out on 1.5 ml from each culture using the GFX micro plasmid
prep kit from Amersham Biosciences. The DNA was eluted in a final volume of 80 µl to
achieve maximal recovery with high end-concentration. All samples were digested
with the restriction enzymes Bam H1 and Nde 1 to verify the presence of H1-CRD in
the isolated plasmid. Cultures of positive clones were re-streaked on plates and sent to
Microsynth for sequencing.
2.7.3 Conventional PCR with mutagenic primers
Mutations residing within 10 amino acids from either end of the H1-CRD sequence
were created by conventional PCR, each reaction consisting of one mutagenic primer
and one reverse fully complimentary primer, i.e. H1-CRD RW in this case.
REDTaq  DNA polymerase was initially used to optimize the PCR conditions in
respect to template amount, primer and dNTP concentration, as well as optimal
annealing temperature for the primers. While Taq polymerase is useful for screening of
settings due to it’s high extension rate, the high-fidelity Pfu polymerase is better suited
for PCR reactions where the products are to be used in downstream applications. The
PCR conditions optimized with REDTaq DNA polymerase were used together with
Pfu DNA polymerase to generate the mutated DNA sequence. The PCR reaction set-up,
using either REDTaq or Pfu DNA polymerase, can be seen in table 12. A negative
control was also included in the PCR run, exchanging the template for sterile water.
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Table 12. PCR reaction set-ups used for mutations attempted by conventional PCR. REDTaq DNA
polymerase was initially used to screen for optimized reaction conditions.
PCR reaction set-up REDTaq DNA polymerase Pfu DNA polymerase
Template (0.8 ng) 1 µl 1 µl
Primer 5’ (20 µM) 1 µl 1 µl
Primer 3’ (20 µM) 1 µl 1 µl
dNTP (10 mM) 1 µl 1 µl
10X polymerase buffer 5 µl 5 µl
RedTaq DNA polymerase 2.5 µl -
Pfu DNA polymerase - 1 µl
H20 (sterile) 38.5 µl 40 µl
Σ 50 µl 50 µl
The samples were prepared on ice and the DNA polymerase added last. The PCR was
run as described in table 13.
Table 13. PCR program for mutations created by conventional PCR.
Step Cycles Temperature Time
Denaturation 1x 95°C 3 min
95°C 1 min
Optimized Atemp 1 minAnnealing 30x
72°C 2 min
72°C 10 min
Elongation 1x
4°C ∞
The final PCR products were analyzed by agarose gel electrophoresis to confirm the
purity as well as size of the DNA fragments. Typically, two PCR reactions run under the
same conditions, showing the same results, were pooled and purified with the
GenElute PCR Clean-Up kit from Sigma, to obtain samples with high end-
concentration. The purified DNA was digested with Bam H1 and Nde 1 according to
set-up 2 (see section 2.4.3) at 37°C for 4 hours. Next, the digested DNA was loaded
onto a 1.25% agarose gel as one sample and run at 80 V for approximately 30-60
minutes. The gel was quickly observed under UV-light and the desired band excised,
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followed by purification using the Perfect Prep Cleanup kit. Final elution was done with
30 µl elution buffer. Ligation was carried out as described in section 2.7.5.
2.7.4 Overlap extension PCR
Overlap extension PCR was attempted when the desired mutation(s) was located more
than 60-70 nucleotides from either end of the H1-CRD sequence. In a first step, two
similar reactions were run, differing only in the primer combination. In reaction A, the
flanking primer H1-CRD FW was paired with e.g. the internal primer H1-CRD mut 164
RW, while reaction B combined flanking primer H1-CRD RW and e.g. internal primer
H1-CRD mut 164 FW. REDTaq DNA polymerase was initially used to optimize the
PCR conditions, as described above for conventional PCR with mutagenic primers (see
section 2.7.3). Once the optimal PCR settings were determined, the reactions were
carried out in duplicates with Pfu DNA polymerase. The DNA products were analyzed
by agarose gel electrophoresis to confirm the success of the reactions. The fragments
were further isolated and purified from a preparative agarose gel, using the Perfect Prep
Clean-up kit. Final elution was done in 30 µl elution buffer.
In a second step, the two fragments were combined for the overlap extension PCR.
Typically, a temperature gradient PCR reaction screening for the optimal annealing
temperature was first performed. Simultaneously, the concentration of the fragments as
well as the time point of primer addition was investigated. Three alternatives for primer
addition were studied; addition from the start of the reaction, after 10 cycles and in a
separate PCR reaction after completing the extension step. The reaction was set up
according to table 14.
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Table 14. Reaction set-up for the second step of overlap extension PCR. The dilution and amount of each
fragment had to be determined individually based on the yields of the first reaction.
PCR set-up Volume
Fragment A – dilution 1/X 1-5 µl
Fragment B – dilution 1/X 1-5 µl
5’ primer (20 µM) 1 µl
3’ primer (20 µM) 1 µl
dNTP (10 mM) 1 µl
10X polymerase buffer 5 µl
Pfu DNA polymerase 1 µl
Water (sterile) 37 µl
Σ 50 µl
The samples were prepared on ice and the Pfu polymerase added last. The PCR was
run as described in table 15.
Table 15.  Program for mutations created by overlap extension PCR.
Step Cycles Temperature Time
Denaturation 1x 95°C 3 min
95°C 1 min
Optimized Atemp 1 minAnnealing 30x
72°C 2 min
72°C 10 min
Elongation 1x
4°C ∞
Aliquots of the resulting PCR products were analyzed by agarose gel electrophoresis
prior to purification of remaining products by the Perfect Prep Clean-Up kit without first
isolating the DNA from an agarose gel. Final elution was done with 30 µl elution
buffer. The purified DNA was digested with Bam H1 and Nde 1 according to set-up 2
(see section 2.4.3) at 37°C for 4 hours. Following digestion, the mutated H1-CRD
sequence was isolated and purified using agarose gel electrophoresis and the Perfect
Prep Clean-Up kit. Final elution was done with 30 µl elution buffer.
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2.7.5 Ligation
Ligation was carried out with the digested and purified insert, using two different set-
ups, see table 16. The samples were prepared by adding the T4 DNA ligase last.
Table 16. Two alternative ligation reaction set-ups used in parallel.
Ligation set-up Set- up I Set-up II
Insert 2 µl 2 µl
Vector 2 µl 1 µl
T4 DNA ligase 1 µl 1 µl
10X ligase buffer 2 µl 1 µl
rATP (10 mM) 2 µl 1 µl
Water (sterile) 11 µl 4 µl
Σ 20 µl 10 µl
The reaction tubes were placed in a RT-water bath and incubated at 4°C O/N. The
optimal temperature for ligation is a balance between the optimal temperature for T4
DNA ligase enzyme activity and the temperature necessary to ensure annealing of the
fragment ends. By placing the reaction tubes in RT-water at 4°C, a range of
temperatures will be covered, passing the optimal temperature for the enzyme [108].
2.7.6 Transformation by electroporation
Prior to transformation of electrocompetent DH5α-cells, the ligated DNA samples were
desalted by dialysis. A petri dish was filled with sterile water and a Millipore
nitrocellulose 0.025 µm filter (Millipore) placed on the water surface. The ligation
samples were positioned as individual drops on the filter and left at RT for 45 minutes.
After dialysis, the samples were collected for electroporation.
Electroporation was performed with 50 µl electrocompetent DH5α cells and 5 µl of
each ligation sample. The procedure was carried out as described in section 2.6.2,
using the same electroporation and incubation settings. Following incubation, 300 µl of
each cell suspension was plated on a LB-ampicillin agar plate. The plates were
incubated at 37°C O/N.
O/N-cultures, 3 ml LB medium with 100 µg/ml ampicillin, were inoculated with
transformed DH5α cells and grown at 37°C and 300 rpm O/N. Plasmid purification
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was carried out on 1.5 ml from each culture using the GFX micro plasmid prep kit. The
DNA was eluted in a final volume of 80 µl and stored at –20°C. Aliquots of the
miniprep samples were digested with the restriction enzymes Bam H1 and Nde 1 to
verify the presence of H1-CRD using set-up 1 (see section 2.4.3). Cultures of positive
clones were either re-streaked on plates and sent to Microsynth for sequencing, or sent
to the in-house sequencing facility.
2.7.7 Big dye 1.1 terminator sequencing
Prior to in-house sequencing, samples were prepared by amplification of the template
DNA with Big dye 1.1 [109] and subsequent precipitation and purification. For this
purpose, primers encoding either the T7 promotor or the T7 terminator sequence were
used. The primers were synthesized by Microsynth and stock solutions prepared as
described in section 2.7.1.
T7 promotor primer: 5’- TAA TAC GAC TCA CTA TAG G -3’  Tm 48.8°C
T7 terminator primer: 5’- TAT GCT AGT TAT TGC TCA G -3’ Tm 48.8°C
The PCR reaction was set up as outlined in table 17.
Table 17. Reaction set-up for labeling of samples prior to sequencing.
Sequencing PCR set-up Volume
Template (miniprep sample) 5 µl
T7 promotor or T7 terminator primer (20 nM) 1 µl
Terminator ready reaction mix 3 µl
Water (sterile) 1 µl
Σ 10 µl
The sequencing sample was prepared on ice and the terminator ready reaction mix
added just prior the start of the PCR, see table 18.
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 Table 18. PCR program for DNA amplification with Big dye 1.1 prior to sequencing.
Step Cycles Temperature Time
Denaturation 1x 96°C 3 min
96°C 10 sec
50°C 5 secAnnealing 25x
60°C 4 min
Elongation 1x 4°C ∞
Precipitation of the DNA was achieved by adding 10 µl sterile water, 2 µl 3 M NaAc
(pH 4.6), 2 µl 125 mM EDTA and 50 µl pure ethanol. The mixture was placed on ice in
the dark for 15-30 minutes, followed by centrifugation at 10000 rpm and 4°C for 20
minutes. The supernatant was removed with a fine tip Pasteur pipette.  50 µl ethanol
70% was added to the pellet and centrifugation repeated. After removing the
supernatant, the pellet was allowed to dry at RT in the dark with open tubes for 30
minutes. The DNA sample was finally given to the sequencing facility at Biocenter
(University of Basel, Switzerland).
2.7.8 Glycerol stocks
Clones containing the correct insert were stored as glycerol stocks. Cultures of 3 ml LB
medium supplemented with 100 µg/ml ampicillin were inoculated with 20 µl O/N-
culture and grown at 37°C and 300 rpm. Bacteria cultures prepared for storage should
be as viable as possible, preferably mid log-phase and not yet entered the stationary
phase. After 3-4 hours, 850 µl cell suspension was added to 150 µl sterile glycerol in
cryovials (TPP) and briefly vortexed. The bacteria was quickly frozen in liquid nitrogen
and stored at –80°C.
2.7.9 Transformation into calcium competent cells
Confirmed mutated constructs of H1-CRD were transformed into calcium competent
AD494(DE3) cells for subsequent protein expression. An aliquot of 80 µl AD494(DE3)
cells was thawed on ice and 1.5 µl mutant DNA added. The sample was incubated on
ice for 30 minutes, followed by a heat-shock at 42°C for 90 seconds. The cells were
transferred to ice for another 2 minutes, prior to addition of 900 µl LB medium with
0.4% glucose and 10 mM MgCl2. The cell suspension was incubated at 37°C and 550
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rpm for 1 hour, and then centrifuged at 13000 rpm for 1 minute. The supernatant was
discarded and the pellet resuspended in 100 µl LB medium, supplemented as specified
above. The cells were plated on a selective LB-agar plate and incubated at 37°C O/N.
2.7.10 Small-scale expression analysis
Transformed AD494(DE3) cells were screened for high expression levels. O/N cultures
of LB medium supplemented with appropriate antibiotics were inoculated with freshly
transformed AD494(DE3) cells, randomly chosen. The cultures, typically 8-10, were
grown at 37°C and 300 rpm O/N. Small expression cultures made up of 4 ml TB
medium, 7.5% glucose, 15 µg/ml kanamycin and 50 µg/ml carbenicillin were
inoculated with 50 µl O/N-culture the next day and grown at 37°C and 300 rpm. One
clone was prepared in duplicates, the additional culture used for OD measurements. As
the cell density reached OD ∼ 0.5, a 1 ml sample was taken from each culture and
centrifuged at 13000 rpm for 2 minutes. Pellets were stored on ice, designated non-
induced samples. Expression was induced by addition of 4 µl 0.4 M IPTG. After 5
hours, another 1 ml sample was taken from every culture and centrifuged at 13000 rpm
for 2 minutes. The pellets were stored on ice and designated expressed samples.
The expression levels were compared by SDS-PAGE analysis. Non-induced and
induced samples were prepared by TCA precipitation. Pellets were resuspended in 1 ml
PBS and 500 µl cell suspension sonicated at RT for 5 minutes. 50 µl TCA was added
and samples vortexed for a minimum of 15 seconds. Samples were incubated on ice for
15 minutes and subsequently centrifuged at 13000 rpm for 10 minutes. After removal
of the supernatant, pellets were washed with 50 µl acetone and centrifuged at 13000
rpm for 5 minutes. Supernatant was removed and pellets allowed to dry, prior to
resuspension in 50 µl PBS. Reducing sample buffer 5X was added and samples
sonicated for 5 minutes. Finally, the samples were incubated at 95°C and 1200 rpm for
5 minutes, before loading onto the SDS-PAGE (see section 2.5.6).
2.7.11 Determination of target protein solubility
The solubility of mutant proteins was determined according to the following protocol
developed by Qiagen [110]. A culture of 10 ml LB medium, 100 µg/ml ampicillin and
15 µg/ml kanamycin was inoculated with freshly transformed AD494(DE3) cells, and
grown at 37°C and 300 rpm O/N. The O/N-culture was diluted 1/20 into a 50 ml
culture the following day and grown at 37°C and 300 rpm until an OD of 0.5 was
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reached. 1 ml cell culture was centrifuged at 13000 rpm for 5 minutes and the pellet
subsequently resuspended in 50 µl SDS-PAGE sample buffer 1X (non-induced sample).
Expression was induced by addition of IPTG to a final concentration of 1 mM. The
culture was grown for another 5 hours. A second 1 ml cell culture sample was
centrifuged at 13000 rpm for 5 min and resuspended in 100 µl SDS-PAGE sample
buffer 1X (induced sample). The cells were harvested by centrifugation at 4°C and 4000
rpm for 20 minutes.
The cell pellet was resuspended in 5 ml lysis buffer, i.e. 50 mM NaH2PO4 (pH 8), 300
mM NaCl, 10 mM imidazole, and subjected to freeze/thawing in a dry ice/ethanol
bath. Complete cell lysis was achieved by sonication on ice for 6 x 10 seconds with 10
seconds pause between the steps. The cell lysate was centrifuged at 4°C and 5000 rpm
for 25 minutes. The supernatant was decanted and stored on ice as crude extract A
(soluble protein fraction). The pellet was resuspended in 5 ml lysis buffer and stored on
ice as crude extract B (insoluble protein fraction). Both crude extracts were prepared for
SDS-PAGE analysis by mixing 10 µl sample with 10 µl SDS-PAGE sample buffer 2X. All
samples were heated at 95°C for 5 minutes and subsequently centrifuged at 13000 rpm
for 1 minute. SDS-PAGE electrophoresis was prepared and run as previously described
in section 2.5.6. The gel was loaded with 20 µl of the non-induced and induced
samples, and 10 µl of both crude extracts.
2.8 Large-scale expression of mutant H1-CRD
Mutant forms of H1-CRD were expressed by E.coli AD494(DE3) cells as previously
described in section 2.5.2. Typically, one or three 500 ml TB cultures were expressed
for 5 hours.
2.8.1 Solubilization and renaturation of mutant H1-CRD
Purification of mutant forms of H1-CRD was carried out according to the protocol
established for the wild-type (see section 2.5.4). In the case of culture volumes larger
than 500 ml, the protocol was scaled up proportionally, but keeping the dialysis set-up
constant, i.e. 3x25 ml protein solution in 400 ml dialysis buffer.
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A different sonicator (Banson Sonifier 250, Skan AG Basel-Allschwil) was used for
purification of the mutant forms of H1-CRD, due to prevailing circumstances.
Sonication was performed with a 50% duty cycle and output control 5 for 15 minutes.
2.8.2 Purification by FPLC affinity chromatography
Mutants of H1-CRD were purified over a 20 ml Gal-Sep column on the FPLC system in
a similar manner to WT H1-CRD (see section 2.5.5). The FPLC program can be seen in
table 19.
Table 19. FPLC program for the purification of mutant forms of H1-CRD by affinity chromatography.
Step Volume (ml) Flow rate (ml/min)
Load 100-225 1
Wash 45 1
Elution 50 1
Wash 2 10 2
Eluted fractions were analyzed by SDS-PAGE and stored at 4°C until further purified.
2.8.3 Separation of monomers and dimers by HPLC IEC
An alternative desalting method was used for the mutant forms of H1-CRD prior to
HPLC IEC. Amicon Ultra-4 centrifugal filter device (Millipore) with a cutoff of 5 kDa
was employed to concentrate and desalt protein samples after purification by FPLC.
The centrifugal device was first prerinsed with 4 ml sterile water at 4°C and 4000 g for
20 minutes in accordance with the supplier’s guidelines. Typically, 7 ml protein sample
was concentrated in two centrifugation steps at 4°C and 4000 g for 20 minutes. The
concentrated protein was then desalted with 2.8 ml running buffer A, i.e. 25 mM Tris-
HCl (pH 8), three times using the same centrifugation settings, giving a final volume of
approximately 1 ml.
Separation of monomers and dimers of mutant H1-CRD was carried out according to
the protocol established for WT H1-CRD (see section 2.5.8).
2.8.4 Purification by HPLC affinity chromatography
Monomeric samples of mutant H1-CRD were purified and concentrated in a final step
of affinity chromatography on HPLC as previously described for WT H1-CRD in section
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2.5.10. Following affinity chromatography, the concentration was determined using the
Bradford assay (see section 2.5.11) and the samples were stored at –20°C.
2.9 Evaluation of WT and mutant H1-CRD
2.9.1 The solid phase competition assay
The in-house developed target-based assay was used to evaluate ligand binding affinity
of mutant H1-CRD compared to the wild-type [77]. β-GalNAc-polymer was initially
prepared and precomplexed with streptavidin-peroxidase according to the set-up listed
in table 20. After mixing the components, the reaction set-up was incubated at 37°C for
2 hours, followed by storage at 4°C.
Table 20. Set-up for formation of the β-GalNAc-polymer-streptavidin-peroxidase-complex.
Components Volume (µl)
Biotinylated β-GalNAc-polymer (1 mg/ml) 20
Streptavidin-POD-conjugate (500 U/ml) 80
Fetal Call Serum 20
HEPES assay buffer 80
Σ 200
 Two different approaches of the assay were undertaken:
1) Incubation with only GalNAc-polymer, indicating percentage binding relative
to WT H1-CRD
2) Incubation with GalNAc-polymer and an inhibitor competing for immobilized
H1-CRD, allowing for IC50 determination.
A 96-well plate was coated with 100 µl protein solution per well. The protein solution,
optimized for a concentration of 3 µg/ml, was prepared with HEPES assay buffer
containing 20 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM CaCl2. 1-2 rows were filled
with buffer only, serving as background and blank. In addition, the outer wells were
filled with 150 µ l HEPES assay buffer to ensure that all wells were kept under
equivalent conditions. The plate was placed in a humid chamber and incubated at 4°C
O/N.
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Following coating, the protein solution was discarded by flipping the plate upside
down and tapping it on tissue paper. 150 µl blocking buffer (1.5% BSA, 0.1% NaN3 in
HEPES assay buffer) was added to all wells, incubating at 4°C in the humid chamber for
a minimum of one hour. The blocking buffer was discharged and the plate washed
three times with 150 µl HEPES assay buffer per well. In between the washing steps, the
plate was dried by tapping it on tissue paper. Next, the plate was to be incubated either
with only polymer or polymer competing with an inhibitor substance.
Incubation of the protein with only polymer was performed by adding 100 µl β-
GalNAc-polymer to the wells at a concentration of 0.5 µg/ml in HEPES assay buffer. In
the second approach, a dilution series of GalNAc, acting as inhibitor, was first prepared
in HEPES assay buffer, ranging from 2 mM to 0.006 mM. 50 µl GalNAc was then added
to the wells, followed by 50 µl 1 µg/ml β-GalNAc-polymer. Consequently, the final
polymer concentration was identical in both assay set-ups. The wells serving as blank
were incubated with buffer only. The plate was incubated at 37°C for 2 hours followed
by washing two times as described above.
In a final step, 100 µl ABTS substrate solution was added to each well. The horseradish
peroxidase substrate solution was freshly prepared by mixing solution A and B of the
ABTS peroxidase substrate kit from Biorad in a ratio of 10:1. The reaction between the
peroxidase and the substrate could be monitored through green color that was seen to
develop over time. When the color was deemed strong enough, the reaction was
interrupted by addition of 100 µl 2% oxalic acid. OD was measured at 415 nm.
2.9.2 The Biacore assay
All Biacore studies within this work were carried out by Daniel Ricklin, who also
developed the assay for ASGP-R H1-CRD [95]. A Biacore 3000 system and research
grade CM5 sensor chips, all from Biacore AB, was employed for all SPR experiments.
Samples of H1-CRD, WT and mutants, were immobilized on separate flow cells of a
CM5 sensor chip using standard amine coupling procedure [80]. The protein samples,
originally in 10 mM HEPES (pH 7.4), 2 mM EDTA, were diluted in 10 mM acetate
buffer (pH 4.5) to a final concentration of approximately 20 µg/ml. After activating the
surface for 5 to 10 minutes at a flow rate of 5 µl/min, the protein was immobilized on
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the sensor chip by injection for 5 to 15 minutes. Afterwards the surface was deactivated
for a time corresponding to the activation phase.
Stock solutions of Gal and GalNAc were prepared by dissolving the monosaccharides
in running buffer (10 mM HEPES (pH 7.4), 50 mM CaCl2) to a final concentration of
100 mM. High-resolution screening was performed by injecting twofold serial dilutions
between 5 mM and 5 µM as randomized triplicates. Each sample was injected for 30
seconds with an undisturbed dissociation phase of 20 seconds using the instruments
kinject command at a flow rate of 50 µl/min. No regeneration or washing steps had to
be applied. Five buffer blanks were injected at the beginning and one between the
triplicate series. Signals of an untreated flow cell and averaged blank injections were
subtracted from the sample sensograms. Since referenced sensograms showed negative
SPR signals, the whole data set had to be mirrored by multiplication of each data point
with -1. Mirrored steady state data were evaluated between 10 and 20 seconds of the
injection period and were fitted to a single site binding model [95].
2.10 NMR studies of H1-CRD
All NMR experiments within this work were carried out by Dr. Brian Cutting at IMP.
Furthermore, all NMR spectra were processed using the XWINNMR software package
commercially available from Bruker AG. The samples were measured at 200 µl using a
restricted volume, Shigemi, NMR tube [111]. The Shigemi tubes minimized the
quantity of protein needed as the sample was contained only in the active volume of
the NMR probe. The use of traditional NMR tubes requires approximately 500 µl for
high magnetic field homogeneity. Shigemi tubes allowed the use of a reduced volume
as the liquid is contained within magnetic susceptibility plugs optimized for H2O both
above and below.
2.10.1 T1rho measurements
To assess ligand binding to WT and mutant H1-CRD, transverse relaxation rates were
measured. The measurement used an in-house sequence to quantitate T1rho, which is
a measure of the transverse relaxation, but is less sensitive to magnetic field
inhomogeneity. T1rho is advantageous since changing from the free ligand to the
ligand with the protein might have different levels of magnetic field homogeneity.
Transverse relaxation can be used to determine ligand binding because the rate of
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relaxation increases with molecular weight [112]. Hence, the protein-ligand complex
displays a greater rate of relaxation compared to the free ligand.
T1rho experiments were conducted with the triple mutant to assess binding affinity to
GalNAc. An equivalent measurement with the wild-type protein served as reference.
The protein concentrations were in the range 16 to 30 mM, while a GalNA c
concentration of approximately 300 mM was used. For all T1rho experiments, the
buffer consisted of 20 mM Tris-HCl (pH 7), 1 mM CaCl2 in 99.5% D2O.
To estimate the transverse relaxation rate, five decay times, beginning from 10 ms and
ending at 200 ms, were measured. All T1rho measurements were performed on a 500
MHz Bruker DRX NMR spectrometer. The signal loss with increasing relaxation times
was quantified and analyzed with the Prism curve-fitting software package from
GraphPad Software, Inc.
2.10.2 Stability measured by T1rho
T1rho experiments were also performed with WT H1-CRD monomers purified by
HPLC RP. The sample concentration was 45 mM H1-CRD and 500 mM GalNAc
added. To better understand potential complications arising with the measurement of
the binding, additional stability measurements were conducted. Eight measurements of
the T1rho relaxation of the GalNAc mixed with the protein were recorded over a
period of 56 days. In each case, the signal decay after 200 ms was compared with the
decay after 10 ms. During the 56 days of observation, the sample was stored at RT.
2.10.3 Saturation transfer difference measurements
The saturation transfer difference (STD) NMR experiment was used as a complementary
diagnosis of binding. The STD measures an intermolecular Overhauser transfer of
magnetization. Due to the mechanism of the Overhauser process, the transfer is
strongly distance dependent and limited to internuclear distances of approximately 4
Angstroms or less. This enables a qualitative assessment of binding as evidenced by a
signal from the ligand in the STD spectrum upon irradiation of the protein [113].
STD was used to evaluate binding to WT H1-CRD purified either by HPLC RP or HPLC
IEC. Samples of a protein concentration of 45 mM H1-CRD and 500 mM GalNAc
added were analyzed. The NMR experiment was performed as described by Meyer et
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al., with the exception that the protein was saturated with a train of 40 E-Burp-1 pulses
[114] of 40 Hz root-mean-square intensity for 50 ms at 0 ppm [115]. All STD
measurements were performed on the 500 MHz Bruker DRX NMR spectrometer.
2.11 Expression of isotope labeled H1-CRD
Isotope labeled protein is a prerequisite for 2D- and 3D heteronuclear NMR. The most
straightforward way to obtain such protein is to grow the expression host in isotope
enriched medium. For this purpose, different medias and set-ups are routinely being
employed [86]. Here, two strategies applied within this work are presented.
1) Two-stage protocol, i.e. growth in rich medium and expression in minimal
medium
2) Growth and expression in minimal medium
2.11.1 Minimal medium for bacterial growth and protein expression
The minimal media and supplements used for bacterial growth and expression of
isotope labeled proteins are listed below. The M9 minimal medium is adapted from
Sambrook and Mantias [88]. All medias and additives were prepared using sterile
Millipore water. The M9 salts, NH4Cl 1%, MgSO4 and CaCl2 were autoclaved at 121°C
for 20 minutes, while the thiamin and D-glucose stock 20% solutions were filter
sterilized.
M9 minimal medium, 1 liter
M9 salts 5X 200 ml
NH4Cl 1% 100 ml
D-glucose stock 20% 20 ml
1M MgSO4 2.0 ml
1M CaCl2 0.1 ml
Supplement with appropriate antibiotics
M9 minimal medium plus vitamins, 1 liter
M9 salts 5X 200 ml
NH4Cl 1% 100 ml
D-glucose stock 20% 20 ml
1M MgSO4 2.0 ml
1M CaCl2 0.1 ml
BME Vitamins 100X 1ml
Thiamin 20 mg/ml 0.1ml
Supplement with appropriate antibiotics
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M9 salts 5X, 1 liter
KH2PO4 15 g
Na2HPO4 30 g
NaCl 2.5 g
adjust pH to 7.2
NH4Cl 1% stock, 0.5liter
NH4Cl 5 g
adjust pH to 7.2
2.11.2 Expression of isotope labeled protein using a two-stage protocol
The two-stage protocol for expression of isotope labeled protein, presented by Marley
et al., generates cell mass using unlabeled rich media followed by exchange into
labeled minimal media for protein expression [90]. It was initially applied for isotope
labeling of H1-CRD in collaboration with an external colleague [116].
2.11.2.1 Growth and expression trial using the two-stage protocol
Growth and expression in minimal medium was controlled with a set of initial
experiments. Cultures of 3 ml LB medium supplemented with appropriate antibiotics
and inoculated with transformed AD494(DE3) or BL21(DE3) cells were grown at 37°C
and 300 rpm O/N. The cultures were subsequently inoculated in 200 ml TB or LB
medium with appropriate antibiotics and in the former case also supplemented with
1% glucose, aiming at an OD of 0.1. The cultures were grown at 37°C and 300 rpm
until an OD of 1-2.0 was reached. The cells were collected at 4°C and 5000 rpm for 30
minutes, and pellets washed with 40 ml M9 salts. Centrifugation was repeated and the
cells resuspended in 100 ml M9 minimal medium, concentrating the cells with a factor
of 2X or 4X depending on the OD at which they were harvested.
The cultures were further grown at 30°C or 37°C at 300 rpm for 1.5-2 hours prior to
induction. A 1 ml sample was removed from each culture, centrifuged at 13000 rpm
for 3 minutes and the pellet stored on ice. Expression was induced by addition of IPTG
to a final concentration of 0.4 mM, and growth continued under the same conditions.
The growth was continuously controlled by measuring the OD. 1 ml samples were
regularly removed at different time points from each culture and pellets stored on ice
for subsequent analysis (see section 2.11.4).
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2.11.2.2 Optimization of the expression set-up using experimental design
The expression set-up can be optimized in respect to a number of variables to achieve
optimal yields, e.g. cell concentration, expression temperature, expression time,
medium composition etc. Optimization of the conditions using a “one-factor-at-a-
time”-approach can prove not only to be time-consuming, but may also lead to the
wrong conclusions. [117,118]. A more efficient way to identify the most favorable
settings is to apply experimental design, in which a small set of experiments is devised
varying the factors systematically. In fractional factorial design, one class of
experimental design set-ups, a number of experiments are chosen out of all possible
options to given the maximum amount of variation and information with the smallest
number of experimental runs. [119] The ideas behind this approach were adopted for
the optimization of expression of isotope labeled H1-CRD according to the two-stage
protocol. The growth and expression conditions that were to be optimized can be seen
in table 21.
Table 21. Growth and expression conditions that were to be optimized for the two-stage protocol,
specified with the alternatives chosen.
Factor Options
Expression temperature 3:   25°C, 30°C, 37°C
Cell concentration factor 3:   2X, 4X, 6X
Growth culture medium 2:   LB, TB
IPTG concentration 2:   0.4 mM, 1 mM
Investigating all possible combinations of the factors would require 36 different
experiments. Instead 14 experimental runs were chosen in an attempt to reach as broad
diversity as possible, while simultaneously attain maximum amount of information. The
choices are illustrated in figure 16.
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Figure 16. A graphic presentation of the options when optimizing the growth and expression conditions.
Three choices are given for the expression temperature and concentration factor of cells, while two options
are given for the inoculation culture medium, resulting in 18 possible set-ups. In addition, a fourth
dimension is added when considering the two choices of IPTG concentration, doubling the number of
expression set-ups. The experiments finally chosen and realized are marked with circles.
In addition, the optimal expression time was to be determined for each individual
expression set-up. Also, addition of labeled full medium to the minimal medium was
considered.
Transformed BL21(DE3) cells were grown in small cultures of LB medium
supplemented with 100 µg/ml ampicillin at 37°C and 300 rpm O/N. The cultures were
subsequently inoculated in 100, 200 or 300ml cultures of LB or TB medium
supplemented with 1% glucose and 100 µg/ml ampicillin, aiming at an initial OD of
0.1. Cultures were grown at 37°C and 300 rpm until an OD of 1.0 was reached. The
cells were collected at 4°C and 5000 rpm for 30 minutes, and pellets washed with 40
ml M9 salts. Centrifugation was repeated and the cells resuspended in 50 ml M9
minimal medium plus vitamins concentrating the cells with a factor of 2X, 4X or 6X.
The cultures were further grown at 25°C, 30°C or 37°C at 300 rpm for 1 hour prior to
induction. A 1 ml sample was removed from each culture, centrifuged at 13000rpm for
3 minutes and the pellet stored on ice. Expression was induced by addition of IPTG to a
final concentration of 0.4 mM or 1 mM, and growth continued under the same
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conditions. 1 ml samples were regularly removed at different time points and pellets
stored on ice for subsequent analysis (see section 2.11.4).
2.11.2.3 Expression of H1-CRD according to the two-stage protocol under
optimized conditions
Transformed BL21(DE3) cells were grown in small cultures of 3 ml LB medium with
100 µg/ml ampicillin at 37°C and 300 rpm O/N. The cultures were subsequently
inoculated in 3x500 ml TB medium supplemented with 1% glucose and 100 µg/ml
ampicillin, aiming at an initial OD of 0.1. Cultures were grown at 37°C and 300 rpm
until an OD of 1.0 was reached. The cells were collected at 4°C and 5000 rpm for 30
minutes, and each pellet washed with 40 ml M9 salts. Centrifugation was repeated and
the cells resuspended in 400 ml M9 minimal medium plus vitamins concentrating the
cells with a factor of 4X. The cultures were further grown at 30°C and 300 rpm for 1
hour prior to induction. Expression was induced by addition of IPTG to a final
concentration of 1 mM. After 5 hours, the cells were collected by centrifugation at 4°C
and 5000 rpm for 15 minutes.
2.11.2.4 Alternative expression set-up of the two-stage protocol
Transformed BL21(DE3) cells were grown in small cultures of 3 ml LB medium with 50
µg/ml carbenicillin at 37°C and 300 rpm O/N. The cells were subsequently inoculated
in 400 ml LB medium supplemented with 1% glucose and 50µg/ml carbenicillin,
aiming at an initial OD of 0.1. The culture was grown at 37°C and 300rpm until an OD
of 1.0 was reached. The cells were collected at 4°C and 5000rpm for 30 minutes, and
the pellet(s) washed with 40 ml M9 salts. Centrifugation was repeated and the cells
resuspended in 100 ml M9 minimal medium plus vitamins (carbenicillin substituting
ampicillin), concentrating the cells with a factor of 4X. The culture was further grown at
30°C and 300 rpm for 2 hours prior to induction. Expression was induced by addition
of IPTG to a final concentration of 0.4 mM. After 5 hours, the cells were collected by
centrifugation at 4°C and 5000 rpm for 15 minutes.
2.11.3  Expression of isotope labeled protein by exclusive use of minimal
medium
A second method routinely used for production of isotope labeled protein is the
exclusive use of minimal medium for both generating cell mass and expressing protein.
[120,121]. By varying the composition of the medium different labeling patterns can be
attained, e.g. 15N and/or 13C labeling, selective amino acid labeling etc [86].
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2.11.3.1 Expression of H1-CRD in minimal medium
Transformed BL21(DE3) cells were grown in small cultures of 3 ml LB medium with 50
µg/ml carbenicillin at 37°C and 300 rpm for approximately 8-9 hours. The cells were
then collected as three individual pellets by centrifugation at 4°C and 5000 rpm for 10
minutes. Each pellet was subsequently resuspended in 50 ml unlabeled M9 minimal
medium plus vitamins and incubated at 37°C and 300 rpm O/N. The cells were
collected anew as three pellets by centrifugation, followed by washing with 40 ml M9
salts per pellet. Centrifugation was repeated and each pellet resuspended in 500 ml
labeled M9 minimal medium plus vitamins. The cultures were further grown at 37°C at
300 rpm. When an OD of 1.0 was reached, expression was induced by addition of
IPTG to a final concentration of 0.4 mM. After 5 hours, the cells were collected by
centrifugation at 4°C and 5000 rpm for 15 minutes.
2.11.4 Sample preparation for SDS-PAGE electrophoresis
Pellets collcected for SDS-PAGE analysis were well resuspened in lysis buffer (20 mM
Tris-HCl (pH 8), 8 M urea and 0.01% beta-mercaptoethanol), briefly vortexed and
sonicated for 10 minutes. The lysate was centrifuged at 13000 rpm for 10 minutes.
Samples were prepared with reducing SDS-PAGE sample buffer 5X and incubated at
95°C and 1200 rpm for 5 minutes. SDS-PAGE electrophoresis was run as previously
described (see section 2.5.6).
2.11.5 Solubilization and renaturation of isotope labeled H1-CRD
The isotope labeled H1-CRD was purified and refolded as previously described in
section 2.5.4. Bacteria pellets collected after the two-stage method were lysed in
proportions to the total volume of rich media that was used rather than the volume of
minimal media. The reason for this was to ensure complete lysis of all bacteria and
maximal extraction of protein.
Similar to purification of mutant forms of H1-CRD, a different sonicator (Banson
Sonifier 250, Skan AG Basel-Allschwil) was used. Sonication was performed with a
50% duty cycle and output control 5 for 15 minutes.
77
2.11.6 Purification by FPLC affinity chromatography
Refolded protein was purified over a 10 ml Gal-Sepharose column on the FPLC system
as described in section 2.5.5. Collected fractions were analyzed by SDS-PAGE
electrophoresis.
2.11.7 Separation of monomers and dimers by HPLC IEC
HPLC IEC was used to separate monomers and dimers of the isotope labeled H1-CRD
as described in section 2.5.8. Prior to the chromatography run, the protein samples
were desalted using Amicon ultra-4 centrifugal filter devices.
Following the separation, collected monomer fractions were concentrated to
approximately 500 µ l with Amicon ultra-4 centrifugal filer devices. A further
concentration step with simultaneous buffer exchange to reduce the calcium content
was done with Microcon ultracel YM-10 centrifugal filter device. 15N labeled H1-CRD
was kept in water, while double-labeled H1-CRD was exchanged into deuterium for
future NMR experiments. Final protein sample in 25 mM Tris-HCl (pH 7.4), 1 mM
CaCl2 was stored at –20°C.
2.11.8 Separation of monomers and dimers by HPLC RP
HPLC RP was used to separate monomers and dimer for subsequent MS analysis.
Separation was done according to the procedure described in section 2.5.9.
Monomeric samples were submitted for MS analysis after lyophilization.
2.11.9 Mass spectrometry analysis
Isotope labeled H1-CRD was analyzed by MS to determine the level of isotopic
enrichment. Protein mass analysis was performed using electrospray ionisation
technology. All mass spectrometry experiments were carried out in the MS facility in
the laboratory of Prof. Paul Jenö (Biocenter, University of Basel, Switzerland).
2.11.10 NMR studies of isotope labeled H1-CRD
As previously noted, the NMR experiments were carried out by Dr. Brian Cutting.
Shigemi NMR tubes were used also for the studies of isotope labeled H1-CRD, as well
as the XWINNMR software.
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2.11.10.1 Heteronuclear Multiple Quantum Coherence (HMQC)
Heteronuclear Multiple Quantum Coherence experiments [122] were performed at 500
MHz 1H resonance frequency (11.7 Tesla). The 1H and 13C pulses used for the
experiments were calibrated using a standard sample containing 20 mM glucose
enriched in 13C. The spectral widths in the experiment were 70 ppm in the 13C
dimension, centered at 40 ppm, to ensure that all the Ca and side-chain carbons were
measured in the protein. The 1H spectral width was 5.5 ppm, centered at 2.6 ppm. Due
to the uncertainty regarding the level of enrichment, more scans were recorded than
were typically used for this experiment. 512 increments were recorded in the indirect
13C dimension, each of which was constructed with 24 scans. The delay between scans
was 1.5 seconds resulting in total experimental time of 10.2 hours. Decoupling in both
dimensions was achieved by an 1800 pulse and a GARP method.
2.11.10.2 HSQC at 800 MHz 1H resonance frequency
Heteronuclear Single Quantum Coherence experiments [123] were performed at 800
MHz 1H resonance frequency (18.8 Tesla) on a spectrometer equipped with a high-
sensitivity cryoprobe. The spectrometer was kindly made available by Prof. S. Grzesiek.
To increase the quality of the measurement, the sensitivity-enhanced version of the
HSQC was performed [124]. The 1H and 15N pulses used for the experiments were
calibrated using a standard sample containing 50 mM urea enriched in 15N.
The spectral widths in the experiment were 25 ppm in the 15N dimension, centered at
116 ppm, to ensure that all the backbone amide and side-chain nitrogens were
measured in the protein. The 1H spectral width was 6.0 ppm, centered at 9.0 ppm. 256
increments were recorded in the indirect 15N dimension, each of which was
constructed with 32 scans. The delay between scans was 2.3 seconds resulting in an
approximate experimental time of 6 hours. Decoupling in both dimensions was
achieved by an 1800 pulse and a GARP method. No spectral referencing was
performed.
2.11.10.3 HSQC at 600 MHz 1H resonance frequency
HSQC experiments were performed at 600 MHz 1H resonance frequency (14.1 Tesla).
The spectrometer was kindly made available by Prof. S. Grzesiek. To increase the
quality of the measurement, the sensitivity-enhanced version of the HSQC was
performed [124]. The spectral widths in the experiment were 25 ppm in the 15N
dimension, centered at 110 ppm, to ensure that all the backbone amide and side-chain
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nitrogens were measured in the protein. Due to the particular method of processing,
the apparent width of the 15N dimension appears twice as broad of the actual width.
The 1H spectral width was 6.0 ppm, centered at 9.0 ppm. 128 increments were
recorded in the indirect 15N dimension, each of which was constructed with 4 scans.
The delay between scans was 0.8 seconds resulting in an approximate experimental
time of less than 10 minutes. Decoupling in both dimensions was achieved by an 1800
pulse and a GARP method. No spectral referencing was performed.
2.11.10.4 Ligand titration measured by HSQC at 600 MHz 1H resonance frequency
HSQC experiments, using the same parameters described in section 2.11.10.3, were
performed at 600 MHz. A series of different concentrations of GalNAc was added to
the protein to determine the binding affinity. One HSQC was measured for each
concentration and the chemical shift changes of the protein upon binding were
monitored [125].
To minimize the volume added to the Shigemi NMR tube, two stock solutions of
GalNAc, dissolved in D2O, were used, 20 mM or 100 mM. The seven different HSQC
experiments corresponded to measurement of the protein with GalNAc concentrations
ranging from 0 mM to 1500 mM. The total volume added was 6.2 µl of GalNAc to the
200 µl solution of protein.
HSQC spectra were processed identically for each GalNAc concentration using
XWINNMR. Each spectrum was then plotted with XWINPLOT, saved as postscript
format, read into and superimposed with Adobe Illustrator.
2.11.10.5 13C isotopic enrichment experiments
Half-filter [126] experiments were created to estimate the level of isotopic enrichment
in the protein samples. The experiment measures 1H signals either from 13C or from 12C
depending upon the experimental conditions. The ratio of the 1H signals originating
from 13C to that of those originating from 12C provided an estimate of the incorporation
level. To validate the method, two control samples were measured prior to the protein.
An in-house synthesized E-Selectin antagonist [127], with natural abundance 13C
(1.11%), and acetic acid fully enriched in 13C. The experiments were performed on the
same spectrometer used for the [1H, 13C] HMQC spectra. The delays used in the half-
filter experiment were chosen for a value of a coupling constant of 145 Hz, resulting in
a delay of 3.45 ms.
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3 Results
3.1 Expression, purification and analysis of H1-CRD
Protein in preparative amounts is a necessity for structural and biochemical studies. A
method for expression and purification of ASGP-R H1-CRD from E.coli, initially
developed by Meier et al. [5], and further improved by Rita Born at IMP [94], was used
within this work.
3.1.1 Expression and purification of H1-CRD
E.coli strain AD494(DE3) was used for overexpression of H1-CRD. Expression was
induced by addition of IPTG and lasted five hours. As bacteria lack the ability to
correctly fold recombinant proteins and do not support the formation of native disulfide
bonds in the cytoplasm, expressed H1-CRD was accumulated as inclusion bodies. Lysis
of the bacteria and complete denaturation of the protein content was carried out to
solubilize the aggregated protein. The protein was subsequently refolded by stepwise
dialysis and purified by affinity chromatography on a FPLC system. The protein could
be seen in the chromatogram as a sharp peak during the elution phase, indicating
correct folding and binding to galactose (Figure 17). The peak was collected as different
fractions.
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Figure 17. FPLC chromatogram of WT H1-CRD. FT corresponds to the flow-through, followed by the wash
(W) to remove any unbound proteins. A distinct peak can be seen during the elution phase (E),
representing H1-CRD.
Eluted fractions were analyzed by reducing SDS-PAGE (Figure 18). The low molecular
weight marker in lane 1 was used as reference. H1-CRD was predominately observed
in lane 8 and 9, corresponding to the elution peak in the chromatogram. The protein
had clearly been enriched as seen when compared to the sample load (lane 3) before
affinity chromatography. H1-CRD could also be spotted in the flow-through (lane 4),
indicating either overloading of the column or alternatively misfolded protein.
Figure 18. Reducing SDS-PAGE analysis of fractions collected during affinity chromatography of H1-CRD
(15% gel, silver staining).
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Western blot was used to verify the identity of H1-CRD after affinity chromatography
on FPLC. A polyclonal anti-H1-CRD-IgY antibody produced in chicken [94] was
utilized in the initial antigen-specific binding step, followed by a secondary antibody
coupled with alkaline phosphatase. A thick band representing H1-CRD was clearly
seen after development with NBT/BCIP (Figure 19).
   
Figure 19. A) Reducing SDS-PAGE analysis of purified H1-CRD originating from different batches (15%
gel, silver staining). B) Western blot of an identical gel as seen in figure 19A. A polyclonal anti-H1-CRD-
IgY antibody produced in chicken was used for detection [94].
Analysis with non-reducing SDS-PAGE revealed occurrence of both monomeric and
dimeric H1-CRD (Figure 21, lane 2). No consistent ratio of the two species could be
determined as the fractions appeared to vary among different batches. To separate the
monomers and dimers, HPLC IEC was employed. Protein samples were loaded onto a
DEAE column and eluted with a Tris/CaCl2 buffer gradient. Monomeric H1-CRD, less
charged than the dimeric form, were found to elute at a lower CaCl2 concentration,
while the dimers emerged at higher CaCl2 concentration. Repeated injections of H1-
CRD showed highly similar chromatograms, confirming the reproducibility of the
method. The monomers (peak 1) could be seen in the chromatogram as the first peak
with a tailing shoulder. A small, unidentified peak (peak 2) was seen following the
monomers and preceding the dimers, and is most likely an impurity. The final peak
(peak 3) corresponds to dimers of H1-CRD (Figure 20).
Gel A – WT H1-CRD
Lane 1: Marker
Lane 2: Reference
Lane 3: H1-CRD batch 1
Lane 4: H1-CRD batch 2
Western blot B – WT H1-CRD
Lane 1: Marker
Lane 2: Reference
Lane 3: H1-CRD batch 1
Lane 4: H1-CRD batch 2
A 1.1.1.1
 1        2        3        4   1         2          3         4
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Figure 20. A) Separation of monomers and dimers by HPLC IEC. The monomers can be seen as peak 1
with a tailing shoulder, while the dimers elute in the end (peak 3). B) A second batch showing a higher
content of dimer, but with a highly similar separation profile. Repeated injections show high
reproducibility.
Collected fractions were analyzed by non-reducing SDS-PAGE to verify the separation
of monomers and dimers of H1-CRD (Figure 21). The gel revealed traces of dimeric
H1-CRD in the monomeric (lane 3 and 7) as well as the monomeric shoulder (lane 4)
fraction. The assumed impurity (lane 5 and 8) could be seen to correspond to a band
appearing closely below the dimers in the crude sample of H1-CRD (lane 2). Finally,
the dimeric fraction (lane 6 and 9) exhibited pure dimers when analyzed, without
contamination of either monomers or the impurity.
Figure 21. Non-reducing SDS-PAGE analysis of fractions collected during HPLC IEC. The monomer
fractions (lane 3, 4 and 7) are clearly enriched in monomers, but also contain traces of dimers (15% gel,
silver staining).
In an effort to concentrate the purified monomers and simultaneously confirm that the
protein had maintained binding affinity for its ligand(s) throughout the purification
procedure, affinity chromatography on HPLC was utilized. The sample was loaded
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onto a 2 ml GalNAc-sepharose column and eluted with HEPES buffer containing EDTA.
The protein could be observed in the chromatogram as a single peak, indicating that
both folding and binding affinity remained intact (Figure 22). The peak was also seen to
increase in size when increasing the sample load, but eluting at roughly the same
retention time.
Figure 22. Monomers pooled and purified by HPLC affinity chromatography using a GalNAc-Sep column.
The peak was collected in three fractions, i.e. the rise of the peak, the central peak and
the tail of the peak, in order to maximize the protein content in one final sample.
Therefore, all fractions corresponding to the central peak after each HPLC affinity run
were combined in a single sample, intended for future use in assays etc. The Bradford
assay was used to determine the concentration of final samples, which were
subsequently aliquoted and stored at –20°C.
The applied procedure for production of H1-CRD is summarized below in figure 23.
Estimated yields are based on results obtained from different batches.
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Figure 23. Flow-chart of the production scheme for H1-CRD. Estimated yields are specified for each step.
3.1.2 Reference batch of H1-CRD
In order to have a homogenous sample for assay development and referencing, a large
batch of H1-CRD was produced following the established standard protocol. 4 liters
expression culture were processed, resulting in a total of four samples of monomer and
dimers, see table 22.
Table 22. Yields of the reference batch of H1-CRD after HPLC IEC and affinity chromatography
respectively.
Final method Monomers Dimers
HPLC IEC 0.24 mg 0.07 mg
HPLC affinity chromatography 4.30 mg 1.23 mg
Final samples were stored as aliquots à 500µl at –20°C and used for development of
the Biacore assay by Daniel Ricklin [95] and the solid-phase competition assay by
Daniela Stokmaier [77]. The batch was also used as a reference in comparative studies
with mutant forms of H1-CRD.
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3.1.3 Separation of monomers and dimers using HPLC reversed phase
chromatography
An alternative method, reversed phase chromatography, was also employed to separate
monomers and dimers of H1-CRD on HPLC. RP chromatography separates proteins
based on their differing hydrophobicity, eluting less hydrophobic proteins first. Samples
of H1-CRD was loaded onto a C18 column and eluted by an increasing gradient of
water/acetonitrile with 0.01 M TFA. Monomeric H1-CRD, less hydrophobic than the
dimers, was seen to elute first in the chromatogram (Figure 24). The dimers followed
closely in a second peak, barely separated from the first. The monomer peak was
therefore collected as two samples to avoid contamination with dimers. Repeated
injections of H1-CRD showed highly similar chromatograms. The peaks were collected
separately and lyophilized.
      
Figure 24. A) Separation of monomers and dimers by HPLC RP. The monomers can be seen as the first
peak, closely followed by the smaller dimer peak. B) Repeated injections show reproducible results.
To verify the separation of monomers and dimers, samples were analyzed by non-
reducing SDS-PAGE (prior to lyophilization) (Figure 25). In addition, a sample taken
after FPLC without separating monomers and dimers was loaded onto the gel to serve
as a reference of the initial ratio. Monomeric H1-CRD clearly dominated the two
monomer samples (lane 4 and 5), but traces of dimers could also be observed, similar
to the samples purified by HPLC IEC. There appeared to be slightly more dimers in the
second monomer sample (lane 5), possibly due to the narrow separation profile. The
second peak showed an exclusive presence of dimers without interfering monomers
(lane 6).
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Figure 25. Non-reducing SDS-PAGE of monomers and dimers after separation by RP chromatography. The
FPLC sample (lane 3) shows a 1:1 ratio of the species prior to separation. Fractions collected after RP show
a clear enrichment of monomers and dimers respectively (15% gel, Coomassie staining).
3.1.4 Comparison of the binding affinity of monomers purified either by
HPLC IEC or RP
RP chromatography is generally not recommended for protein purification. The use of
organic solvents could harm and/or denature the proteins and compromise both
activity and structure [128]. To ensure that H1-CRD monomers purified by HPLC RP
showed equivalent affinity to that of monomers purified by HPLC IEC, a series of assays
was carried out with the two samples for comparison.
3.1.4.1 Evaluation of WT H1-CRD using the solid-phase competition assay
Lyophilized H1-CRD monomers isolated by RP were initially reconstituted as 500
µg/ml in HEPES assay buffer. WT H1-CRD monomers purified by IEC or RP were
coated on 96-well plates at a concentration of 3 or 5 µg/ml protein and incubated O/N.
The plate was blocked with BSA prior to incubation with 0.5 µg/ml GalNAc-polymer.
No inhibitor was added as the purpose was to compare binding of the two protein
samples to the GalNAc-polymer. As an estimate of the binding, the absorbance at 415
nm was measured after the reaction between ABTS substrate and peroxidase. The
results are depicted in the graph below (Figure 26).
Lane 1: Marker
Lane 2: Reference H1-CRD – IEC
Lane 3: H1-CRD eluted from FPLC
Lane 4: Monomer fraction 1 – RP
Lane 5: Monomer fraction 2 – RP
Lane 6: Dimer fraction – RP
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Figure 26. Binding of GalNAc-polymer to H1-CRD monomers purified by HPLC IEC (dark grey) or HPLC
RP (light gray) as measured by the solid-phase competition assay.
A clear distinction could be observed between the two monomer samples. The IEC
sample showed higher absorbance values at both protein concentrations tested,
indicating a higher degree of binding. The RP monomers also showed binding, but to
less extent. The measured values at 3 µg/ml, the optimal protein concentration for the
assay [77], differed with a factor close to 4. In conclusion, the results generated by the
solid-phase competition assay imply that there is a difference in binding affinity exerted
by the two protein samples.
3.1.4.2 Evaluation of WT H1-CRD using the Biacore assay
WT H1-CRD monomers purified either by IEC or RP (reconstituted as in section
3.1.4.1) were immobilized on a Biacore sensor chip using standard amine coupling.
Although the samples were of similar concentrations, the RP monomers proved more
difficult to immobilize. Final protein densities used for the assay were 6000 and 4000
resonance units (RU) of the IEC and RP monomers, respectively. Such a difference does
not constitute an obstacle as far as the assay is concerned, but should be kept in mind
when evaluating the results.
Dilution series of GalNAc and Gal were injected and binding to the protein monitored.
The resulting sensograms were fitted to a 1:1 binding model and KD was determined
(Figure 27).
Protein conc. ( µg/ml)
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Figure 27. A) Binding of Gal (red) and GalNAc (blue) to WT H1-CRD monomers purified by HPLC IEC. B)
Binding of Gal (red) and GalNAc (blue) to WT H1-CRD monomers purified by HPLC RP.
While a difference in KD of GalNAc and Gal bound to the protein samples could be
observed, the variation in the signal intensity was more striking. The signal response
was considerably lower for the RP monomers. With the difference in protein density
taken into account, the RP sample showed only roughly 20% of the signal intensity
measured for the IEC monomers binding GalNAc. In summary, these results suggest
that although the RP monomers are able to bind GalNAc, only a small fraction appears
to be active. The lower signal response could be explained by damage or inactivation
of part of the protein sample, caused by the RP method and/or the subsequent
lyophilization. HPLC IEC is therefore better suited for separation of monomers and
dimers of H1-CRD.
3.1.4.3 Evaluation of WT H1-CRD using NMR
Two independent NMR experiments were performed to assess binding of GalNAc to
H1-CRD monomers purified either by HPLC RP or IEC. The T1rho experiment and the
STD NMR experiment are subject to independent sources of experimental errors. Thus,
a positive identification of ligand binding from both experiments would serve as cross-
validation of the results.
A B
KD GalNAc 90 µM
KD Galactose 1.7 mM
Rmax GalNAc 285
KD GalNAc 140 µM
KD Galactose 2.1 mM
Rmax GalNAc 35
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T1rho experiments measure the transverse relaxation rate, which increases with the
molecular weight. Hence, a ligand that binds to a large receptor displays a faster decay
of magnetization than a free ligand. T1rho was measured at equivalent ratios of protein
and GalNAc for the two monomer samples (Figure 28).
 
Figure 28. A) T1rho measurements of GalNAc in the absence () and presence () of H1-CRD monomers
purified by HPLC IEC. B) T1rho measurements of GalNAc in the absence () and presence () of H1-CRD
monomers purified by HPLC RP. For comparison of the samples, the ratio of signals measured after 200
and 10 ms (dashed lines) was calculated.
The T1rho spectra obtained for the two samples displayed increased relaxation in the
presence of the protein, indicating binding. When viewed at identical relaxation time,
for example 200 ms, the two samples showed comparable losses in magnetization.
While primarily a qualitative assay, the T1rho experiments show that GalNAc binds to
both proteins samples.
The two monomers samples, that were analyzed with T1rho, were also subjected to
STD measurements (Figure 29). STD measures the transfer of magnetization to a bound
ligand following irradiation of the protein. The experiment serves as an assay for
binding since ligands that bind will give rise to a signal in the STD spectrum, while
non-binding ligands will not. The experiment is primarily of a qualitative nature since
the intensity of the STD spectrum is not trivially related to the affinity.
A B
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Figure 29. A) STD measurements of GalNAc in the presence of H1-CRD monomers purified by HPLC IEC.
B) STD measurements of GalNAc in the presence of H1-CRD monomers purified by HPLC RP.
The major peak seen in the STD spectrum was found at 2.0 ppm, and is due to the
methyl group of GalNAc. The signal could be observed for both proteins, indicating
that they bind GalNAc. Control experiments were performed with each sample without
irradiation of the protein, in which no STD signal was observed. These control
experiments confirmed that the previous STD experiments with irradiation of the
protein indeed signaled binding.
Positive results for binding from the T1rho as well as STD experiments were observed,
adding to the certainty that both monomer samples retained GalNAc affinity regardless
of either purification method.
3.1.4.4 Evaluation of the stability of WT H1-CRD using NMR
T1rho experiments with the RP monomer sample were also performed over a period of
56 days to assess protein stability. The signal at 200 ms was divided by the signal at 10
ms for each measurement (Figure 30). The protein sample was stored at RT between the
measurements. The purpose of this analysis was to ascertain whether the structure of
the protein would remain intact during the long-term period needed for three-
dimensional NMR experiments required for structure elucidation.
A B
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Figure 30. Repeated T1rho measurements of GalNAc and H1-CRD monomers purified by HPLC RP over
time. A ratio of the signal measured after 200 ms to that after 10 ms was determined and compared in
between the measurements.
The results showed a high degree of protein stability over time, as proved by the small
fluctuation in the measured signals. The signal measured at the outset of the trial was
nearly indistinguishable from that measured after almost two months. These
preliminary results demonstrate that the protein can be expected to be stable during the
time required for three-dimensional NMR experiments.
3.2 Site-directed mutagenesis of H1-CRD
3.2.1 Cloning of H1-CRD
A prerequisite for site-directed mutagenesis based on PCR is access to template DNA in
the form of an isolated DNA sequence or the target sequence present in a plasmid. In
the latter case, plasmid DNA isolated from cloning strains of E.coli is preferable as both
yields and quality are higher [59,66]. Therefore, the construct pET-3bH1 was extracted
from E.coli AD494(DE3) cells in a first step, subsequently transformed into E.coli DH5α
and Top10 cells and isolated after bacteria proliferation to serve as template. The
accuracy of the cloned sequence was confirmed at the outset, showing 100%
agreement with the DNA sequence of H1-CRD as determined 1985 [129] and posted
in the ExPASY protein database [130].
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The plasmid was isolated by alkaline lysis using commercial kits. Following extraction,
the DNA was digested with restriction enzymes and analyzed by electrophoresis
(Figure 31).
                  
Figure 31. Non-digested and digested plasmids carrying the sequence of H1-CRD, isolated from DH5α
and Top10 cells.
Digested DNA samples originating either from DH5α or Top10 cells displayed two
fragments of expected molecular weight, i.e. the vector (4639 bp) below 5090 bp and
the insert (435 bp) at 517/506 bp. In contrast, non-digested samples were seen at
different molecular weights depending on the host strain. DNA extracted from Top10
cells were seen at 4072 bp as one dominant band, while the DH5α samples exhibited
three bands all above 5090 bp. This difference is likely due to various forms of the
extracted DNA, which migrate through the gel at different velocities [68].
Quantification of DNA was carried out using agarose gel electrophoresis. The
concentration of the plasmid samples were estimated based on comparison with a
dilution series of known concentrations λ-DNA (Figure 32).
Figure 32. Quantification of miniprep samples isolated from DH5α and Top10 cells compared to
standardized amounts of λ-DNA.
Lane 1: DNA marker X
Lane 2: Non-digested sample 1 from Top10
Lane 3: Digested sample 1 from Top10
Lane 4: Non-digested sample 2 from Top10
Lane 5: Digested sample 2 from Top10
Lane 6: Non-digested sample 1 from DH5α
Lane 7: Digested sample 1 from DH5α
Lane 8: Non-digested sample 2 from DH5α
Lane 9: Digested sample 2 from DH5α
 1    2   3   4   5    6   7   8   9
5090 bp
517/506 bp
Lane 1: DNA marker X
Lane 2-11: λ-DNA in increasing
amounts: 2.5, 5, 10, 20, 30,
45, 60, 80, 100, 200 ng
Lane 12: Sample 1 from Top10 (5 µl)
Lane 13: Sample 1 from DH5α (5 µl)
Lane 14: Sample 2 from DH5α (5 µl)
 1     2    3    4    5     6    7    8    9   10   11       12   13  14
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The concentration of miniprep samples T1, D1 and D2 were determined by visual
assessment, while quantification of the maxiprep sample was done using the software
Quantity One from Biorad Laboratories, Inc. A calibration curve was initially
established, from which the concentration of the maxiprep sample could be derived.
The results are summarized in table 23.
Table 23. Concentration of the DNA samples as determined by agarose gel electrophoresis analysis.
DNA sample Conc. (ng/µl)
T1 12
D1 8
D2 8
Maxiprep 547
3.2.2 Site-directed mutagenesis
There exist numerous methods for introducing site-specific mutations in a DNA
sequence. Three methods were attempted within this work to create point mutations in
H1-CRD, namely ExSite PCR-based site-directed mutagenesis system, conventional
PCR with mutagenic primers and overlap extension PCR.
3.2.2.1 ExSite PCR-based site-directed mutagenesis system
The commercial kit ExSite PCR-based site-directed mutagenesis system from Stratagene
was employed to generate a double substitution of Cys152 and Cys153 to serines. The
mutagenesis reaction was carried out in accordance with the recommended protocol,
varying the concentration of template and primers, as well as using different DNA
polymerases. A total of 4 reaction set-ups (A, B, C and D, see section 2.7.2) were tested
and analyzed by agarose gel electrophoresis (Figure 33).
   
Figure 33. A) Agarose gel analysis of reaction A. Samples taken after PCR (lane 2), Dpn 1 digestion (lane 3)
and dilution (lane 4). The arrow indicates the 4072 bp band in the marker. B) Agarose gel analysis of
Gel A – reaction A
Lane 1: DNA marker X
Lane 2-4: Samples of reaction A
Gel B – reaction C and D
Lane 1: DNA marker X
Lane 2-4: Samples of reaction C
Lane 5-7: Samples of reaction D
A B
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reaction C (lane 2-4) and D (lane 5-7), after PCR, Dpn 1 digestion and dilution respectively. The arrow
indicates the 4072 bp band in the marker.
DNA fragments around 4072 bp, thought to correspond to the PCR product, could be
spotted in all samples after completing the initial PCR run. Reaction A clearly exhibited
the most intense band, with additional bands residing at higher molecular weight.
Reaction B (not shown), C and D looked essentially the same, showing single bands of
decreasing intensity in the same order. Aliquots from the reaction set-ups analyzed after
digestion with Dpn 1 and dilution highly resembled the initial PCR samples. It was
decided to proceed with ligation and transformation of reaction B, C and D. Reaction A
was omitted as it failed to give a single clean band, most likely due to excess template,
present also after digestion.
Calcium-competent XL1-blue cells were transformed with samples of reaction B, C and
D, and grown on selective plates. Randomly chosen single clones were cultivated for
plasmid isolation followed by restriction digestion by Bam H1 and Nde 1, and agarose
gel analysis (Figure 34).
Figure 34. Agarose gel analysis of digested plasmid samples purified from XL1-Blue cells transformed with
ExSite mutagenesis reaction B. The upper arrow denotes the 4072 bp band in the marker, while the lower
arrow marks the 517/506 bp band.
Digested samples were seen to show two fragments of expected molecular weight, i.e.
a band around 4072bp corresponding to the vector and a smaller fragment close to
517/506bp matching the insert of 435bp. Samples showing only the higher molecular
weight fragment were also observed. Clones such as these, growing on selective plates
and containing a plasmid but lacking the target sequence are referred to as false
positives (see section 3.2.3).
Lane 1: DNA marker X
Lane 2: Sample 1 – digested
Lane 3: Sample 2 – digested
Lane 4: Sample 3 – digested
Lane 5: Sample 4 – digested
Lane 6: Sample 5 – digested
Lane 7: Sample 6 – digested
Lane 8: DNA marker X  1           2         3          4           5          6         7          8
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Digested samples showing the expected fragments were chosen for sequencing, carried
out by Microsynth GmbH sequencing group (Balgach). Samples originating from all
three reactions were submitted, but without successful results. Out of twelve samples,
six retained the wild-type sequence. One sample showed a severe frame-shift at the site
of the intended mutations. Four of the samples were observed to partially have
incorporated the mutations, but simultaneously caused a frame-shift. Finally, one
sample had successfully integrated the mutations, but lacked two preceding amino
acids and was therefore not perceived as eligible for downstream applications.
In summary, the ExSite PCR-based site-directed mutagenesis system did not meet the
expectations and was therefore excluded as an option from further work.
3.2.2.2 Conventional PCR with mutagenic primers
A traditional approach to create site-specific mutations in H1-CRD was attempted,
entailing a single PCR reaction with mutagenic primers followed by ligation of the
mutated insert and a predigested vector. The method was used for mutations residing
within 10 amino acids from either end of the H1-CRD sequence, i.e. single and double
substitutions of Cys152 and Cys153 to serines.
The PCR conditions were initially optimized in respect to template amount, primer and
dNTP concentration, as well as optimal annealing temperature for the primers, using
REDTaqpolymerase. A set-up utilizing a final concentration of 0.4 µM primer, 0.2
mM dNTP and 16 pg/µl template gave the best results, as proved by agarose gel
analysis, and was used throughout the following mutagenesis reactions. The optimal
annealing temperature for primer pair H1-CRD mut 152/153 and H1-CRD RW was
found to be 61.3°C. This temperature was also used for mutagenesis reactions with
primer H1-CRD mut 152 and H1-CRD mut 153, as all three primers had identical
melting points, 69.8°C, and were therefore expected to behave in a similar fashion.
Two PCR reactions à 50 µl were run for each intended mutation, with an additional
negative control exchanging the template for sterile water. Aliquots of the final PCR
products were observed by agarose gel analysis to confirm the purity as well as the size
of the DNA fragments prior to pooling of the samples and purification. The purified
DNA was digested with restriction enzymes Bam H1 and Nde 1, and isolated through
preparative agarose gel electrophoresis. Recovery of the digested mutated sequence
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was confirmed by agarose analysis, while simultaneously comparing it with the vector
DNA before ligation (Figure 35).
  
Figure 35. A) Agarose gel analysis of the mutated sequence C152/153S after a PCR reaction with Pfu
polymerase at 61.3°C. B) Analysis of the gel purified insert (mutant C152/153S) and pET3b vector after
restriction digestion.
3.2.2.3 Overlap extension PCR
Overlap extension PCR was used to create mutations located more than 60-70
nucleotides from either end of the H1-CRD sequence. Conventional PCR is not eligible
for such mutations as it would require very long primers, risking unspecific binding and
inaccurate DNA synthesis. As a result substitution of Cys164, Pro237, Glu238, His256,
Asp259 and Asp260, all fulfilling mentioned criteria, was performed by overlap
extension PCR.
In a first step, two reactions were carried out in parallel, generating overlapping halves
of the target sequence, both carrying the desired mutation(s). Similarly to the
conventional PCR set-up, the conditions were initially optimized with REDTaq
polymerase, showing that a final concentration of 0.4 µM primer, 0.2 mM dNTP and
16 pg/µl template yielded the best results. The optimal annealing temperatures are
summarized in table 24. PCR products intended for downstream applications were
ultimately generated using Pfu polymerase and analyzed to confirm that the fragments
showed the expected size (Figure 36). Occasionally, additional bands of higher
molecular weight were observed, but these were considered to be of less importance as
the desired fragments were isolated and purified by preparative agarose gel
electrophoresis. Hence, contamination with PCR products larger or smaller than
expected was avoided.
Gel A – PCR samples of mutant C152/153S
Lane 1: DNA marker X
Lane 2: Reaction 1 (10 µl)
Lane 3: Reaction 2 (10 µl)
Lane 4: Negative control (10 µl)
Gel B – Insert C152/153S and vector
Lane 1: DNA marker X
Lane 2: Purified insert C152/153S (2 µl)
Lane 3: Predigested vector (2 µl)
Lane 4: DNA marker X    1     2     3     4      1     2     3     4
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Figure 36 Agarose gel analysis of fragment A and B of mutant H256E after the first step of overlap
extension PCR. The expected size of the fragments is estimated to 351 and 114 nucleotides, respectively.
The second step of overlap extension PCR combines the two fragments, allowing for
annealing and extension at the overlapping sequences, with simultaneous amplification
accomplished by the flanking primers. In a first trial attempting to generate mutant
C164S, the overlap and extension was run as one individual PCR reaction, excluding
the flanking primers and only comprising 10 cycles of annealing and elongation. The
annealing temperature was set to 61°C, corresponding to the optimized conditions of
the first PCR reaction. However, the set-up failed to achieve an overlap extension,
resulting only in amplification of fragment B, the larger half produced in the first step.
Agarose gel analysis clearly showed the final PCR product and fragment B to be of
equal size, while the positive control could be spotted at higher molecular weight
(Figure 37A).
The second step was repeated to optimize the conditions, running 30 cycles of
annealing and elongation. A temperature gradient ranging from 55°C to 65°C was
tested in different rounds. Reactions with or without (w/o) addition of the flanking
primers were run in parallel. In addition, the ratio of fragment A and B was also varied,
trying 1:1 and 3:1.
Agarose gel analysis could show that none of the reactions run without flanking primers
were able to produce a visible product (Figure 37B). In contrast, reactions including the
primers showed a very intense and broad band between 517/506 and 369 bp. Due to
the position, the PCR product was deemed likely to contain the expected full-length
fragment, but it also appeared to be heavily contaminated with fragment B. The success
of the isolation and purification of the desired product from such a sample seemed
improbable. Bands of lower molecular weight and lower intensity could also be
observed and were believed to represent non-completed products.
Lane 1: DNA marker X
Lane 2: Fragment A – reaction 1
Lane 3: Fragment A – reaction 2
Lane 4: Fragment A – negative control
Lane 5: Fragment B – reaction 1
Lane 6: Fragment B – reaction 2
Lane 7: Fragment B – negative control
Lane 8: DNA marker X
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Figure 37. A) Agarose gel analysis of the second step of the overlap extension PCR of mutant C164S
without addition of flanking primers. The reaction sample (lane 3) can be seen to correspond to the size of
fragment B (lane 4) rather than the expected full-length fragment (lane 2). The upper arrow marks the
517/506 bp band in the reference, while the lower arrow points at the 396 bp band. B) Agarose gel
analysis of the second step of the overlap extension PCR of mutant C164S. The reactions in lane 3-5 were
run without addition of flanking primers at 59.9°C, 57.2°C and 55.0°C respectively. In contrast, the
reactions in lane 7-9 were run with addition of the flanking primers at the same temperatures as mentioned
above.
Yet another strategy was tested with addition of the flanking primers after 10 cycles of
annealing and elongation and then continuing to run the PCR for another 20 cycles. A
temperature gradient was applied, running the reactions at 60°C, 56.2°C, 52°C and
50°C respectively. Furthermore, fragment B was diluted 1/10 from which 3 µl was
added to the reaction set-up. Fragment A was not diluted and added as 1 µl to the
sample mix. Following the PCR, the samples were analyzed by agarose gel
electrophoresis together with a positive control and fragment B. This strategy proved to
be very successful and also an exceptionally illustrative example of the importance of
optimal annealing temperature as seen in figure 38.
Gel A – OE-PCR mutant C164S
Lane 1: DNA marker X
Lane 2: Positive control H1-CRD
Lane 3: Reaction sample 1
Lane 4: Fragment B – control
Gel B – OE-PCR mutant C164S
Lane 1: DNA marker X
Lane 2: Fragment B – control
Lane 3-5: Reaction w/o primers
Lane 6: Positive control H1-CRD
Lane 7-9: Reaction with primers
Lane 10: Fragment B – control
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Lane 1: DNA marker X
Lane 2: Fragment B – control
Lane 3: Reaction sample – 60°C
Lane 4: Reaction sample – 56.2°C
Lane 5: Reaction sample – 52°C
Lane 6: Reaction sample – 50°C
Lane 7: Positive control H1-CRD
Lane 8: DNA marker X
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Figure 38. Agarose gel analysis of the second step of the overlap extension PCR of mutant C164S. The
reactions were run at different temperatures, adding the flanking primers after 10 cycles of annealing and
elongation, followed by another 20 cycles.
While all four reactions (lane 3-6) clearly demonstrated the ability to produce the
expected full-length fragment, the intensity of the product(s) varied significantly. A clear
correlation could be seen between increased band intensity and increased annealing
temperature. Moreover, at the lowest temperature tested, an additional band was seen,
corresponding well to the size of fragment B. This second band further supports the
necessity to optimize the annealing temperature, in order to avoid contamination with
incorrect products or unspecific primer binding. The second vital issue contributing to
the success of the set-up is the time point at which the flanking primers are added. By
excluding the primers during the first 10 cycles, the two fragments are allowed to
anneal and extend without any external interference. However, it is crucial to add the
primers before completing the PCR run to achieve amplification and consequently a
sufficient amount of product for detection and downstream applications. Due to the
most satisfying results obtained when using this set-up for mutant C164S, it was
decided to apply it in further mutagenesis reactions carried out by overlap extension
PCR. Nonetheless, optimal annealing temperature and fragment concentration had to
be determined empirically for each individual reaction (Figure 39).
  
Figure 39. A) Agarose gel analysis of the second step of the overlap extension PCR of mutant H256E. A
temperature gradient was applied, showing highest yields at 62°C (lane 2). B) Agarose gel analysis of the
second step of the overlap extension PCR of mutant D259A. The temperature was kept constant at 61°C,
while the ratio of fragment A and B from the first step was varied. Best result is observed at a ratio of 3:20
(lane 5).
Gel A – OE-PCR mutant H256E
Lane 1: DNA marker X
Lane 2-4: Reaction samples at
selected temperatures (62°C, 60.1°C
and 58.2°C)
Gel B – OE-PCR mutant D259A
Lane 1: DNA marker X
Lane 2-6: Reaction samples using
different ratios of fragment A and B
(3:10, 1:5, 1:20, 3:20 and 1:10)
Lane 7: Negative control  1      2      3     4   1     2     3      4      5      6      7
A B
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The annealing temperatures used in the first and second step of the overlap extension
PCR reactions can be found summarized in table 24.
Table 24. Optimized annealing temperatures used in the first and second step of overlap extension PCR
reactions.
Mutation Annealing temp. 1st step Annealing temp. 2nd step
C164S 61°C 60°C
P237A 60°C 62°C
E238G 58.5°C 61.4°C
H256E 59.5°C 62°C
D259A 59.9°C 61.8°C
D260A 59.9°C 61.8°C
Duplicate reactions were run under optimized conditions and pooled after confirming
presence of pure products by agarose gel analysis. The DNA was purified and digested
by restriction enzymes, followed by isolation and purification by preparative agarose
gel electrophoresis prior to ligation.
3.2.3 Transformation by electroporation
Purified inserts, originating either from conventional PCR or overlap extension PCR,
were ligated with predigested and dephosphorylated pET3b vector O/N. Two set-ups
were used, varying the insert-vector ratio from 1:1 to 2:1.
An aliquot of electrocompetent DH5α-cells were transformed with 5 µl desalted
ligation sample and plated on selective LB-agar plates. Colony formation could be
observed after incubation O/N, seemingly independent of the ligation set-up of the
sample used for transformation. Randomly chosen single colonies were grown for
subsequent plasmid isolation and restriction digestion. Agarose gel analysis was used to
distinguish between false and true positives (Figure 40).
102
  
Figure 40. A) Agarose gel analysis of digested miniprep samples of mutant C152S, isolated from DH5α
cells. The samples show clean bands of expected molecular weight corresponding to that of the insert and
the vector. B) Agarose gel analysis of digested miniprep samples of mutant P237A, isolated from DH5α
cells. Bands of intermediate molecular weight can be observed in some samples in addition to those of the
insert and vector (lane 2, 4, 5 and 7).
Ideally, restriction digestion of the isolated plasmid should result in two bands
corresponding to the vector and the cloned insert. Such a sample signals a true
positive, i.e. the clone pass the selection as a result of the internalized vector, which in
turn succeed to fuse with the insert during the ligation. In contrast, a false positive is a
clone, which has taken up a self-ligated vector and consequently survives the selection,
but fails to present the cloned insert after digestion. A third alternative is that of samples
presenting additional bands. Unexpected bands can be a sign of supplementary
cleavage sites or star activity. The latter can occur when e.g. excess glycerol or enzyme
is present [131]. Use of Bam H1 is known to cause star activity [132], but can be
avoided when adhering to the suppliers’ recommendations and including BSA in the
digestion set-up [133].
Positive clones were sequenced either by Microsynth or the in-house facility in
Biocenter.
3.2.4 Sequencing results
The sequencing results were obtained as nucleotide sequences and converted into
protein sequences using the Translate tool [134] available through the ExPASY
proteomics server [130]. Thus, correct mutations could easily be confirmed while
simultaneously ascertaining the accuracy of the rest of the sequence. In addition, the
obtained sequences were aligned with the WT H1-CRD sequence utilizing the program
LALIGN, also accessible through ExPASY [135]. Alignment serves as a great aid in
highlighting potential differences and was used to validate the correctness of the
mutated sequence (Figure 41).
Gel A – Digestion mutant C152S
Lane 1: DNA marker X
Lane 2-7: Digested samples isolated
from clone 1-6
Gel B – Digestion mutant P237A
Lane 1: DNA marker X
Lane 2-7: Digested samples isolated
from clone 1-6
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WT M  G  S  E  R  T  C  C  P  V  N  W  V  E  H  E  R  S  C 19
:  :  :  :  :  :        :  :  :  :  :  :  :  :  :  :
Mc7 M  G  S  E  R  T  S  S  P  V  N  W  V  E  H  E  R  S  S 19
WT Y  W  F  S  R  S  G  K  A  W  A  D  A  D  N  Y  C  R  L 38
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 Y  W  F  S  R  S  G  K  A  W  A  D  A  D  N  Y  C  R  L 38
WT E  D  A  H  L  V  V  V  T  S  W  E  E  Q  K  F  V  Q  H 57
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 E  D  A  H  L  V  V  V  T  S  W  E  E  Q  K  F  V  Q  H 57
WT H  I  G  P  V  N  T  W  M  G  L  H  D  Q  N  G  P  W  K 76
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 H  I  G  P  V  N  T  W  M  G  L  H  D  Q  N  G  P  W  K 76
WT W  V  D  G  T  D  Y  E  T  G  F  K  N  W  R  P  E  Q  P 95
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 W  V  D  G  T  D  Y  E  T  G  F  K  N  W  R  P  E  Q  P 95
WT D  D  W  Y  G  H  G  L  G  G  G  E  D  C  A  H  F  T  D 114
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 D  D  W  Y  G  H  G  L  G  G  G  E  D  C  A  H  F  T  D 114
WT D  G  R  W  N  D  D  V  C  Q  R  P  Y  R  W  V  C  E  T 133
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 D  G  R  W  N  D  D  V  C  Q  R  P  Y  R  W  V  C  E  T 133
WT E  L  D  K  A  S  Q  E  P  P  L  L  -  -
:  :  :  :  :  :  :  :  :  :  :  :  :  :
Mc7 E  L  D  K  A  S  Q  E  P  P  L  L  -  -
Figure 41. Alignment of the WT H1-CRD sequence with that of clone 7 of mutant C152/153/164S (here
denoted Mc7). Identical residues in the two sequences are marked with a semicolon, while lack thereof
signals a difference. In addition, the residues differing in the two sequences are denoted by a box.
All planned and attempted mutations could be verified through translation and
alignment, demonstrating the capability of the two applied methods and their
usefulness in site-directed mutagenesis.
3.2.5 Transformation into calcium competent cells
DNA sequences shown to contain the correct mutation(s) were transformed into
calcium competent AD494(DE3) cells and plated on selective LB-agar plates. Colony
formation could be observed after incubation O/N. Randomly chosen clones were
cultivated and screened for high expression levels, comparing non-induced and
induced samples by reducing SDS-PAGE electrophoresis (Figure 42).
Important aspects taken into consideration when selecting a clone intended for large-
scale protein production were 1) markedly high expression levels of the mutant H1-
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CRD, and 2) low expression levels of foreign proteins showing minor variation in the
presence of IPTG.  One or two clones meeting posed criteria were identified for each
mutant protein and conserved as glycerol stocks.
3.2.6 Determination of target protein solubility
The solubility of the mutant proteins was probed according to a protocol established by
Qiagen [110]. Samples collected from non-induced and induced cells were compared
with soluble and insoluble fractions derived from induced cultures using SDS-PAGE
electrophoresis.
Overexpression of mutant H1-CRD could be confirmed by comparing the non-induced
and induced samples, supporting previous findings from the small-scale expression
analysis. No mutant H1-CRD could be spotted in the soluble fraction, while a distinct
band was observed in the insoluble matter (Figure 42). Similar to WT H1-CRD, the
mutants of H1-CRD fail to fold correctly and accumulate as insoluble aggregates in the
bacteria cells. Consequently, the protein must be denatured in order to appear soluble
in solution, followed by renaturation to restore the native structure.
Figure 42. SDS-PAGE analysis of non-induced, induced, soluble and insoluble matter derived from E.coli
cells transformed with the mutant sequence C164S. The mutant protein, corresponding well to the
reference sample of WT H1-CRD, can be spotted in the induced sample, as well as the insoluble fraction.
In contrast, no H1-CRD is seen in the soluble fraction (15% gel, silver staining).
3.3 Expression and characterization of cysteine mutants of
the ASGP-R H1-CRD
Mutant forms of H1-CRD created to investigate the functional importance of the three
cysteines (152, 153, 164) closest to the N-terminus, were expressed and purified
Lane 1: Marker
Lane 2: WT H1-CRD reference
Lane 3: Non-induced sample of AD494(DE3)/mutant C164S
Lane 4: Induced sample of AD494(DE3)/mutant C164S
Lane 5: Soluble fraction derived from induced cells
Lane 6: Insoluble fraction derived from induced cells
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according to the method established for the WT protein. Non-reducing SDS-PAGE
electrophoresis was used to detect dimer formation, while the functionality was
analyzed by the solid-phase competition assay, Biacore and NMR.
3.3.1 Expression and purification of cysteine mutants of H1-CRD
The cysteine mutants of H1-CRD were expressed in E.coli and subsequently purified by
complete denaturation, refolding and affinity chromatography using galactose as a
ligand. The chromatogram profile closely resembled that of WT H1-CRD, exhibiting a
distinct, sharp peak during the elution phase. All seven cysteine mutants could be
purified through this method, indicating that they all maintained binding affinity for
galactose. Eluted fractions were analyzed by SDS-PAGE analysis, showing an apparent
enrichment of mutant protein in the fractions corresponding to the peak.
3.3.2 Analysis of dimer content
Non-reducing SDS-PAGE was used to analyze the dimer content of the cysteine
mutants after purification by affinity chromatography. The gels were developed with
silver staining (Figure 43).
Figure 43. Dimer content of samples analyzed by non-reducing SDS-PAGE after affinity chromatography.
A) WT H1-CRD is compared to the three initially created cysteine mutants. The single mutant C164S and
double mutant C152/153S only show traces of dimer compared to the WT, while no dimers are seen at all
for the triple mutant (15% gel, silver staining). B) Comparison of WT H1-CRD and all seven cysteine
mutants. Dimers can be spotted to a higher or lower degree for all protein samples except the triple
mutant. Bands of higher molecular weight than expected can be observed in several samples (mutant
  A   B
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C153S, C152/153S and C152/153/164S), most likely the result of contamination with bacterial proteins
(15% gel, silver staining).
Three main conclusions can be made from observing the resulting SDS-PAGEs. First,
the single mutants show a significant reduction in dimer formation compared to the
WT. These proteins with an even number of cysteine will preferentially form
intramolecular disulfide bonds. However, intermolecular disulfide bonds can also
occur occasionally as seen from the traces of dimers present in the samples. Second,
the double mutants show dimerization similar to the WT, except when Cys164 remains
as the odd fifth cysteine. It is possible that Cys164 is positioned in such a way that it
cannot easily give rise to dimers, which in turn would suggest that it is in fact engaged
in an intramolecular disulfide bond in native H1-CRD. No obvious difference can be
observed between the C152/164S and C153/164S mutants, indicating that both Cys152
and Cys153 are capable of reacting with a free thiol in a neighboring subunit. Finally,
replacement of all three cysteines completely abolishes dimer formation as proved by
the triple mutant. Hence, the dimer formation seen upon expression of H1-CRD in vitro
is indeed caused by the odd cysteine and intermolecular disulfide bonds. Furthermore,
the cysteines taking part in the third disulfide bridge, Cys153-Cys164, can also give rise
to dimers, as shown by mutant C152S (and the other two single mutants). This
observation together with the successful affinity chromatography purification of the
double and triple mutants suggests that the formation of the third disulfide bond is not
crucial for the binding affinity for Gal. In contrast, the remaining four cysteines in the
subunit do not take part in intermolecular disulfide bonds, indicating that the bridges
they form are stable and an absolute necessity for active H1-CRD.
3.3.3 Separation of monomers and dimers
Separation of monomers and dimers was carried out with ion exchange
chromatography for all cysteine mutants, also the ones showing only traces of dimers
or even none, in order to treat all samples equal (Figure 44). The samples with a high
dimer content, as confirmed by SDS-PAGE analysis, showed a separation profile
closely resembling the WT (see mutant C152/164S in figure 44). The monomers eluted
first (peak 1) with a tailing shoulder peak (peak 2), followed by the impurity peak (peak
3) and finally the dimer peak (peak 4). On the contrary, samples containing merely
traces of dimers were seen to display a single peak corresponding to the monomers (see
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mutant C164S in figure 44). Eluted fractions were controlled with non-reducing SDS-
PAGE (Figure 45A).
Figure 44. Superimposed chromatograms of mutant C164S in blue and mutant C152/164S in red. The
single mutant exhibits only one peak corresponding to the monomers, while the double mutant shows a
distinct separation between its monomers and dimers.
In a final step, the monomers were purified and pooled over a GalNAc-Sep-column on
HPLC. All mutant proteins could be seen to elute as an individual peak, indicating that
they all maintained binding affinity for GalNAc. Samples were analyzed by non-
reducing SDS-PAGE to verify the purity of the proteins (Figure 45B).
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Lane 1: Marker
Lane 2: Mutant C152/164S after FPLC
Lane 3: Monomer fraction – major peak
Lane 4: Monomeric shoulder fraction
Lane 5: Impurity fraction
Lane 6: Dimer fraction
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Figure 45. A) Non-reducing SDS-PAGE analysis of fractions collected during HPLC IEC of mutant
C152/164S (15% gel, silver staining). B) Non-reducing SDS-PAGE analysis of WT H1-CRD and all seven
cysteine mutants after final purification by HPLC affinity chromatography (15% gel, coomassie staining).
3.3.4 Evaluation of the binding affinity of the cysteine mutants
The issue concerning the binding affinity of the cysteine mutants was also addressed
within this work. For the proteins to prove useful in further studies, apart from
preventing dimerization, it is equally important that the mutations do not affect the
binding properties of H1-CRD. Therefore, a non-negotiable demand set for the mutants
was that binding affinity and native behavior of the WT protein would be preserved
after the alterations. To ensure that this was the case, i.e. that the cysteine mutants and
WT H1-CRD showed equivalent affinity, a series of assays were carried out for
comparison. The triple cysteine mutant was the prime candidate for these studies as it
was the only mutant successfully escaping dimer formation. Nevertheless, the other six
substituted proteins were also included in some of the experiments to elucidate the role
of the third disulfide bridge.
3.3.4.1 Evaluation of the cysteine mutants of H1-CRD using the solid-phase
competition assay
Binding affinity of the cysteine mutants for GalNAc was tested using the solid-phase
competition assay and compared with that of the WT. Two approaches were adopted,
the first measuring relative binding of a GalNAc-polymer to the proteins and the
second using a competitive binding set-up allowing for determination of IC50 values.
In the first approach, the cysteine mutants and WT H1-CRD were coated onto plates
O/N at a concentration of 3 µg/ml protein. The plate was then blocked with BSA prior
to incubation with 0.5 µg/ml GalNAc-polymer. No inhibitor was added. The degree of
binding was determined by measuring the absorbance at 415 nm after addition of ABTS
substrate. Relative binding of GalNAc to the mutants was calculated using WT H1-CRD
Lane 1: Marker
Lane 2: WT H1-CRD
Lane 3: Mutant C152S
Lane 4: Mutant C153S
Lane 5: Mutant C164S
Lane 6: Mutant C152/153S
Lane 7: Mutant C152/164S
Lane 8: Mutant C153/164S
Lane 9: Mutant C152/153/164S
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as reference for maximum binding. Two independent measurements, carried out within
four months, are depicted in the graph below (Figure 46).
Figure 46. Results of the solid-phase competition assay expressed as percentage of GalNAc-polymer
binding relative to that of WT H1-CRD. The dark grey columns represent the results obtained from the first
trial. The assay was repeated after approximately four months, the results of which are depicted in light
gray.
An obvious distinction in GalNAc binding can be observed when comparing the
cysteine mutants and WT H1-CRD. GalNAc clearly binds with lower affinity to the
cysteine-substituted proteins, exhibiting less than 50% of the signal intensity of the
wild-type protein. Minimum binding is demonstrated by the triple mutant. The single
mutants and the double mutants show similar binding affinities, but without revealing a
possible dependence on one cysteine or another. Still, it can be concluded that not
only is the third disulfide bridge important for maintaining native binding properties,
but also the seventh odd cysteine. Moreover, comparison of assays carried out at
different occasions demonstrates comparable results, but with a further decrease in
signal intensity and binding of the cysteine mutants. Ranking of the mutant proteins
remains roughly the same, with the triple mutant consistently showing the lowest
degree of binding of all proteins tested. The single and double mutants also display
highly similar results, with minor individual changes. The seemingly time-dependent
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decrease in binding affinity could originate from reduced stability of the cysteine
mutants due to structural alterations, further discussed in section 4.2.2 Furthermore, the
mutant proteins were of rather low concentration, less than 200 µg/ml, which could
also have a negative influence on the protein stability. Taken together, the results
suggest that the cysteine mutants are susceptible to inactivation and it is possible that
only a fraction of the protein samples are actually active and able to bind GalNAc.
The second approach was carried out similarly to the first, but with two exceptions.
The cysteine mutants and WT H1-CRD were coated onto plates O/N at a concentration
of 3 µg/ml protein and 20 mM CaCl2 instead of the previous 1 mM. The calcium
concentration was increased as it had been shown to affect the signal intensity (data
not shown). The plate was blocked with BSA prior to incubation with 0.5 µg/ml
GalN Ac-polymer. Monovalent GalN Ac, acting as inhibitor, was added in
concentrations ranging from 2 mM to 0.06 mM simultaneously with the polymer.
Binding was determined by measuring the absorbance at 415 nm after addition of
ABTS substrate. The results were plotted as percentage polymer binding against
concentration of monovalent GalNAc as seen in figure 47. Maximum binding was
represented by polymer binding in the absence of monosaccharide.
Figure 47. GalNAc-polymer competing with monovalent GalNAc for binding to the cysteine mutants. A)
Percentage polymer binding to mutant C152S in the presence of increasing concentrations of monovalent
GalNAc. B) Percentage polymer binding to mutant C152/153/164S in the presence of increasing
concentrations of monovalent GalNAc.
The resulting graphs, showing a sigmoid dependency curve, were used to determine
the IC50 of GalNAc binding to the different forms of H1-CRD. To facilitate the
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evaluation of the cysteine mutants, relative IC50 (rIC50) values were calculated using
WT H1-CRD as reference. The results are summarized in table 25.
Table 25. Summary of rIC
50
 values derived from the solid-phase competition assay performed with
monovalent GalNAc competing with GalNAc-polymer for binding to the cysteine mutants.
Assay
(rIC50)
C152S C164S C152/153S C152/164S
C152/153
/164S
WT
1 0.32 0.50 0.53 0.31 0.58 1
2 0.40 0.59 0.52 0.42 0.50 1
3 0.32 0.55 0.46 0.38 0.45 1
X±Std. 0.35±0.05 0.55±0.05 0.50±0.04 0.37±0.06 0.51±0.07 1
All cysteine mutants show rIC50 values below zero, indicating that the monovalent
GalNAc is able to inhibit polymer binding to the mutants at lower concentrations than
compared to the WT. The GalNAc-polymer, which is expected to bind stronger due to
its polyvalent nature, clearly exhibits higher affinity for the wild-type protein. The
mutant proteins could experience folding or stability problems, disturbing their
structure and as a result affect their capacity for ligand binding negatively. Comparison
of the mutants reveals rather consistent values around 0.5, with the exception of a
single mutant showing a rIC50 closer to 0.3. Somewhat surprisingly, the triple mutant
does neither show the lowest rIC50 nor does it deviate from the other mutants.
Conversely, it can be argued that it ought to behave similar to the double mutants, also
missing a third disulfide bridge, and not suffer from lack of the odd cysteine. Instead, a
marked divergence between the single mutants and the other altered proteins would be
expected and is further discussed in section 4.2.2. As an additional remark it should be
noted that the cysteine mutants generally gave rise to lower signal intensities than the
WT. One explanation for this observation is the lower polymer binding, but it could
also be attributed to a lesser fraction of active protein present in the mutant samples.
In summary, the cysteine mutants and WT H1-CRD do indeed differ in binding affinity
for GalNAc as proved by the solid-phase competition assay. The ligand consistently
shows higher binding to the wild-type protein, while the mutants repeatedly fall short
in signaling binding. In addition, the stability of the mutated proteins is questioned as
suggested by the reduction in ligand binding over time.
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3.3.4.2 Evaluation of the triple cysteine mutant of H1-CRD using the Biacore
assay
The triple cysteine mutant was immobilized alongside WT H1-CRD on a Biacore
sensor chip using standard amine coupling. Final protein densities obtained were 3400
and 5100 RU of the triple mutant and the wild-type monomers respectively. Dilution
series of GalNAc and Gal were injected and binding to the proteins monitored. The
resulting sensograms were fitted to a 1:1 binding model and KD determined (Figure 48).
Figure 48. A) Binding of Gal (red) and GalNAc (blue) to the triple cysteine mutant of H1-CRD measured by
Biacore. B) Binding of Gal (red) and GalNAc (blue) to WT H1-CRD measured by Biacore.
A conspicuous difference can be observed between the two resulting graphs. The signal
intensity of the triple cysteine mutant is significantly lower compared with that of WT
H1-CRD. While the maximum response recorded for GalNAc binding to the native
protein is around 240, the substituted protein gives rise to a mere 8. The experimentally
determined KD values of GalNAc also differs with 88.5 µM and 157 µM for WT H1-
CRD and the mutant respectively. However, the accuracy of the latter value is difficult
to conclude due to the low signal response. Nevertheless, even though complicated to
quantify, the triple cysteine mutant clearly suffers from problems hampering its activity,
e.g. decreased affinity, deactivation and/or stability problems etc.
KD GalNAc 157 µM
KD Galactose 2.3 mM
Rmax GalNAc 8
KD GalNAc 88.5 µM
KD Galactose 1.7 mM
Rmax GalNAc 240
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3.3.4.3 Evaluation of the triple cysteine mutant of H1-CRD using NMR
T1rho experiments were performed with GalNAc interacting with the triple cysteine
mutant and compared to reference spectra of GalNAc with the wild-type protein (see
section 3.1.4.3). Binding was observed on a qualitative level with a faster decay of
magnetization for the GalNAc in the presence of the mutant protein than in its absence
(Figure 49).
Figure 49. T1rho experiments with GalNAc binding to the triple mutant. The squares () represent GalNAc
bound to the mutant protein, while the triangles () symbolizes the free GalNAc.
Although the spectra obtained for the mutant showed good agreement with the
reference spectra (Figure 28), the results cannot be used for a quantitative measure of
the binding.
3.4 Investigation of the binding site of the ASGP-R H1-CRD
Mutant forms of H1-CRD, created to investigate the functional importance of individual
amino acid residues in the binding site, were expressed and purified according to the
method established for the wild-type protein. The functionality of the mutant proteins
was analyzed by the solid-phase competition assay and Biacore.
3.4.1 Expression and purification of binding site mutants of H1-CRD
The binding site mutants of H1-CRD were expressed in E.coli and subsequently purified
by complete denaturation, refolding and affinity chromatography using galactose as a
ligand.  The chromatograhic profile closely resembled that of the wild-type, exhibiting
a distinct, sharp peak during the elution phase. All five binding site mutants, i.e. P237A,
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E238E, H256E, D259A and D260A, could be purified through this method, indicating
that they all maintained binding affinity for galactose. Eluted fractions were analyzed
by SDS-PAGE analysis, showing an apparent enrichment of mutant protein in the
fractions corresponding to the peak. For mutant H256E, the flow-through and the
eluted peak was seen to be of similar height, indicating a high fraction of non-bound
proteins. In addition, SDS-PAGE analysis showed a protein band corresponding to the
mutant protein in the flow-through, presumably misfolded. In an attempt to recover the
lost protein, the flow-through fraction was denatured and refolded once more. Affinity
chromatography was repeated, showing a small peak during the elution phase. SDS-
PAGE analysis confirmed that the peak consisted of mutant H256E, but the amount was
estimated to be rather low. Therefore, a second denaturation and refolding procedure
was deemed to be of minor significance and contribution, and excluded from further
purification procedures.
Separation of monomers and dimers was carried out with HPLC IEC, showing good
correlation with the separation profile seen for WT H1-CRD. Monomeric protein was
seen to elute first, followed by dimers. In a final step, the monomers were purified and
pooled over a GalNAc-Sep-column on HPLC. All mutant proteins could be seen to
elute as an individual peak, indicating that they all maintained binding affinity for
GalNAc.
3.4.2 Evaluation of the binding site mutants of H1-CRD using the solid-
phase competition assay
The solid-phase competition assay was initially carried out with binding site mutant
P237A and H256E to estimate the relative binding of GalNAc-polymer to the proteins.
The two mutant proteins and WT H1-CRD were coated onto plates O/N at a
concentration of 3 µg/ml protein. The plate was subsequently blocked with BSA,
followed by incubation with 0.5 µg/ml GalNAc-polymer. No inhibitor was added. The
absorbance at 415 nm was measured after addition of ABTS substrate. Relative binding
of GalNAc to the mutants was calculated using WT H1-CRD as reference of maximum
binding. Two independent measurements are depicted in the graph below (Figure 50).
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Figure 50. Results of the solid-phase competition assay performed with mutant P237A and H256E,
expressed as percentage of GalNAc-polymer binding relative to that of WT H1-CRD. The dark grey
columns represents the results obtained from a first trial, while the light gray values are derived from a
second attempt.
Similar to the cysteine mutants, GalNAc binds with decreased affinity to the binding
site mutants compared to the wild-type protein. The first assay showed a relative
binding of 37% and 40% for P237A and H256E respectively. In a repeated assay six
month later, the binding was significantly lower for both mutants. P237A displayed a
mere 12% binding, while H256E was even lower at 5%. The substantial variation in
the experimental data makes it difficult to accurately determine the degree of GalNAc
binding. Nonetheless, while unable to provide a reliable measure of the binding, these
results suggest that the mutant proteins do differ from the wild-type in respect to ligand
binding and/or protein stability. As previously remarked for both the WT monomers
purified by RP and the cysteine mutants, the binding site mutants might suffer from
inactivation, leaving only part of the protein sample active.
The second assay approach was undertaken for all five binding site mutants and
performed in an identical manner to that of the cysteine mutants. The proteins were
coated O/N at a concentration of 3 µg/ml protein and 20 mM CaCl2. Blocking with BSA
was followed by simultaneous incubation of 0.5 µg/ml GalNAc-polymer and
monovalent GalNAc. The latter was added in concentrations ranging from 2 mM to
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0.06 mM. The absorbance at 415 nm was measured after addition of ABTS substrate.
The results were plotted as percentage binding of the polymer against concentration of
monovalent GalNAc (Figure 51).
Figure 51. GalNAc-polymer competing with monovalent GalNAc for binding to binding site mutants of
H1-CRD. A) Percentage polymer binding to mutant D259A in the presence of increasing concentrations
monovalent GalNAc. B) Percentage polymer binding to mutant D260A in the presence of increasing
concentrations of monovalent GalNAc. A reliable IC
50
 value could not be determined (nd) from the graph.
As for the cysteine mutants, IC50 of monovalent GalNAc binding to the mutants was
determined and expressed as rIC50 using WT H1-CRD as reference. The results are
summarized in table 26.
Table 26. Summary of rIC
50
 values derived from the solid-phase competition assay performed with
monovalent GalNAc competing with GalNAc-polymer for binding to the binding site mutants.
Assay
(rIC50)
P237A E238G H256E D259A D260A WT
1 0.75 2.89 0.57 0.71 nd. 1
2 0.72 4.19 0.54 0.58 nd. 1
3 0.87 5.85 nd. 0.74 nd. 1
X±Std. 0.78±0.08 4.31±1.48 0.56±0.02 0.68±0.09 (-) 1
Of the five binding site mutants, four display an average rIC50 below one, indicating
that the GalNAc polymer binds the mutant proteins with lower affinity compared to
WT H1-CRD. Two mutants, P237A and D259A exhibit values fairly close to one,
suggesting that the effect of the mutations is minor. The residues in question have not
previously been implicated in ligand binding and could be of structural rather than
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functional importance, further discussed in section 4.3.1. Mutant H256E also show a
rIC50 below one, as can be expected. Previous studies have identified His256 as a
critical residue in the selectivity and binding of GalNAc [7]. Binding site mutant
D260A failed to produce convincing results. The signal intensity was very low despite
prolonged detection time, complicating the evaluation. The resulting graphs would
barely show a sigmoid curve. Adding to the uncertainty is the variability in absorbance
measured for the replicates of different concentrations of monovalent GalNAc which
were tested. Although the experimental data suggest that the binding affinity of mutant
D260A for GalNAc is significantly decreased, a quantitative measure could not be
determined. Finally, one of the five binding mutants appeared to bind the GalNAc
polymer with a higher affinity than WT H1-CRD. Mutant E238G displayed
exceptionally strong signals in the assay, resulting in high IC50 values and rIC50s above
one. However, the rIC50s showed a rather high variation and while it can be said that
GalNAc binds the mutant protein roughly three times better than the wild-type, a
second assay is needed to corroborate these findings.
3.4.3 Evaluation of the binding site mutants of H1-CRD using the Biacore
assay
Mutant P237A was immobilized alongside WT H1-CRD on a Biacore sensor chip,
resulting in protein densities of 5300 and 5100 RU for the mutant and wild-type
monomers, respectively. Dilution series of GalNAc and Gal were injected and the
obtained sensograms fitted to a 1:1 binding model (Figure 48B, Figure 52).
Figure 52. Binding of Gal (red) and GalNAc (blue) to mutant P237A as measured by Biacore. The reference
data are derived from the graph presented in section 3.3.4.2.
Mutant P237A
KD GalNAc 71.4 µM
KD Galactose 1.4 mM
Rmax 145
Reference WT H1-CRD
KD GalNAc 88.5 µM
KD Galactose 1.7 mM
Rmax 240
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Mutant P237A can be seen to show binding affinities in the same range as WT H1-
CRD, even though the signal intensity admittedly is lower. The mutant protein displays
a maximum response of 145 compared to 240 of the wild-type. Despite the difference
in signal intensity, the KD values for GalNAc showed good agreement with 88.5 µM
and 71.4 µM for WT H1-CRD and the mutant respectively.
3.4.4 Probing pH-dependent ligand binding of mutant H256E
Ligand binding to mutant H256E was also studied at different pHs to deduce the pH-
dependency. His256 in H1-CRD has been implicated as an important residue for
ligand release at endosomal pH [96]. Ligand binding is likely to be interrupted due to
protonation of the histidine and subsequent destabilization of a calcium- and ligand
binding residue in the binding site. A glutamate, the corresponding residue in H2-CRD,
is expected to be less influenced by the endosomal pH 5.4 as it would remain
deprotonated and able to accept stabilizing hydrogen bonds. To verify this assumption,
mutant H256E was analyzed by the solid-phase assay and Biacore at different pHs.
3.4.4.1 Probing pH-dependent binding affinity with the solid-phase competition
assay
The solid-phase competition assay was carried out according to the first approach, only
adding polymer to the protein. In order to investigate the effect of pH on binding, the
polymer was prepared in buffer of different pHs, ranging from 7.4 to 5. Each pH was
tested with four protein replicates. Following incubation and washing, the absorbance
at 415 nm was measured after addition of ABTS substrate. The results were depicted in
separate graphs for the mutant protein and the WT (Figure 53).
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Figure 53. A) Binding of GalNAc polymer to WT H1-CRD measured at different pHs. B) Binding of
GalNAc polymer to mutant H256E measured at different pHs. Note that the graphs are only qualitatively
comparable, and not quantitatively. The mutant protein required longer detection time than the WT, which
in turn would have reached saturation during the corresponding time period.
The results obtained for the WT showed a significant decrease in signal intensity
accompanying the decrease in pH. Binding of the GalNAc polymer was reduced as the
1.1.1.6
B
A
120
pH was lowered beyond 7. At pH 5, only a tenth of the binding at physiological pH
could be detected. A decrease in binding could also be observed for mutant H256E,
but not to the same extent. The lowest signal intensity was detected at pH 6,
approximately a third of that seen at pH 7.4. In this context it should also be remarked
that the results of the two proteins cannot be directly compared. Since mutant H256E
suffered from low signal response, the development time had been prolonged. In
contrast, the WT gave rise to strong signals within a fairly short time, threatening to
reach saturation if extended further. Still, even though the absolute signal values are not
comparable, the profiles are.
3.4.4.2 Probing pH-dependent binding affinity using Biacore
WT H1-CRD and two independently produced batches of mutant H256E were
immobilized on a Biacore sensor chip. Even though all three protein samples were of
similar concentrations, both mutants required prolonged immobilization times, 20 vs. 5
minutes. Still, the final protein density obtained was lower for the mutants, 3000 RU
compared to 5300 RU for the wild-type. GalNAc was screened in buffers at different
pHs, ranging from 7.4 to 5.5, and both affinity and intensity was monitored (Figure 54).
KD of GalNAc was determined for each individual pH tested.
Figure 54. A) GalNAc binding affinity of WT H1-CRD (full line) and mutant H256E at pH ranging from 7.4
to 5.5. Two separately prepared samples of mutant H256E were included, represented by the two dashed
lines. B) Percentage GalNAc binding capacity of WT H1-CRD and mutant H256E at pH ranging from 7.4
to 5.5.
All H1-CRD samples could be seen to show a dramatic loss of affinity below pH 6.0.
The KD is stable between pH 7.4 and 6.0, but deviates noticeably once the pH is
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lowered further. Comparison of the mutant and the wild-type revealed that, although
affected, the former appeared less sensitive to the drop in pH. This observation is
further supported by the fact that the two mutant samples showed close to identical
results. However, similar to the triple cysteine mutant, mutant H256E also suffers from
the drawback of low signal intensity with a maximum response around 23 compared to
263 of WT H1-CRD.
3.5 Expression and purification of isotope labeled H1-CRD
Isotope labeled protein has shown to be invaluable for structural and dynamic studies
with biomolecular NMR. By incorporating isotopes such as 13C and 15N, heteronuclear,
multidimensional NMR experiments can be performed, permitting routinely analysis of
proteins on the order of 20 kDa in molecular weight [83]. In this project, a method to
generate uniformly isotope labeled H1-CRD was developed, with the further aim to
study protein-ligand interactions and solve the protein structure by NMR.
3.5.1 Expression of isotope labeled H1-CRD using a two-stage protocol
Expression of isotope labeled H1-CRD was initially attempted by using the two-stage
protocol developed by Marley et al., [90]. E.coli AD494(DE3) and BL21(DE3) cells,
transformed with pET-3bH1, were grown to high density in rich medium and
subsequently exchanged into minimal medium. After 1.5-2.0 hours’ incubation,
allowing for depletion of remaining unlabeled nutrients, expression was induced by
addition of IPTG. Growth and expression levels were monitored throughout the
experiment. Non-induced and induced samples were lysed and denatured prior to
analysis by reducing SDS-PAGE (Figure 55).
  
Figure 55. A) Reducing SDS-PAGE analysis of induced fractions collected from AD494(DE3) cells grown in
minimal medium (15% gel, silver staining). Only traces of H1-CRD can be spotted in the expressed
samples (lane 2-5). B) Reducing SDS-PAGE analysis of non-induced and induced fractions collected from
Gel A – AD494(DE3) cells
Lane 1: Reference H1-CRD
Lane 2-5: Induced samples after
4, 15, 20 and 24 hours
Gel B – BL21(DE3) cells
Lane 1: Marker
Lane 2: Reference H1-CRD
Lane 3: Non-induced sample
Lane 4-7: Induced samples after
2, 4.5, 8, 19.5 and 24.5 hours
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BL21(DE3) cells grown in minimal medium (15% gel, silver staining). H1-CRD can be observed in all
induced samples (lane 4-7), already after 2 hours expression.
Induced samples of AD494(DE3) failed to show expression of H1-CRD in minimal
medium. At best, traces of protein corresponding to the size of monomeric H1-CRD
were seen, though the actual identity of the protein remained disputable. In contrast,
BL21(DE3) clearly exhibited overexpression of H1-CRD in minimal medium. Distinct
bands of H1-CRD could be seen expressed over time in analyzed samples.
At further comparison of the two bacteria strains, a difference in growth rate was
observed (Figure 56). AD494(DE3) showed an increase in cell number of maximum
25% after inoculation in minimal medium, while corresponding measure for
BL21(DE3) was roughly 66%. In this context it should be remarked that the two
expression attempts were not completely equivalent as expression temperature and
inoculation OD varied between the set-ups. Still, repeated expression attempts with
AD494(DE3) grown at different temperatures indicated the same, the strain failed to
grow in minimal medium. Hence, the distinction in growth rate between the two
strains should be kept in mind.
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Figure 56. Superimposed growth curves of E.coli AD494(DE3) (blue) and BL21(DE) (green). Cells were
initially grown in rich medium, followed by an exchange into minimal medium (represented by the gaps in
the curves). Induction by IPTG is marked by an orange dot.
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Based on these results, it was decided to use BL21(DE3) for expression of isotope
labeled H1-CRD.
3.5.1.1 Optimization of the expression set-up using experimental design
The set-up for expression of isotope labeled H1-CRD from E.coli BL21(DE3) according
to the two-stage protocol was optimized in terms of expression temperature, cell
concentration factor, inoculation culture medium, IPTG concentration and expression
time. An experimental design approach was undertaken to determine the most
favorable conditions, i.e. a number of experiments was run in which the factors were
varied systematically. Following the expression attempts, non-induced and induced
samples from each culture were initially compared at each selected temperature level
by SDS-PAGE analysis (Figure 57).
Figure 57. Reducing SDS-PAGE analysis of samples collected after H1-CRD expression at 25°C in minimal
medium. After growth in rich medium, either LB (lane 3-7) or TB (lane 8-12), the BL21(DE3) cells were
inoculated in minimal medium and concentrated with a factor of 2. Expression levels over time were
monitored (15% gel, coomassie staining).
Samples showing the highest expression levels were identified, indicating which
conditions were most favorable at each specific expression temperature. The results
were summarized and displayed as shown in figure 58 below.
Lane 1: Marker
Lane 2: Reference H1-CRD
Lane 3: Non-induced sample – LB medium
Lane 4-7: Induced samples after 1, 5, 16 and 23
hours
Lane 8: Non-induced sample – TB medium
Lane 9-12: Induced samples after 1, 5, 16 and 23
hours
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Figure 58. Optional growth and expression conditions, when using the two-stage protocol, graphically
presented. The performed experiments are marked with circles. In addition, the set-up showing best yields
at each selected temperature level is denoted with a cross.
Based on the experiments and the summary, a number of conclusions could be made.
First, use of TB medium as growth culture medium gave the highest expression yields
regardless of the expression temperature. It appears that preconditioning of the cells, to
provide them with excess nutrients, have a positive influence on the protein expression
in minimal medium. Second, to concentrate the cells as much as up to 6 times did not
show to be optimal at any of the temperature levels tested. A concentration factor of 4
exhibited best outcome at the lower temperatures, i.e. 25°C and 30°C, while a
concentration factor of 2 was most favorable at 37°C. In short, a considerable increase
in cell concentration will result in higher protein yields at low temperatures, but it is
not beneficial to increase the cell number above an OD of 2 at 37°C. Third,
experiments carried out at 37°C showed highest protein yields during the first 10 hours,
while samples taken at later stages exhibited less H1-CRD. In contrast, expression
carried out at 25°C displayed a relatively constant protein amount after 5, 16 and 23
hours. Taken together these results indicate that, when expressed in E.coli, H1-CRD is
more stable at lower temperatures, possibly due to decreased or slower protein
degradation. Fourth, a conclusion about the optimal IPTG concentration proved
difficult to make as no obvious difference could be discerned between cultures induced
by the lower of higher concentration during the experiments. The expression yield
appeared to increase slightly with a high IPTG concentration at the lower temperatures.
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In order to determine the optimal expression temperature, the samples presenting the
best protein yields for each level were analyzed together by reducing SDS-PAGE
electrophoresis (Figure 59).
Figure 59. Reducing SDS-PAGE analysis of induced samples presenting the best protein yields at each
temperature level tested (15% gel, coomassie staining).
Expression at 30°C could be seen to result in the highest yields of H1-CRD (lane 5).
Compared to the expression set-up at 25°C (lane 7 and 8), which was identical apart
from the temperature, more intense bands of H1-CRD were observed at 30°C (lane 5
and 6). Looking at the samples induced at 37°C (lane 3 and 4), a significant difference
in protein yields could be seen. Expression of both H1-CRD and other proteins was
substantially lower at 37°C. In this case, it should be considered that the expression set-
up differed also in regard to the concentration factor of cells. At 37°C, a concentration
factor of 2 was used, while the cells were concentrated up to 4 times at 30°C. The
lower concentration of cells could explain why the samples at 37°C, in particular the
bacterial proteins, differ so much in intensity. Nonetheless, it was concluded that the
optimal expression temperature was 30°C. As previously mentioned, TB medium and a
concentration factor of 4 had been determined as the most favorable conditions at that
temperature.
Optimal expression time and IPTG concentration were determined in a separate
experiment. The expression trial was run according to the optimized conditions, using
two cultures differing only in IPTG concentration, i.e. 0.4 mM and 1 mM IPTG,
respectively. Samples were collected regularly and analyzed with reducing SDS-PAGE
(Figure 60).
  1       2        3       4       5        6       7       8
Lane 1: Marker
Lane 2: H1-CRD (1µg)
Lane 3: Sample - 37°C, 2X, 6.5 hrs
Lane 4: Sample - 37°C, 2X, 23 hrs
Lane 5: Sample - 30°C, 4X, 4 hrs
Lane 6: Sample - 30°C, 4X, 10 hrs
Lane 7: Sample - 25°C, 4X, 5 hrs
Lane 8: Sample - 25°C, 4X, 16hrs
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Figure 60. Reducing SDS-PAGE analysis of culture samples induced either by 0.4 mM (lane 3-8) or 1.0
mM (lane 9-14) IPTG (15% gel, coomassie staining).
The two cultures showed highly similar expression patterns. Most H1-CRD could be
spotted after 3 and 5 hours, while samples taken later showed decreased levels, an
observation true for both set-ups. Due to this and previous evaluations, it was decided
that expression should be kept to maximum 5 hours. At further comparison, a small
difference could be detected in the intensity of the protein bands between the samples,
indicating a higher yield at induction with 1 mM IPTG. It was concluded that the
higher IPTG concentration tested was most beneficial and was to be used in further
experiments.
Possible benefits of adding labeled rich medium to the minimal medium were
evaluated in a final experiment in the optimization trial. The expression trial was run
according to the optimized conditions, using two cultures differing only in addition of
rich medium, i.e. one was grown according to the standard protocol and one
supplemented with 20% E.coli OD2 Silantes [136]. Samples were collected regularly
and analyzed with reducing SDS-PAGE. However, addition of rich medium was seen to
result only in a modest increase of expressed H1-CRD. The culture supplemented with
E.coli OD2 Silantes exhibited bands of H1-CRD slightly more intense than the control
culture. However, since the difference appeared to be minor, it was not deemed as
significant enough to include addition of rich medium in the procedure. Labeled rich
media, such as E.coli OD2 Silantes, are more expensive than minimal medium and to
use the former as a supplement would not be cost effective in the long run.
Lane 1: Marker
Lane 2: Reference H1-CRD
Lane 3: Non-induced sample – 0.4 mM IPTG
Lane 4-8: Induced samples after 3, 5, 19, 24 and
29 hours
Lane 9: Non-induced sample – 1 mM IPTG
Lane 10-14: Induced samples after 3, 5, 19, 24
and 29 hours
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3.5.1.2 Expression of H1-CRD according to the two-stage protocol under
optimized conditions
Uniform labeling with only 15N as well as combined with 13C was carried out according
to the two-stage protocol. E.coli BL21(DE3) cells were grown to high density in TB
medium and subsequently exchanged into minimal medium according to the
optimized conditions. After 1 hour’s incubation, expression was induced by addition of
1 mM IPTG and left for 5 hours. The bacteria were shown to increase in cell numbers
after inoculation in the minimal medium. Following addition of IPTG, the growth rate
slowed down and reached steady state. A 400 ml culture was seen to result in
approximately 6 gram of bacteria pellet after centrifugation.
Collected bacteria pellets were lysed in proportion to the initial volume of rich media
used to ensure complete lysis of all bacteria and maximal extraction of protein. Hence,
a pellet from a 400 ml minimal medium culture was treated according to its initial
growth conditions, i.e. 3x525 ml, during the purification. The protein was subsequently
refolded by stepwise dialysis and purified by affinity chromatography on a FPLC
system. The dialysed protein solution was divided into two runs à 115 ml load each to
avoid overloading the column. H1-CRD could be observed in the chromatogram as a
sharp peak, indicating correct folding and binding to galactose. Eluted fractions were
analyzed by reducing SDS-PAGE, in which H1-CRD was found in the fractions
corresponding to the peak. Traces of H1-CRD could also be spotted in the flow-
through, but to such a low extent it was not deemed as significant.
HPLC IEC was used to separate monomers and dimers of the isotope labeled H1-CRD
prior to studies by NMR. Monomeric H1-CRD indisputably dominated the isotope
labeled samples, seen as a high peak with a tailing end during IEC. In contrast, the
dimeric peak was considerably lower, best seen in the double-labeled sample of H1-
CRD. The difference could also be observed in the 15N labeled sample, although it was
less pronounced. Collected fractions were analyzed with non-reducing SDS-PAGE
electrophoresis (Figure 61).
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Figure 61. Reducing SDS-PAGE analysis providing an overview of the purification of 13C/15N labeled H1-
CRD (15% gel, coomassie staining).
The analysis confirmed previous findings, i.e. the monomeric fraction exhibits traces of
dimers even after the separation step. The dimeric fraction on the other hand appears
homogenous with one single band. Furthermore, the monomers could be shown to
exceed the dimers in numbers prior to the separation, supporting the results of the
HPLC IEC.
Collected monomers were concentrated with a simultaneous buffer exchange prior to
concentration determination by Bradford. Samples were stored at –20°C until use for
NMR studies (Table 27).
Table 27. Samples of isotope labeled H1-CRD generated by the two-stage protocol.
Sample Culture volume Conc. (µg/ml) Amount (µg)
15N H1-CRD 400 ml 465 930
13C/15N H1-CRD 400 ml 182 182
3.5.2 Analysis of the isotopic enrichment using NMR
The double labeled H1-CRD, expressed according to the two-stage protocol, was
analyzed by 1D NMR half-filter experiment to assess the extent of 13C enrichment. Prior
to its analysis, two control experiments were performed to establish reference spectra
for a sample at natural abundance versus one with 100% 13C enrichment.
The half-filter experiment separates the data into two spectra, one resulting from
hydrogens directly bound to 12C, and the other from hydrogens directly bound to 13C
(Figure 62). For the sample at natural abundance, an E-selectin antagonist [127] was
analyzed. The result derived from the 12C bound hydrogens displayed a spectrum with
Lane 1: Marker
Lane 2: Reference H1-CRD
Lane 3: 13C/15N sample – FPLC
Lane 4: Sample desalted and concentrated
prior to HPLC IEC
Lane 5: Monomer sample – IEC run 1
Lane 6: Dimer sample – IEC run 1
Lane 7: Monomer sample – IEC run 2
1      2       3       4      5       6     7
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several intense peaks, while the corresponding spectrum for the 13C bound hydrogens
showed significantly diminished (if any) peaks. These results are in good agreement
with the known 1.1% natural occurrence of 13C. For acetic acid, the sample fully
enriched with 13C, the resulting spectra showed a reversed pattern. Nearly all of the
signals were filtered into the spectrum corresponding to 13C bound hydrogens while
only a minor response was detected for the 12C bound hydrogens. These two control
samples indicated that the experiment was optimized sufficiently to test for an
unknown level of 13C enrichment.
Figure 62. NMR half-filter experiments designed to estimate isotopic incorporation. The upper two rows
correspond to control samples used to verify the method with an expected result. The lowest row is the
actual test performed on the double labeled H1-CRD.
The half-filter experiment applied to the double labeled H1-CRD demonstrated that the
level of 13C enrichment was much less than expected. The majority of signals appear in
the 12C filtered spectrum with the peaks in the range of 0 to about 3 ppm corresponding
to side-chain hydrogens. Peaks at similar frequencies can also be seen in the equivalent
13C spectrum. The peaks in the 13C spectrum differ from those in the 12C spectrum as the
former are composed of doublets, dividing each peak in two and subsequently
decreasing signal height. The intense peaks found at 3.8 and 4.7 ppm can be attributed
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to residual buffer and water, respectively. The absence of these intense peaks in the 13C
filtered spectrum is to be anticipated as they are not bound to 13C nuclei. To accurately
determine the extent of isotopic incorporation, the frequency range needed to be
integrated. Upon integration, the relative distribution of signals indicated that
approximately 60% of hydrogens were bound to 12C and 40% to 13C. A low level of
isotopic enrichment (>90%) would require prolonged experimental measurement time,
which would not be possible given finite magnetic field and protein stability. In
addition, a high incorporation rate is more critical for 13C than for 15N [85].
3.5.3 Mass spectrometry analysis of isotope labeled H1-CRD produced by
the two-stage protocol
HPLC RP chromatography was used to separate monomers and dimers prior to MS
analysis, aiming to determine the incorporation of 15N and 13C. Even though the RP
chromatography method was shown to negatively influence the activity of H1-CRD
(see section 3.1.4), it holds an advantage when preparing samples for MS. The resulting
protein samples can easily be lyophilized, unlike samples prepared by HPLC IEC.
Furthermore, MS analysis can be performed regardless of whether the protein is
correctly folded or not, and therefore the activity is of less concern. The monomers
could be seen in the chromatogram as a sharp peak, close but clearly separated from
the following dimer peak. The monomeric fraction was lyophilized and analyzed by
MS. An equivalent sample of unlabeled monomeric H1-CRD was used as reference.
Deconvolution of the resulting MS spectra revealed an unexpected high degree of
similarity between the samples (Figure 63).
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Figure 63. A) MS spectra of unlabeled H1-CRD. The major fragment shows a mass of 16853 Da, explained
by cleavage of the N-terminal methionine. B) MS spectra of 13C/15N labeled H1-CRD. The major fragment
shows a mass of 16854 Da.
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The average mass of unlabeled H1-CRD is estimated to 16991 Da, while
corresponding masses for 15N and 13C/15N labeled H1-CRD are 17201 and 17953 Da,
respectively.  The major peak seen in the reference spectra of unlabeled H1-CRD
showed a mass of 16853Da. The difference of 138 Da can be deduced to cleavage of
the N-terminal Methionine (-131 Da) and reduction of the disulfide bridges (+2 Da per
broken bond). Unexpectedly, the major peak shown in the spectra of 13C/15N labeled
H1-CRD has a mass of 16854 Da, closely resembling the unlabeled sample. A minor
peak can be seen at 16929 and lots of small, merged peaks around 17750 Da. The
latter peaks correspond well with masses expected for double-labeled H1-CRD, but
constitute an inferior part of the protein sample. Similar results were found for the 15N
labeled H1-CRD with a major peak at 16853Da. In summary, the MS results proved
that primarily unlabeled H1-CRD was expressed during the experiments and only a
minor population of labeled H1-CRD was present in the final samples.
Multidimensional NMR experiments rely on usage of highly enriched isotope labeled
proteins and these samples, produced according to the two-stage protocol, would
therefore not be of satisfactory quality. The method either needs to be improved or
exchanged in order to fulfill the demands.
3.5.4 HSQC of 15N labeled H1-CRD expressed according to the two-stage
protocol
15N labeled H1-CRD, expressed according to the two-stage protocol, was recorded
using a 2D HSQC experiment on a 800 MHz NMR equipped with a low-temperature
cryoprobe. The HSQC spectrum, although weak in intensity, displays numerous signals
that are significantly stronger than the noise and therefore correspond to 15N enriched
amino acids (Figure 64).
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Figure 64. HSQC spectrum of 15N labeled H1-CRD. The vertical and horizontal insets are taken from the
frequencies of the circled peak, which represents the most intense signal.
The peaks are well dispersed in the 1H dimension, indicative of a stable tertiary
structure. One factor determining the distribution of amide hydrogen chemical shifts in
a folded protein is the various degrees of hydrogen bonding in different structural
elements. If the protein was not folded, the amide hydrogens would experience an
averaged chemical shift due to a high degree of flexibility. Consequently, the amide
hydrogen peaks would be expected to be confined within a narrower range of 1H
frequencies [137,138].
Even though the amide hydrogens of the protein could be observed, a measurement
time longer than expected was required to obtain clear signals with a reasonable
degree of confidence. At the current level of technology, an 800 MHz NMR using a
cryoprobe is among the most sensitive spectrometers available [139]. Assuming a high
15N incorporation rate and high protein concentration, an adequate measurement time
of 10 minutes would have been anticipated, rather than of 6 hours. Three-dimensional
NMR experiments, aiming to determine the structure, would need at least one month
measurement time each with this sample. Due to the drift of the magnetic field during
this time, and the availability of the instrument, such experiments would be impossible.
134
Therefore, either the sample quality or quantity or both ought to be substantially
improved before attempting structural analysis.
3.5.5 HMQC of 13C/15N labeled H1-CRD expressed according to the two-
stage protocol
13C/15N labeled H1-CRD, expressed according to the two-stage protocol, was recorded
using a 2D HMQC experiment on a 500 MHz NMR. The spectrum shows the
characteristic diagonal distribution of alpha and beta carbons associated with a protein
(Figure 65). The downfield region represents the alpha carbons, while the beta carbons
can be seen in the upfield region.
Figure 65. HMQC spectrum of 13C/15N labeled H1-CRD. The vertical and horizontal insets are taken from the
frequencies of a representative peak.
The observed signals were weak given the extended measurement time. Similar to the
15N H1-CRD sample measured by HSQC at 800 MHz, the double enriched sample did
not show satisfying results to fulfill the prerequisites for structural analysis.
3.5.6 Alternative expression set-up of the two-stage protocol
Uniform labeling of H1-CRD with 15N was attempted with the alternative two-stage
protocol, aiming to improve the labeling efficiency. E.coli BL21(DE3) cells were grown
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to high density in LB medium and subsequently exchanged into minimal medium,
concentrating the cells with a factor of 4. After 2 hours’ incubation, expression was
induced by addition of 0.4 mM IPTG and left for 5 hours. The cell numbers were fairly
constant, showing a small decrease, during the first 2 hours. Following induction, an
increase in cell density could be observed. A 100 ml minimal medium culture gave a
final bacteria pellet of 1.75 gram.
H1-CRD was purified by the previously described and applied procedure, comprising
denaturation, refolding and purification by affinity chromatography. HPLC RP
chromatography was used to separate monomers and dimers prior to MS analysis (see
section 3.5.3). The monomers could be seen in the RP chromatogram as a peak with a
tailing shoulder, closely separated from the following smaller dimer peak.
The monomeric fraction was lyophilized and analyzed by MS, aiming to determine the
incorporation of 15N. As stated earlier, the expected molecular weight of H1-CRD
completely labeled with 15N is 17201 Da. This most recent sample showed a major
fragment with an average molecular weight of 17053 Da. The level of isotope
incorporation can be calculated by dividing the difference of the experimental labeled
and unlabeled masses with the difference of the theoretical labeled and unlabeled
masses. Using the data from the MS analysis of unlabeled H1-CRD (see section 3.5.5)
gives an experimental difference of 200, compared to a theoretical difference of 211.
Consequently, the isotope enrichment could be calculated to 95%.
3.5.7 Expression of isotope labeled H1-CRD by exclusive use of minimal
medium
As the two-stage protocol initially failed to produce isotope labeled H1-CRD, a second
method was attempted. Uniform labeling with only 15N as well as combined with 13C
was carried out according to the protocol for expression by exclusive use of minimal
medium. A small preculture was grown in unlabeled minimal medium O/N and
subsequently diluted 10X in labeled minimal medium the following day. Expression
was attempted at 30°C and 37°C, favoring the latter temperature as the protein yields
appeared slightly higher. Expression was induced at an OD of 1.0 and lasted 5 hours.
Growth and expression levels were monitored throughout the experiment. Cell
numbers could be seen to increase steadily after addition of IPTG. A batch of 3 cultures
à 500 ml would typically yield around 14 gram bacteria pellet. The protein was
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purified according to the standard method established for H1-CRD. Following
solubilization and refolding, the protein was purified by affinity chromatography on a
FPLC system (Figure 66).
Figure 66. FPLC affinity chromatography of 15N labeled H1-CRD expressed by exclusive use of minimal
medium. A sharp peak can be seen during the elution phase, representing the purified protein.
H1-CRD could be seen in the chromatogram as a sharp peak during the elution phase,
indicating correct folding and binding to galactose. Eluted fractions were analyzed by
reducing SDS-PAGE, showing good agreement with the affinity chromatography and
indicating a high yield of purified H1-CRD.
HPLC IEC was used to separate monomers and dimers of the isotope labeled H1-CRD
prior to studies by NMR (Figure 67). The resulting chromatograms showed one
dominant peak with a tailing shoulder at the time expected for elution of monomers.
The impurity could not be detected, while the presence of dimers was negligible. The
separation profile looked the same for both 15N and 13C/15N labeled H1-CRD.
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Figure 67. Separation of monomers and dimers by HPLC ion exchange chromatography of 13C/15N labeled
H1-CRD. An dominant peak of monomers can be seen, while the presence of dimers is negligible.
Collected monomers were concentrated with a simultaneous buffer exchange prior to
concentration determination by Bradford. Samples were stored at –20°C until use for
NMR studies (Table 28).
Table 28. Samples of isotope labeled H1-CRD generated by exclusive use of minimal medium.
Sample Culture volume Conc. (mg/ml) Amount (µg)
15N H1-CRD 3 x 500 ml 2.88 720
13C/15N H1-CRD 3 x 500 ml 2.43 608
HPLC RP chromatography was used for separation of monomers and dimers prior to
MS analysis (see section 3.5.3). The monomers could be seen as a peak with a tailing
shoulder, while the dimeric fraction was minor. The monomers were lyophilized and
submitted for MS (Figure 68).
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Figure 68. MS spectra of 15N labeled H1-CRD. The major fragment shows a mass of 17060 Da.
Analysis of 15N labeled H1-CRD showed a major fragment with an estimated average
molecular weight of 17060 Da, i.e. a difference of 207 Da compared to the reference
spectra of unlabeled H1-CRD. Dividing the experimental mass difference with the
theoretical difference of 211 Da gives an isotopic enrichment of 98%. Corresponding
results for the 13C/15N labeled H1-CRD displayed a deviation of 935 Da when
comparing the experimental data. With an expected mass difference of 962 Da, the
isotope incorporation can be determined to 97%.
3.5.8 HSQC of 15N labeled H1-CRD produced by exclusive use of minimal
medium
15N labeled H1-CRD was recorded using a 2D HSQC experiment on a 600 MHz NMR.
The HSQC spectrum acquired within 10 minutes measurement time showed strong
signals, which indicated that a significant amount of isotopically enriched protein was
present (Figure 69). Similar to the measurements with the sample used on the 800
MHz, the peaks were well dispersed in the 1H dimension, indicative of a stable tertiary
structure. The greater signal-to-noise of the peaks measured at 600 MHz increased the
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reliability that the observed signals actually corresponded to amide resonances in the
protein. The high quality of the sample, as proved by this initial NMR experiment and
the MS analysis, makes it eligible to attempt more challenging experiments required for
protein NMR assignment and structural analysis.
A
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Figure 69. HSQC spectrum of 15N labeled H1-CRD. A) The entire spectral width of the protein is shown
with a series of different GalNAc concentrations. B) To aid in visualization, one of the amide residues
showing a perturbed resonance in the presence of GalNAc is expanded. In addition to the aforementioned
residue, several other residues are shown which remain at their location and are therefore assumed not to
be involved in binding.
Binding to the protein was investigated by adding a series of different concentrations of
GalNAc and monitoring changes in HSQC peak positions (Figure 69) [93]. The
observed peaks in the spectrum represent the average chemical shift of the free and
bound form of the protein at each concentration of GalNAc. With no GalNAc added,
this average is purely due to the free form. In contrast, at a saturating concentration of
GalNAc, all protein will exist in a bound state. At intermittent concentrations, both free
and bound forms of the protein are present, shifting the position of the peak in between
the two extremes. Analysis of the changes in the peak position with differing amounts
of ligand allows the determination of the affinity constant. Superimposing HSQC
spectra of H1-CRD with different GalNAc concentrations demonstrated that the
majority of the peaks were unaffected, however, a number of peaks could be seen to
change location. The relocated peaks moved in a uniform manner, reaching their final
position at the same GalNAc concentration, proving the specificity of the binding. The
preliminary results indicated that the KD of GalNAc to H1-CRD was 100 µM. This value
B
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was determined from the concentration of GalNAc required to shift the peaks halfway
from their initial position to their saturated location.
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4 Discussion
4.1 Expression and purification of H1-CRD – protein
production interrupted
Access to protein in milligram amounts is a prerequisite for structural and functional
protein studies. Recombinant DNA technology combined with heterologous expression
systems have been of immense importance to facilitate protein production and to fulfill
these needs. A protocol for the expression of ASGP-R H1-CRD in E.coli has previously
been established and enabled determination of the crystal structure of the subunit in
2000 [5]. The original protocol was further optimized in a doctoral thesis by Rita Born
at IMP, greatly improving the yields [94]. The optimized expression and purification
method was employed within this PhD-thesis. The protein, present in inclusion bodies
after expression, is denatured and reduced during the purification procedure. To
recover the native structure, it is refolded through step-wise dialysis and finally purified
by affinity chromatography. The procedure is fairly straightforward and only utilizes
conventional reagents. However, it suffers from a major setback as the final protein
sample consists of two protein populations, namely monomers and dimers of H1-CRD.
The dimers present a predicament due to their abnormal formation. Although ASGP-R
certainly is an oligomeric receptor, the subunits associate via the extracellular stalk
segment and not at the CRD. The dimerization in vitro is further problematic as it
cannot be controlled and its incidence is variable. Consequently, the samples become
largely heterogeneous, both within and in between batches of H1-CRD.
At the outset of this PhD thesis, little was known about the dimers of H1-CRD. An odd
cysteine was suggested as the cause of the dimer formation, supported by the absence
of dimers under reducing conditions during SDS-PAGE analysis. Yet, the theory had not
been verified, nor had the odd cysteine been properly identified. Furthermore, the
behavior of dimeric H1-CRD compared to pure monomers had not been determined,
leaving the possibility that the two protein species exhibit different binding affinities.
Until such a difference, or the opposite, had been established, it was resolved to
perform further studies with samples of pure monomeric H1-CRD.
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A method to separate monomers and dimers using HPLC IEC, developed by Daniel
Ricklin at IMP [95], was used in this work. The two protein species were successfully
divided during the run of the program and collected as separate fractions. The large
batch that was produced during this PhD thesis, and that subsequently aided the
development of the Biacore assay and the solid-phase competition assay, was purified
by HPLC IEC and resulted in 4 mg monomers of H1-CRD. However, SDS-PAGE
analysis revealed that a small fraction of dimers was present in the monomer samples
even after the separation step. It can reasonably be assumed that these dimers formed
after the IEC as a consequence of the high concentration of monomers. Aliquots of
monomeric H1-CRD were stored either at -20°C or at 4°C after being thawed and
opened. Once in liquid state, monomers are theoretically able to associate in dimeric
complexes until an equilibrium is reached. While SDS-PAGE analysis could
demonstrate that the monomers still constituted a majority of the samples even after
storage at 4°C, the presumed eradicated dimers were also clearly present. Under these
conditions, a new aliquot of H1-CRD would need to be thawed for each new
experiment to ensure a high content of monomers, but even then the homogeneity of
the sample would remain uncertain.
An alternative method, based on HPLC RP and developed by Dr. Said Rabbani at IMP,
was also attempted for separation of monomers and dimers of H1-CRD. The major
appeal of the method was the possibility to store the final protein samples as powder
after the chromatography and lyophilization. It was theorized that the stability of the
protein, over time, would improve in the solid state. In addition, liquid protein samples
of fixed concentrations could be prepared on demand. However, the aptness of the
method was questioned due to the relatively harsh conditions used during the
chromatography step. Monomers purified by HPLC RP were therefore compared to
monomers purified by HPLC IEC in a series of assays determining binding affinity to
GalNAc. Binding of GalNAc could be detected in three independent studies to both
protein samples. While the NMR data could only provide a qualitative statement, a
clear difference in the binding could be observed in the Biacore experiments and the
solid-phase competition assay. Binding of GalNAc occurs to less extent to the RP
purified monomers when equivalent amounts of protein are used. While the
determined KD values were in a similar range, the signal intensity between the protein
samples differed substantially in both assays. Taken together the results suggest that
only a small fraction of protein is fully active in the RP sample, as indicated by the KD.
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The majority of protein, however, appears inactive and incapable of GalNAc binding,
resulting in low signal response. As the two monomer samples only differ in the final
purification step, it lies close at hand to assume that the RP step and/or the
lyophilization harms the protein and renders it inactive. Consequently, IEC remains as
the method of choice for separation of monomers and dimers of H1-CRD.
Although a symptomatic relief, the separation method(s) cannot be considered an
optimal solution as the dimer formation is in fact neither cured nor abolished. The
production of H1-CRD suffers from a significant protein loss on behalf of the
dimerization as monomeric H1-CRD is trapped in dimers. Moreover, even after going
to the lengths required for separating the two protein species, a stable and invariable
sample of monomers cannot be guaranteed. Finally, additional purification steps are
known to decrease the final protein yields [128], which is also true for the production
of H1-CRD. In summary, a method able to prevent dimer formation, either through
complete inhibition or at an early point of the protein purification, would be highly
advantageous for the production of H1-CRD.
Protein dimers arising as a result of intermolecular covalent disulfide bonds can be
inhibited by modification of the cysteine(s) involved. An effective way to abolish dimer
formation caused by covalent disulfide bonds is to substitute the involved cysteine for
serine or alanine through site-directed mutagenesis [140,141]. This approach was
undertaken within this work and is discussed further in section 4.2. An alternative
method is to chemically modify the cysteines by thiol reagents such as N-ethyl-
maleimide (NEM), 5,5’-dithiobis-(2-nitrobenzoate) (DTNB) or iodoacetamide
[142,143]. As an example, NEM was utilized in a study investigating activity and
oligomeric state of the lactose transport protein (LacS). By incubating a cysteine mutant
of the protein with NEM, the activity of LacS was considerably reduced. In contrast, a
second mutant lacking a cysteine was left unaffected by the NEM treatment [144].
Initial experiments combining H2-CRD with NEM carried out within a master thesis
project by Daniela Abgottspon at IMP have shown promising results [145]. Following
expression and purification by affinity chromatography on FPLC, samples of H2-CRD
were incubated with different concentrations of NEM. Non-reducing SDS-PAGE
analysis could reveal that the dimer content in the NEM treated samples was
significantly lower compared to the negative controls after one day as well as one
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week. A small fraction of dimers was present in the NEM samples, but is supposedly
the result of dimerization occurring already during the refolding and purification of the
protein. If, as the preliminary results suggest, NEM can prevent dimer formation of the
ASGP-R subunits, and it is combined with the HPLC separation method, samples of
pure monomers can be obtained. Furthermore, if added at an early stage of the protein
purification, protein loss due to dimerization could be minimized as NEM will block
the free cysteine. Similarly, purified monomers, modified by NEM, would also remain
stable after separation from the dimers.
4.2 Expression and characterization of cysteine mutants of
ASGP-R H1-CRD
Site-directed mutagenesis is often resorted to when investigating the functional
importance of cysteine residues [146,147], and also as a means of inhibiting formation
of protein dimers or higher oligomers [141]. In one study, the technique was used to
prevent non-native disulfide bonding during expression of human fibroblast β-
interferon (IFNβ) in E.coli [148]. The initially expressed wild-type protein was revealed
to show only a tenth of the expected activity. In addition, most of the IFNβ was found
to exists as dimers or higher oligomers that were inactive. As the protein contains three
cysteine residues, it was theorized that one or more of them could be involved in non-
native intermolecular disulfide bridging. Comparison with the structurally similar
protein IFNα indicated Cys17 as a likely candidate for dimer formation and the residue
was therefore substituted for a serine. No multimeric complexes were formed during
expression of the mutant IFNβ-C17S, proving the assumption to be right. Moreover, the
mutated protein showed a specific activity similar to that of purified native fibroblast
interferon. Similar to the study of IFNβ, SDM was applied in this work to prevent the
formation of non-native dimers of H1-CRD formed upon expression and purification
from E.coli.
H1-CRD contains seven cysteines, six of which are engaged in disulfide bridges,
Cys153-Cys164, Cys181-Cys276 and Cys254-Cys268. The odd cysteine, Cys152 as
proposed by the crystal structure, has no counterpart to react with within the subunit,
leaving it free to form intermolecular disulfide bonds. Cys164 has also been suggested
as the odd cysteine in earlier work at IMP [94]. As the odd cysteine remained
unidentified at the outset of this thesis, it was decided to mutate the three cysteines
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152, 153 and 164, individually and collectively, to determine their potential
involvement in dimerization of H1-CRD. In addition, the functional relevance of the
odd cysteine and the third disulfide bridge, either Cys152-Cys153 or Cys153-Cys164,
was to be concluded. Even though the primary goal of the mutagenesis studies was to
inhibit the dimerization, it is of outmost importance that the activity and ligand binding
affinity of the subunit is sustained in order for the mutated protein to be of further use.
4.2.1 Dimer formation can be stopped by site-directed mutagenesis…
The three cysteines closest to the N-terminus in H1-CRD, i.e. C152, C153 and C164
were exchanged for serines, either as single, double or triple mutations, generating
seven mutant proteins in total. The mutations and the accuracy of the DNA sequence
were verified by sequencing, prior to protein expression in E.coli.  Similar to WT H1-
CRD, the mutant protein(s) were found to accumulate in inclusion bodies and the
protein content was therefore denatured and reduced. The native structure was restored
by stepwise dialysis, followed by purification by affinity chromatography. All seven
mutants showed to both express and purify well by the procedures established for the
wild-type protein. Hence, it could be concluded that, qualitatively, the cysteine
mutants of H1-CRD maintained binding affinity for galactose.
The dimer content of the purified mutant samples was investigated by non-reducing
SDS-PAGE analysis and compared with WT H1-CRD. Out of the seven protein samples
only one showed to be completely devoid of dimers, namely the triple mutant. The
single mutants, even though containing an even number of cysteines, were all seen to
show traces of dimers. Although the cysteines at the N-terminus preferentially form an
intramolecular disulfide bridge, regardless which of the three cysteines it is formed
between, they can also engage in intermolecular bonding. It can therefore be argued
that a single point mutation would not be sufficient to eliminate the dimer formation.
The double mutants show a high content of dimers, as can be expected. An odd
number of cysteines, as in the wild-type, leaves one free to react with a cysteine in a
neighboring subunit. However, an exception to this theory could also be observed in
the case of mutant C152/153S, in which Cys164 was the fifth unpaired cysteine.
Mutant C152/153S only displayed traces of dimers, more resembling the single mutants
than WT H1-CRD. The lack of dimers suggests that Cys164 is indeed engaged in an
intramolecular disulfide bond in native H1-CRD, as suggested by the crystal structure.
However, whether it is paired with Cys152 or Cys153 cannot be determined by these
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results. Finally, as previously mentioned, the triple mutant was found to exist
exclusively as monomeric protein. Based on these observations it can be concluded
that the dimer formation of H1-CRD in vitro is caused by the three cysteines closest to
the N-terminus. The odd cysteine is predominately responsible for the dimerization, but
the other two cysteines can also contribute. Concurrently, it can be concluded that the
remaining four cysteines in H1-CRD, i.e. Cys181, Cys254, Cys268 and Cys276, do not
take part in the dimer formation, as no dimers were detected in the triple mutant
sample. Considering the crystal structure, the intramolecular disulfide bonds formed by
these four cysteines are expected to be of crucial importance for the functionality of the
subunit.
In summary, site-directed mutagenesis has proved to be a most powerful tool for
preventing the dimer formation of H1-CRD when expressed and purified from E.coli.
4.2.2 …but at the expense of protein affinity and stability
Following the purification by affinity chromatography on FPLC, all mutant samples
were loaded onto the anion-exchange column on HPLC. In a final step, the mutant
monomers were purified and pooled over the GalNAc-Sep-column on HPLC. The
samples were used to determine ligand binding affinity of the mutant proteins.
Emphasis was put on the triple mutant, as it was the only sample showing a complete
lack of dimers.
The results derived from the solid-phase competition assay were unambiguous. The
cysteine mutants all showed lower affinity for GalNAc compared to the wild-type. The
signal intensity of the mutant proteins was constantly lower, indicating weaker binding
of the GalNAc polymer. Further support for this observation was seen in the
competitive approach, where the calculated rIC50 values of the mutants compared to
the wild-type were all below zero. That is to say, a lower concentration of monovalent
GalNAc is needed to inhibit binding of the GalNAc polymer to the mutants.
Further studies were undertaken with the triple cysteine mutant and included NMR and
Biacore experiments. While NMR clearly could show binding of GalNAc to the mutant
protein, it could not provide a quantitative measure. In contrast, the Biacore
experiment resulted in a KD value for comparison with WT H1-CRD. The KD values
differed significantly, with a factor of almost two, in favor of the wild-type. In
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agreement with previous results, the Biacore experiments indicated that the mutant
protein exhibit a lower affinity for GalNAc. However, it should also be noted that the
signal intensity of the triple mutant was exceptionally low, only slightly higher than the
background, and could therefore limit the accuracy of the final results.
A second concern to be addressed is that of the stability of the mutant proteins. In the
first approach of the solid-phase competition assay, only binding of the polymer
without a competing inhibitor substance was measured. Repeated attempts of the assay
set-up showed significantly reduced ligand binding over time. All seven mutants
displayed a reduction in signal intensity, seemingly in similar proportions. The protein
samples used in the different assays originated from the same batches, but new aliquots
were thawed for the assays performed in the second run. In contrast, the wild-type did
not appear to lose affinity during the equivalent time period, but showed consistent
results when examined in the assay.
The decrease in stability, and indirectly also in affinity, can partly be explained by the
loss of the third disulfide bridge. Disulfide bonds are known to improve the stability of
proteins, making them more resistant to e.g. high temperatures, acidic or basic pH,
high concentrations of organic solvent, or to increase the half-life of protein
therapeutics [149]. There are also examples of protein engineering where disulfide
bridges have been introduced to increase the stability of specific proteins. In one study,
T4 lysozyme was subjected to SDM and mutants with one or more non-native disulfide
bonds were constructed. One double-disulfide mutant turned out especially successful
as it was not only fully active, but also retained activity at temperatures substantially
higher than the wild-type enzyme [150]. In a study more closely related to H1-CRD,
disulfide mutants were created of the H2b subunit [151]. The exoplasmic domain of
H2b, as H1, has eight cysteines, proposed to form four disulfide bonds. The importance
of each individual bond was investigated by converting corresponding cysteines to
alanines and in doing so disrupting the disulfide bridge. The mutant proteins were
subsequently expressed in 3T3 fibroblasts. The results revealed that one mutant, lacking
bond Cys157-Cys171 nearest to the transmembrane region, was able to fold correctly
and was found expressed on the cell surface. In contrast, mutations of the other three
disulfide bonds prevented proper folding of the subunit, and all three mutant proteins
were degraded in the endoplasmic reticulum. To conclude, the study showed that three
of the four disulfide bridges in H2b are essential for proper folding of the protein.
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Corresponding bridges in H1 are Cys153-164, Cys181-Cys276 and Cys254-Cys268.
Hence, it can be assumed that the bridge formed between Cys153 and Cys164 is
important for the structure of H1-CRD. Consequently, the lack of the bond could
explain the reduced protein stability observed in the studies with the cysteine mutants
and it could also reflect negatively on the affinity. It does, however, not explain the
results obtained for the single mutants, or at the every least mutant C152S, in which the
third bridge ought to be intact. If the bridge were indeed important for the subunit
stability and affinity, a marked difference between the single mutants and the other
mutated proteins would be expected. However, as all seven cysteine mutants did show
similar signal intensities and rIC50 values, the altered properties cannot be attributed
exclusively to an absence of the third bridge.
In summary, even though dimer formation of H1-CRD can be inhibited by substitution
of three cysteines, the mutant protein does not constitute an optimal solution. The
affinity as well as the stability of the subunit is compromised by the mutations, making
it behave differently compared to the WT. Therefore, SDM cannot be considered an
eligible method in this case.
4.3 Investigation of the binding site of ASGP-R H1-CRD
Another part of this PhD thesis has been dedicated to investigate the relative
importance of specific amino acid residue located in the binding site of H1-CRD.
While the majority of the residues in the binding site, stretching from Arg236 to
Cys268, have been studied and their contributions to the functionality of the subunit
have been deduced, a few residues have remained unexamined. This subproject has
aimed to further expand the overview of residues in the binding site.
4.3.1 Identification of residues important for the functionality of ASGP-R
H1-CRD
Five mutant proteins were created, namely P237A, E238G, H256E, D259A and
D260A. The mutations were confirmed by sequencing prior to protein expression in
E.coli. The mutant proteins were purified according to the procedure established for
WT H1-CRD. After the initial purification by affinity chromatography, the proteins were
subjected to HPLC IEC for separation of monomers and dimers. Final samples were
obtained after running the monomeric fractions over the GalNAc-Sep-column on
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HPLC. The solid-phase competition assay and Biacore was used to evaluate binding
affinity of the binding site mutants of H1-CRD.
Mutant P237A was investigated with both the solid-phase competition assay and
Biacore. Taken together, the results demonstrated binding affinity for GalNAc in the
same range as the wild-type. The KD derived from the Biacore data was slightly lower
than that for the WT. Concurrently, IC50 values obtained from the solid-phase
competition assay resulted in rIC50s just below one. Although the mutant displayed a
lower signal response compared to the WT in both assays, it was clearly sufficient for
evaluation of the data. Based on the results, it can be concluded that Pro237, located in
loop four within the binding site of H1-CRD, plays a minor role in the functionality of
the subunit. In general, proline is considered a rigid structure, which reduces the
flexibility of the protein whenever it occurs. It is often found in β-turns, due to its ability
to assume cis configuration [55]. It can be theorized that Pro237 is of importance for
the local structure and stability of H1-CRD, but its conversion has little influence on the
binding affinity.
The neighboring residue, Glu238 was converted to a glycine. Previous studies have
shown that simultaneous insertion of Arg236 and Gly238 into corresponding positions
of MGR increased the selectivity for GalNAc twofold [7]. Glycine is the native residue
found in RHL-1, in which Arg236, as in H1-CRD, is also present. Mutant E238G was
created to investigate potential differences in affinity caused by the two amino acids.
The solid-phase competition assay showed a convincing increase in binding affinity for
GalNAc of the mutant compared to the wild-type. Even though the standard deviation
calculated for the three determined rIC50 values was fairly large, the results were
unanimous. As suggested by earlier studies, residue 238 in H1-CRD can influence the
binding affinity for GalNAc. Based on the results obtained within this work, binding is
clearly favored by glycine compared to glutamate. While glycine is unlikely to interact
with the ligand itself, it may influence the structural flexibility of the protein and by
doing so facilitate binding. In contrast, glutamate carries a larger side chain, limiting its
flexibility. Examination of the wild-type crystal structure reveals that Glu238 is
positioned at the surface of the protein in a solvated area. Glutamate can be found
deprotonated under physiological conditions and as it can form hydrogen bonds with
surrounding water molecules, it is likely to have a positive influence on the protein
solubility.
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Histidine 256 in H1-CRD has previously been revealed as a critical residue involved in
GalNAc binding to the subunit [7,49]. It has also been implicated in the ligand release
during endocytosis [96,97]. In this work, His256 was converted to a glutamate to
further investigate pH dependent ligand binding associated with the residue.
Purification of mutant H256E proved to be more complicated compared to the other
mutant proteins. Affinity chromatography resulted in only a minor elution of the
mutant, while the protein could also be detected in the flow-through. Repeated
denaturation and refolding of the flow-through was able to recover a small fraction of
the initially misfolded H256E protein. The mutant was analyzed by the solid-phase
competition assay and Biacore, confirming previous results. KD of GalNAc determined
by Biacore was higher for the mutant compared to WT H1-CRD, while the rIC50 based
on the solid-phase competition assay was found to be below 1. Hence, His256 is
important for binding of GalNAc and exchanging the residue will result in a decrease
in binding affinity. The influence of pH on the ligand binding is discussed separately in
section 4.3.2 below.
Mutant D259A was investigated with the solid-phase competition assay. The calculated
rIC50 values, just below one, showed a slight decrease in binding of the polymer and
hence affinity for GalNAc. However, the resulting rIC50 values closely resemble those
determined for mutant P237A. It is possible that a second method would show binding
similar to the WT, as was seen for mutant P237A. The corresponding residue in RHL-1
is a threonine. Although predicted as too distant for direct contact with a bound ligand,
it has been shown to influence binding of GalNAc, possibly through positioning of
His256 [7]. Therefore, any differences in binding affinity arising as a consequence of
varying the residue at position 259 are likely to depend on the residue’s ability to
modify the protein structure. Converting Asp259 to alanine appears to be of minor
importance for the binding of GalNAc. Observation of the crystal structure of H1-CRD
locates Asp259 at the surface of H1-CRD (Figure 70).
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Figure 70. Close-up of the crystal structure of H1-CRD, focusing on D259 and D260. The residues are
found at the surface of the protein. Asp259 can form hydrogen bonds with surrounding water molecules,
while Asp260 can be seen to stabilize Arg262 [50].
The side chain is directed towards the surroundings, forming a hydrogen bond with a
proximate water. Substitution with alanine causes the residue to lose its ability to act as
a hydrogen acceptor and the solubility and the structure of the protein could be
affected.
Aspartate 260, the final residue to be mutated, is conserved in both H1- and H2-CRD
of human, mouse and rat. It was converted into alanine, to explore its contribution to
the functionality of H1-CRD. The mutant protein was analyzed by the solid-phase
competition assay. Detection of GalNAc binding was very limited due to the low signal
response, also for protein replicates incubated exclusively with polymer. Even though
the development time after addition of the substrate was prolonged, the results did not
improve much. Taken together, the results suggest that the mutation D260A causes a
major loss in binding affinity for GalNAc. The crystal structure shows Asp260 at the
surface of the protein, closely interacting with a second residue, arginine 262 (Figure
70). The two residues are connected by three hydrogen bonds, stabilizing the loop in
which they are situated and also the local protein structure. In contrast, alanine is
unable to act as a hydrogen bond acceptor. The mutation is therefore likely to result in
a destabilization of the protein as well as a change in the structure, reflecting negatively
on the binding affinity of the subunit.
D259
D260
R262
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4.3.2 Histidine 256 – responsible for pH dependent ligand binding
Previous mutagenesis studies of RHL-1 have shown that histidine 256 plays an
important role in the pH dependent ligand binding exhibited by the subunit [96,97]. In
this work, His256 of H1-CRD was substituted by glutamate, the corresponding residue
in H2-CRD. Binding of GalNAc to mutant H256E and WT H1-CRD was investigated by
the solid-phase competition assay and Biacore at different pH ranging from 7.4 to 5.
The solid-phase competition assay showed that binding of the GalNAc-polymer
decreased at pH 6 or lower. Similar results were obtained from the Biacore
experiments. KD of GalNAc was seen to increase at pH lower than 6, signaling a
reduction in affinity. While these observations were true for both the mutant and WT
protein, a more dramatic change in ligand binding and KD was detected for the latter.
Histidine 256 clearly renders H1-CRD more sensitive to low pH compared to a
glutamate in the same position.
His256 has been proposed to interact with Asn264, which in turn is involved in both
calcium- and ligand binding. The histidine stabilizes Asn264 by a hydrogen bond
formed between the imidazole and the amide (Figure 71).
Figure 71. Close-up of the crystal structure of H1-CRD, focusing on N264 and H256 (drawn as ball-and-
sticks). A stabilizing hydrogen bond with an approximate length of 2.43 Å is marked between the residues.
Ligands for the calcium ion (green) are also highlighted as ball-and-sticks [50].
H256
N264
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Protonation of the imidazole, caused by a drop in pH during endocytosis, will disrupt
the hydrogen bond. As a consequence, the asparagine is destabilized and both ligand
and calcium binding is disturbed. In contrast, glutamate is deprotonated at endosomal
pH and theoretically able to accept a hydrogen bond from asparagine. Ligand binding
can therefore be sustained at lower pH compared to the wild-type protein. The results
obtained in this study could also show that mutant H256E was less affected by a
decrease in pH. As H2-CRD contains a glutamate instead of a histidine, it can be
expected that H2-CRD is less sensitive to acid pH than H1-CRD. However, it can also
be anticipated that H2-CRD exhibits lower affinity for GalNAc due to the lack of
His256. This theory is supported by preliminary results obtained within the ASGP-R
project group at IMP [152].
4.4 Isotope labeling of ASGP-R H1-CRD
NMR holds a central position in protein studies. The method is often used to analyze
protein-ligand interactions as a qualitative measure. It can also be applied in more
elaborate studies to determine the 3D structure of proteins [92]. The first step when
attempting structural elucidation by NMR is to generate protein enriched by rare
isotopes such as 15N and/or 13C. As protein in milligram quantities is usually required,
the expression system has to be both efficient and reproducible. The establishment of a
method for isotope labeling of H1-CRD and enable future structure determination by
NMR has been the aim of a third project carried out within this thesis.
Heteronuclear labeled protein is commonly produced by growing E.coli in minimal
medium supplemented with a 15N- and /or 13C source. In order to facilitate bacterial
growth and protein expression, the culture media as well as expression conditions are
routinely optimized. One alternative expression set-up, here referred to as the two-
stage protocol, utilizes unlabeled rich medium for growth of the E.coli, following by
exchange of the bacteria into labeled minimal medium for protein expression [90].
During this work, both the two-stage protocol and exclusive use of minimal medium
was attempted for labeling of H1-CRD.
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4.4.1 H1-CRD expressed by the two-stage protocol – a vanishing act of
13C and 15N
The two-stage protocol was initially applied for expression of isotope labeled H1-CRD.
Growth and expression conditions were optimized in terms of starter culture medium,
concentration factor of cells, expression temperature and time as well as IPTG
concentration. After determining the conditions resulting in the highest protein yields,
H1-CRD labeled with 15N, or both 15N and 13C, was expressed. The purification
procedure established for WT H1-CRD was employed with good results as evidenced
by sharp peaks seen during both FPLC affinity chromatography and HPLC IEC. NMR
analysis of the two protein samples could confirm that the protein was well folded.
However, the signals were fairly weak and the measurement time had to be prolonged
beyond what is considered standard procedure. It was suspected that the isotopic
incorporation level might be lower than initially expected, a suspicion that proved to
be true. MS analysis and a NMR half-filter experiment showed that the majority of the
protein sample was indeed unlabeled. Isotope labeled H1-CRD could also be
observed, but to less extent. Due to the nature of multidimensional NMR experiments,
a protein sample has to be isotopically enriched to a minimum of 90% in order to
prove useful. Hence, the current method was evidently not optimal for the task it was
intended and therefore needed to be improved. Furthermore, the obvious lack of
labeled H1-CRD was found most peculiar as the protein had been expressed in
minimal medium, in which the only nitrogen- and/or carbon source(s) were isotopically
labeled. Similarly, the dominant population of unlabeled H1-CRD could initially not be
explained. It can be argued that some unlabeled metabolites might remain in the
bacteria also after inoculation in minimal medium and could be incorporated into the
protein during expression, but it does not account for the clear majority of unlabeled
protein. Moreover, the protocol includes one hour incubation in minimal medium prior
to induction, partly to allow clearance of such unlabeled metabolites. Since expression
is only induced after transferring the bacteria into the labeled minimal medium, the
fraction of unlabeled protein should be kept to a minimum.
An explanation for the expressed unlabeled protein was proposed by external fellow
scientists working with isotope labeling [153]. It was suggested that the problem arose
due to unintended induction during the growth phase in rich medium. Rich medium,
such as LB or TB, can contain traces of lactose, which in turn can induce the lacUV5
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promotor and expression of T7 RNA polymerase. Hence, the bacteria would initiate
expression already in the rich medium, explaining the high content of unlabeled
protein.
The phenomenon of unintended induction of the T7 expression system was addressed
in a recent paper [154]. Two different batches of N-Z-amine were used for protein
expression and while the use of one was observed to cause unintended induction, the
other one did not. A sample of Bacto tryptone from Difco (the brand used within this
work) was also shown to cause unintended induction. It was concluded that the
differences in inducing activity were likely to be dependent on varying amounts of
lactose in the media components. N-Z-amine and tryptone are derived from enzymatic
digestion of casein, a milk protein. Even though the casein would have been purified
prior to digestion, trace amounts of lactose could remain in the final product.
TB medium contains more tryptone and yeast extract than LB, and consequently runs a
higher risk of unintended induction. As TB medium had been used during the
expression of H1-CRD, it was suggested to repeat the experiment using LB medium as
starter culture medium instead. In addition, it was proposed to prolong the incubation
time in minimal medium prior to induction. As the growth temperature was decreased
following the medium exchange, the rate of bacterial metabolism could be affected. To
ensure complete clearance of unlabeled metabolites it was therefore advised to extend
the time between media change and induction. Finally, it was suggested to use
carbenicillin instead of ampicillin, as ampicillin is more sensitive to culture conditions
and degradation. Use of carbenicillin decreases the risk of possible contamination of
non-transformed bacteria. The proposals were implemented in the method and referred
to as an alternative expression set-up of the two-stage protocol. To examine whether
the suggestions would improve the labeling efficiency, a small batch of 15N labeled H1-
CRD was prepared. Following expression, the protein was purified according to the
standard procedure and HPLC RP was used to prepare a monomeric sample for MS
analysis. The results showed a clear improvement in isotope enrichment with an
incorporation level of 95%. However, while improving the first protocol, a second
method using only minimal medium had simultaneously been attempted. The latter
proved to result in an even higher labeling efficiency and it was chosen as the method
of choice. It can be argued that a method based solely on minimal medium is more
reliable as it will never risk incorporation of unlabeled metabolites.
157
4.4.2 Expression of isotope labeled H1-CRD
The second method made use of minimal medium for both bacterial growth and
protein expression. To adapt the bacteria to medium poor in nutrients, the cells were
initially grown in unlabeled minimal medium O/N. The starter culture was
subsequently diluted 10X in labeled minimal medium and expression induced at an
appropriate OD. High efficiency labeling was achieved for both 15N and 13C/15N,
resulting in incorporation levels of 98% and 97%, respectively. The yield varied
between 400 and 500 µg per liter expression culture. Initial NMR experiments with the
15N labeled H1-CRD could confirm that the protein was well folded. A HSQC spectrum
was acquired within 10 minutes and strong signals recorded, supporting the results of
the MS analysis, i.e. the protein was highly enriched by 15N. Binding of GalNAc was
also investigated by adding different concentrations of the monosaccharide to the
protein sample and monitoring changes in the peak positions. Taken together, the
results indicate that the protein sample and hence, the method by which it was
produced, provide a good basis for a future structure determination of H1-CRD by
NMR. A high level of isotopic incorporation can be achieved and the final protein is
both pure and well-behaved in terms of folding and ligand binding.
4.5 Summary and outlook
The work carried out within this thesis has strived to improve the knowledge on the
H1-CRD subunit of the ASGP-R. Three subprojects were undertaken with the common
goal to deduce the functionality of different structural elements of the subunit. Both
single residues as well as the whole subunit have been targeted in the different projects.
The individual aim of each project, as posted in the introduction, can be found
summarized together with the obtained results and an outlook below.
4.5.1 Role of the three N-terminal cysteines
The goal of the project was to determine whether dimer formation of H1-CRD is
caused by one of the cysteines closest to the N-terminus. Furthermore, it aimed to
clarify how the cysteines are relevant for the functionality of the subunit.
The results showed that the dimerization seen upon expression of H1-CRD in E.coli is
indeed dependent on the cysteines closest to the N-terminus, primarily Cys152 and/or
Cys153. A single cysteine-to-serine point mutation was seen to reduce the dimer
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content substantially. Merely traces of dimers were spotted compared to the wild-type
protein. Double mutations did not improve the situation further, but substitution of all
three cysteines abolished the dimer formation completely.
The cysteine mutants were further analyzed in respect to binding affinity for GalNAc.
Disappointingly, all seven mutant proteins showed a decrease in affinity compared
with the WT. No apparent difference could be observed between the single, double or
triple mutants. The undisputable decrease in affinity suggested that not only the third
disulfide bridge is important for the functionality of the subunit, but also the seventh
odd cysteine.
In summary, although able to prevent dimer formation of H1-CRD, site-directed
mutagenesis cannot be regarded as a suitable method due to the loss in GalNAc
affinity. Alternative strategies, which do not influence the binding behavior of the
subunit, ought to be considered. Chemical modification of the odd cysteine, using e.g.
NEM or iodoacetamide, constitutes one such alternative and interesting approach.
4.5.2 Investigation of the binding site of H1-CRD
The importance of individual residues in the binding site of H1-CRD was to be
determined by SDM. In addition, the project aimed to elucidate the role of histidine vs.
glutamate at position 256 in pH-dependent ligand binding
Five mutant proteins were created containing single point mutations, namely P237A,
E238G, H256E, D259A and D260A. Two of the mutant proteins, P237A and D259A,
showed GalNAc affinity in the same range, or slightly lower, as WT H1-CRD. Hence, it
can be concluded that these residues are of minor relevance for the functionality of the
subunit. Conversion of Glu238 to glycine resulted in an increase in affinity for GalNAc.
While previous studies exclude interaction between glycine and a ligand, the residue
may influence the local structure of the protein and by doing so facilitate ligand
binding. The fourth mutant, D260A, resulted in a substantial loss in binding affinity for
GalNAc. Observation of the crystal structure of H1-CRD revealed Asp260 to form close
interactions with a neighboring residue. The residue is expected to be important for the
structural stability and indirectly also the ligand binding.
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In summary, these results provide indications of the relevance of the investigated
residues for the functionality of H1-CRD. An additional assay would be beneficial to
accurately quantify the contributions of the residues to ligand binding.
Finally, mutant H256E was created to investigate the influence of histidine vs.
glutamate on pH dependent ligand binding. While WT H1-CRD showed a dramatic
loss in binding affinity for GalNAc at low pH, the change observed for the mutant
protein was substantially less. It should be remarked, however, that the mutant protein
showed lower binding affinity for GalNAc at physiological pH as a result of the
substitution. In summary, His256 confers pH sensitivity as well as high ligand binding
affinity to H1-CRD. Although H2-CRD theoretically would be able to sustain ligand
binding at acidic pH, it lacks high affinity for GalNAc as glutamate, instead of histidine,
is present in position 256.
4.5.3 Isotope labeling of H1-CRD
The aim of the project was to establish a method for high efficiency isotope labeling of
H1-CRD to enable future structure determination by NMR.
Two methods were attempted. The first, referred to as the two-stage protocol,
combined growth in unlabeled rich medium with expression in labeled minimal
medium to reduce costs and increase yields. Despite much effort aimed to optimize the
expression set-up, the final protein sample showed an unexpected high degree of
unlabeled H1-CRD. Presence of the unlabeled H1-CRD was suggested to be due to
unintended induction caused by lactose traces in the rich medium. After modification
of the protocol, a protein sample with a 15N incorporation level of 95% was obtained.
A second method, relying solely on use of minimal medium, was employed as the two-
stage protocol initially failed to produce isotope labeled H1-CRD. The second method
was immediately successful as a high enrichment of 15N, 98%, could be achieved.
Repeated expression with 13C and 15N showed reproducible results with an overall
incorporation level of 97%. In addition, preliminary NMR experiments with the 15N
labeled H1-CRD could confirm that the protein maintained a stable tertiary structure
and that GalNAc affinity was preserved.
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In summary, a method for high efficiency isotope labeling of H1-CRD has been
established. The method makes use of only minimal medium, thereby minimizing the
risk of unintended induction and expression of unlabeled protein. Obtained protein
samples show high isotope incorporation levels and high quality, making them suitable
for structural elucidation by NMR.
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